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ABSTRACT
An Exploration of the Relationships between Chronic Pain, Inflammation, and
Herbal Medicine
Termeh Feinberg
Introduction: Inflammation is often a component of chronic pain, yet its potential role in fibromyalgia
syndrome (FMS) remains inconclusive. FMS is a complex chronic pain condition affecting ~2% of the
population; management is challenging and treatment options remain limited. Many herbs contain
antiinflammatory properties, and herbs indicated for analgesia and rheumatic conditions have traditionally
been used in Appalachia. Despite the popularity of herbs in the US, determinants and patterns of herbal
use with regard to pain management have not been well studied, particularly in Appalachia, where
prevalence of chronic pain and related comorbid conditions is high and access to medical care is often
reduced. In this series of three studies, we investigate the: 1) relation of FMS to serum C-reactive protein
(CRP) in a large Appalachian population; 2) demographic, lifestyle, and health-related correlates of herbs
and other complementary health approaches (CHAs) used for pain in a sample of Appalachian chronic
pain patients, using a newly developed survey instrument; and, 3) the relation of herbal supplement use to
FMS in two nationally representative samples of U.S. adults (NHIS 2007 and 2012), as well as trends in
patterns of herbal use over time.
Methods: All participants completed comprehensive health surveys in these three cross-sectional studies.
To investigate the relation between diagnosed FMS and serum levels of the proinflammatory marker CRP
(Study 1), we used data on 52,535 adult Ohio Valley residents (FMS =1,125), collected in 2005-2006 as
part of the C8 Health Project. Medical history, including physician diagnosis of FMS, was ascertained via
self-report. To determine the correlates and patterns of herbal and other CHAs used specifically for pain
in an Appalachian chronic pain population (Study 2), we collected data on 301 patients from four WV
pain and rheumatology clinics using our newly developed survey instrument, the Complementary Health
Approaches for Pain Survey (CHAPS) (2014-2016); correlates relating specifically to pain were measured
using the Short-Form Global Pain Scale (SF-GPS). To assess the relation of diagnosed FMS to herbal
supplement use (at 30 days, past 12 months, and ever) and to examine potential changes in the patterns of
use over time (Study 3), we used data from the 2007 and 2012 National Health Interview Surveys (NHIS)
(N = 20127 and N = 30672 adults, respectively). Logistic and linear regression (complete-case analysis)
were used to examine associations and to evaluate the potential modifying influence of gender and
number of health conditions; multivariate models were adjusted for an array of demographic, lifestyle, and
health factors. To account for missing data (Study 2), we also conducted additional sensitivity analyses
using multiple imputation.
Results: Study 1. In this large Appalachian population, mean serum CRP was significantly higher among
participants reporting a diagnosis of FMS than those without FMS (5.54± 9.8 vs.3.75±7.2 mg/L,
p<0.0001)). CRP serum level showed a strong, positive association with FMS (unadjusted OR for highest
vs. lowest quartile=2.5 (CI 2.1,3.0; P for trend(p<0.0001); adjustment for demographics and lifestyle
factors attenuated but did not eliminate this association (adjusted odds ratio (AOR) for highest vs. lowest
quartile = 1.4, (CI 1.1, 1.6). The addition of body mass index (BMI) and comorbidities to the model
further weakened the relationship between CRP and FMS (AORs, respectively, for highest vs lowest CRP
quartile=1.2 (CI 1.0,1.4) and 1.1 (CI 0.9, 1.3), suggesting that these factors may partially explain the
observed associations. Study 2: In our sample of 301 WV chronic pain patients, 8% reported using herbs
and 58.8% reported using other CHAs, including mind-body practices (28.9%),; acupuncture,
manipulative treatments, massage, and/or movement therapies (28.1%), and non-herbal dietary
supplements (53.6%). Herbal use in this sample was marginally, inversely associated with age (OR

adjusted for education=0.97 (CI 0.94,1.01) and positively associated with education (OR adjusted for
age=4.94 (CI 1.6,15.3); Herbal use also showed strong positive associations with use of other CHAs (
(AOR=11.5 (CI 1.5,87.9); specific CHA AORs ranging from 2.4 to 10.3). Use of other CHAs was
marginally, inversely associated with age (OR adjusted for education/exercise=0.98 (CI 0.96,1.0), and
significantly and positively associated with education and physical activity (AOR’s for Bachelor’s+ vs.
<HS/GED= 2.7 (CI 1.1,6.4; Exercise per 30 min p/w increment = 1.14 (CI 1.01,1.3); concomitant use of
other CHAs was significantly and positively associated with all CHA categories after adjustment for
multiple confounders. Neither herbal use nor CHA use overall was associated with pain severity or use of
prescription medications. Sensitivity analyses using multiple imputation did not appreciably change any
observed associations. Study 3. Prevalence of diagnosed FMS was significantly higher in 2012 compared
to 2007 (1.7% vs. 1.3%), whereas reported use of herbs declined from 57 to 41% for ever use (p <0.0001).
In both nationally representative samples of US adults (NHIS 2007, 2012), adults with FMS were
significantly more likely to use herbs at 30 days, 12 months, or ever relative to adults without FMS; these
positive associations remained highly significant even after controlling for a broad array of demographic,
lifestyle, and health-related factors (Ranges: 2007 AOR’s = 2.3 – 2.7; 2012 AOR’s = 1.5 – 1.6;
p’s<.0001).
Conclusion: Results of these studies suggest that 1) FMS is positively associated with serum CRP, an
association that may be largely explained by obesity and comorbidity, suggesting the role of inflammation
in this chronic pain syndrome may be complex 2) CHA use specifically for pain in chronic pain patients in
northern WV is high, and although overall reported use of herbs for pain is low, many herbs were reported
by those disclosing herbal use; and 3) the use of herbs is strongly and positively associated with FMS
diagnosis. Further prospective research is needed to confirm these findings, to further explore the role of
inflammation in FMS to further investigate the patterns and determinants of herbal and related CHA use
in FMS and other chronic pain populations, including those in Appalachia and other poor, underserved
areas.
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CHAPTER 1: Project overview
Introduction

Fibromyalgia, a Chronic Pain Syndrome
Impact of Chronic Pain Syndromes

Chronic pain, defined as ongoing or recurrent pain, lasts beyond the usual course of acute illness
or injury for more than three to six months, and is both debilitating and costly. Over 20% of adults may
eventually experience chronic pain (1-3), and as many as 100 million individuals are affected in the
United States alone (4). The effects of pain exact tremendous health care costs, rehabilitation and lost
worker productivity, as well as the emotional and financial burden placed on patients and their families.
The costs of unrelieved pain result in longer hospital stays, increased rates of re-hospitalization, increased
outpatient visits, and decreased ability to function fully leading to lost income and insurance coverage;
unrelieved chronic pain problems often lead to work disability and maintenance of health insurance (5).
Chronic pain costs the U.S. more than $635 billion annually in medical costs and lost productivity, which
equates to approximately $2,000 per person in the U.S. The Institute of Medicine stresses the importance
of increased research into the translation of effective treatments into practice and into the distribution,
prevalence, and burden of pain (6).

Fibromyalgia Syndrome Prevalence & Risk Factors

Fibromyalgia syndrome (FMS) is a non-fatal rheumatologic chronic pain syndrome affecting
approximately 0.5-5% of populations in developed countries (7), including 1.75% of those in the U.S. (8).
FMS is a “central” pain syndrome characterized by a constellation of somatic symptoms that are typically
present in addition to widespread pain (e.g., fatigue, sleep disturbance, memory, and mood problems)
(912). FMS is also characterized by morning stiffness, headaches, and increased sensitivity to loud
noises, bright lights, and temperature extremes; women with FMS often report painful menstrual periods
(13). Although FMS affects both sexes and people of all ages, the majority (80-90%) have been Caucasian
(13, 14) middle-aged women (13). Family members of FMS patients are at a higher risk for FMS (15); the
cause is unknown.
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Between 80 and 90% of people diagnosed with FMS are middle-aged women, although FMS can
affect both sexes and people of all ages (13). FMS is similar to many regional pain syndromes in that
peripheral or mechanical factors do not contribute, or contribute only minimally to the widespread chronic
pain typifying FMS; standard laboratory tests fail to reveal a physiologic reason for the pain experienced
(16). The cause of FMS is still poorly understood, and there are currently no diagnostic laboratory tests for
FMS, with diagnosis typically based on distribution of pain (with at least 11 of 18 painful ‘tenderpoints’
for at least 3 months, according to 1990 American College of Rheumatology Diagnostic Criteria (17), and,
updated 2010 diagnostic criteria incorporating quality-of-life impact of FMS(17)) and exclusion of other,
competing causes of pain. Because there are no established objective tests, and very limited management
options for FMS, some doctors may conclude a patient’s pain is not real, or they may tell the patient there
is little they can do (18).

Etiology of Fibromyalgia Syndrome

While the etiology of FMS is unknown, there may be a number of factors involved. Many people
associate the development of FMS with a physically or emotionally stressful or traumatic event, such as
an automobile accident or repetitive injuries, while some link it to another illness (11). FMS occurs
spontaneously in others, and limited research has investigated if it may be caused by a virus that changes
the way the brain perceives pain (11). People with FMS may have abnormal spinal fluid levels of
Substance P, a chemical which helps to transmit and amplify pain signals to and from the brain (11).
Despite the potential variation in underlying cause(s), however, it is clear that people with FMS have an
increased sensitivity to pain. Because genes regulate the way the body processes painful stimuli, people
with FMS may have a gene or genes that cause them to react strongly to stimuli that most people would
not perceive as painful (19). Several genes have been identified to occur more commonly in FMS
patients; studies indicate that women who have a family member with FMS are more likely to have FMS
themselves; several cerebrospinal MircoRNAs were recently identified in FMS cases in a small
casecontrol study (20). However, it is unknown if heredity is solely responsible, or if shared
environmental factors play a role as well. Further research on the perception of pain and related variables
among people with FMS is needed.
Like arthritis, FMS is considered a rheumatic condition, a medical condition that impairs the
joints and/or soft tissues and causes chronic pain; individuals with higher BMI (21), autoimmune
conditions (22), osteoarthritis (23), kidney (24), respiratory (25), cardiovascular (24), liver (26), and
endocrine (24) disease, diabetes (27), severe allergies (24) and sinus disease (28), stomach conditions (24,
26), and headache (29) may be more likely to have FMS. Those with FMS are also more likely to have
2

two or more coexisting pain conditions in addition to FMS, suggesting the plausibility of a common
underlying cause; however, shared mechanisms between comorbid conditions and FMS have remained
largely unexplored (13).
Role of Inflammation in Chronic Pain Syndromes and Fibromyalgia Syndrome

Chronic pain remains an unresolved problem in human medicine which greatly impairs quality of
life and prolongs treatment. Developing and identifying effective therapies is difficult due to the array of
mechanisms and signaling pathways through which chronic pain may be generated (30, 31). A common
underlying mechanism of chronic pain is the presence of inflammation at the site of the damaged or
affected tissue (31), and inflammatory responses in the peripheral and central nervous systems play key
roles (32). The release of pro-inflammatory and immunoactive substances such as cytokines (which are
chemical messengers and can also be anti-inflammatory), neurotrophic factors, and chemokines initiate
local actions and can result in a more generalized immune response by directly activating nociceptive
sensory neurons, leading to or promoting the generation of prolonged pathologic pain (33), and,
ultimately, to a persistent chronic pain condition (31).
Certain inflammatory cytokines are also involved in nerve-injury/inflammation-induced central
sensitization, and are related to the development of contralateral hyperalgesia (an extreme, exaggerated
reaction to a stimulus) and allodynia (central pain sensitization following painful, often repetitive
stimulation) (33). FMS is a condition that typically causes hyperalgesia and allodynia (34).
Although inflammation, as a characteristic reaction of tissues to injury or disease marked by
physical swelling, redness, heat, and pain, is not a classical symptom of FMS (18), further investigation is
necessary to rule out the existence of chronic, low-level inflammation among people with FMS.
Currently, cytokines are being investigated by the National Institutes of Health (NIH) in lab/pre-clinical
studies to determine the extent to which chronic pain in FMS patients is associated with the activation of
cells in the nervous system (18). The possible link between systemic inflammation and FMS must be
investigated since existing studies suffer from limited generalizability and potential misclassification bias.
Some of these investigations (35-49), but not others (43, 50) reported increased likelihood of FMS among
those with elevated levels of various pro-inflammatory indicators. However, only five of these studies
measured C-reactive protein (CRP) (44, 47-49, 51), which is a marker of inflammation that is a commonly
ordered lab workup among patients whose symptoms may indicate the presence of FMS (16); Four
suggested a positive association between CRP and FMS (44, 47-49). In addition, interpretation of findings
in these studies is hindered by small sample sizes. To date, only one large, cross-sectional, populationbased study has examined the association of CRP to FMS (48). The study excluded women, and combined
FMS with other pain syndromes, rendering assessment of the specific relationship between CRP and FMS
3

difficult. Thus, the role of inflammatory mediators in FMS also needs to be elucidated by larger,
population-based studies.
Current treatments for Fibromyalgia Syndrome

Family physicians, general internists, rheumatologists, and some pain clinics treat those who have
FMS (13). However, not all physicians are familiar with FMS and its treatment. Therefore, some FMS
patients experience difficulty in receiving diagnosis and consistent care for their symptoms. Treatment for
FMS and other chronic pain conditions is often poorly handled.
Although there is ‘gold’ level evidence (Cochrane) that supervised aerobic exercise training has
beneficial effects on physical capacity and FMS symptoms (52), and some evidence that cognitive
behavioral therapy may provide a small incremental benefit in reducing pain, negative mood and disability
at the end of FMS symptom treatment and at long-term follow-up (53) (Appendix A), people with FMS
are typically treated with pain medicines, antidepressants (54), muscle relaxants, and sleep medicines (11).
Often, neuromodulators (substances which alter the way nerves communicate with each other, affecting
the overall activity level of the brain, potentially reducing the amount of pain (55)) and anti-epileptics are
used for treating FMS. These and other drugs used to treat FMS carry significant side effects and include
Gabapentin (56), Fluoxetine (57), Pramipexole (57), Amitriptyline (54), Duloxetine (58, 59), and
Tramadol plus Paracetamol (57). Although three drugs (Lyrica, Cymbalta, and Savella) have been
approved by the FDA for treatment, they also carry significant side effects (57, 60, 61), and the
mechanism by which these drugs produce their effects is unknown. For some FMS patients, these drugs
are not effective (11). Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) inhibit prostaglandins, which
play a role in pain and inflammation; these are given as treatment for FMS symptoms (18), but carry
significant side effects for as many as 25% of long-term users (62).
For a subset of people with FMS, narcotic medications are prescribed for severe muscle pain.
However, concrete evidence is lacking regarding the efficacy of narcotics for the management of chronic
pain for the majority of those with FMS. Many doctors hesitate to prescribe narcotics for long-term use
because of the potential that the person taking them will become physically or psychologically dependent
on them (18). However, more than four-fifths of FMS patients receive opioid therapy (63); Because
specific recommended treatments for this chronic disease are highly variable, a consensus on effective
treatment for the disease is not known (64-66). Pharmaceuticals used for other diseases may be prescribed
as treatment for FMS, but there is limited quality research to support this practice, particularly regarding
Phenytoin (67), Clonazepam (68), Carbamazepine (61, 69), Topiramate (70), Pirlindole (71), Valproate
(61, 72), Lamotrigine (61, 73), Lacosamide (61, 74), and lastly, the narcotic Oxycodone (75).
4

Complementary Health Approaches (CHA) are often used by those with chronic pain. Further, the
American College of Rheumatology suggests that people with FMS consider non-drug treatments in
addition to their pharmaceutical approaches, and that certain CHAs may be helpful in managing FMS
symptoms. However, many of these treatments, including herbal dietary supplements, have not been well
tested in FMS patients (76-78).
While Mind-Body therapies (a group of CHAs such as meditation, hypnotherapy, relaxation, and
guided imagery) may improve self-efficacy, quality of life, and pain for people with FMS, systematic
reviews and meta-analyses on other treatments for FMS indicate a need for further research in the areas of
acupuncture (79), multidisciplinary rehabilitation for musculoskeletal disorders (a commonly used
intervention) (80), resistance training (81), and traditional Chinese medicine (82). We attempted to
conduct a meta-analysis in December 2014 to assess if herbal use (including Eastern or Western) was
simply a placebo effect for FMS treatment. The inclusion criteria were randomized clinical trials only
including FMS patients, compared herbs with placebo or pharmacological therapies, and included clinical
outcomes assessing FMS symptom severity and/or pain and/or quality of life. However, no trials met this
criteria, indicating a lack of research assessing the potential impact of herbs on FMS.

Opioids: an Imperfect Treatment for Chronic Pain

Over the past decade, the worrisome trend of increased prescription and utilization of opioids for
the treatment of chronic nonmalignant pain, including FMS, has emerged (83). Opioid pain relievers—
also called prescription painkillers—such as Oxycodone, Hydrocodone, Fentanyl, and Hydromorphone,
were responsible for three-fourths of all prescription drug overdose deaths in the United States in 2010
(84). Despite recommendations against the use of opioids for the treatment of FMS, evidence suggests
widespread and increasing clinical utilization (85). Recent evidence shows that over four-fifths of FMS
patients receive opioid therapy and that treatment using approved medications not only does not reduce
this trend but also tends to increase opioid utilization rates (63). Nationally, deaths involving opioids
(using age-adjusted data) have more than quadrupled since 1999 (84). West Virginia ranks among the
worst states for its health disparities, especially for opioid pain medication misuse and abuse. West
Virginia’s overdose death rate for 2010 (28.9 per 100,000 population) was more than double the national
rate (12.4 per 100,000 population), which has also been climbing over time (86).
Opioid treatment for chronic pain management presents a great challenge in the unique demographic of
Appalachia. Many chronic pain patients experience poor treatment outcomes (2). Chronic and malignant
pain is difficult to manage, partially due to limited efficacy and negative side effects from conventional
medical therapies, but also because some physicians are reluctant to prescribe opioids (6), while others
overprescribe them (85). West Virginia has the third highest national ranking for prescription opioid use
5

in FMS patients (~19.4%) (87); many patients become dependent on opioids, and opioid use and misuse
remain an important topic in West Virginia (86).
Understanding the usage and efficacy of other, safer forms of chronic pain treatment are
necessary, and may include CHAs. CHA use exists in chronic pain patient populations (88-94), and
encompasses a variety of therapeutic modalities not customarily prescribed by medical doctors to treat
chronic pain, such as natural products (e.g., herbs, dietary supplements, etc.) and mind and body practices
(e.g., yoga, meditation, etc.), as well as the practices of traditional healers, Ayurvedic medicine,
Traditional Chinese Medicine, homeopathy, and naturopathy, among other non-mainstream approaches.
Most people using CHA approaches use them along with conventional treatments (90, 95, 96), and
patients often do not disclose the use of CHAs to their physicians (97, 98); the appropriate role for CHAs
in the primary care of chronic pain remains controversial. Physicians disagree with one another and with
their patients about the cost, validity, and effectiveness of individual CHAs (99). CHA use may reflect
greater autonomy among a population of patients who wish to direct their own health care and are less
dependent upon conventional medicine (88), with patients choosing CHAs because of concerns over the
safety of conventional medicine (100).
Given the continuing rise in fatalities due to opioid misuse, expanding treatment options for pain
is a necessary step in reversing the explosion of deaths on a national- and a state-level for WV. A deeper
understanding of the relationship between analgesic CHAs (such as herbs), which may be safer and more
well-tolerated than opioids and current pharmaceutical treatments, and the role of inflammation affected
by those potential treatments, is warranted.

Herbal Medicine – a Complementary Health Approach (CHA)
The Evolving Definition of Complementary and Alternative Medicine (CAM)

More than 30 percent of adults and about 12 percent of children use health care approaches
developed outside of mainstream Western, or conventional, medicine (88). Surveys have yielded differing
conclusions in explaining the increasing popularity of these approaches (88, 89, 101-103). When
describing these approaches, people often use the terms “alternative” (If a non-mainstream practice is used
in place of conventional medicine) and “complementary” (if a non-mainstream practice is used together
with conventional medicine), and these various approaches (called “therapies” or “modalities” in previous
literature) have, until recently, been called “CAM” (Complementary and Alternative Medicine).
However, true alternative medicine is uncommon, as most people who use nonmainstream approaches use
them along with conventional treatments. Therefore, the National Center for Complimentary and
6

Integrative Medicine (NCCIH), a division of the National Institutes of Health (NIH), recently suggested
the use of the umbrella term “Complementary Health Approaches” in discussing practices and products of
non-mainstream origin, and “Integrative Health” when talking about incorporating complementary
approaches into mainstream health care (104). ‘CAM’, therefore, will henceforth be considered
“Complementary Health Approaches” (CHA) in this dissertation. Examples of CHA approaches include
(but are not limited to) acupuncture, aromatherapy, biofeedback, chiropractic care, energy healing, folk
remedies, herbal medicine, homeopathy, hypnosis, imagery and relaxation techniques, lifestyle diet,
massage, megavitamins, naturopathy, Reiki, copper bracelets, and yoga (105, 106).
In Integrative Health and self-prompted use of CHAs, treatments are individualized for each
patient, and when a practitioner is present, treatments may be individualized for each patient at each
session (107). Sufficient anecdotal evidence suggests that many folk cures do produce their anticipated
result (108), warranting additional research regarding the efficacy of these treatments. It is clear that CHA
usage is popular; in 2007, about $14.8 billion was spent on the purchase of non-vitamin, nonmineral,
natural CHA products in the United States (109). According to the 2012 National Health Interview
Survey (NHIS), which included a comprehensive questionnaire regarding the use of CHAs by Americans,
17.7% of American adults reported consuming dietary supplements other than vitamins and minerals in
the past year, making these products the most popular CHA used in the U.S. (104).
Compared with nonusers, CHA users tend to be women, white, middle-aged, of higher income,
and better-educated (90, 106, 110-116). The use of CHA approaches is higher for chronic conditions than
for acute conditions (112, 116), and users are more likely to be wellness-oriented (116, 117), with the
primary use for health promotion (89, 90, 116, 118).

Definition of Herbal Medicine

Herbs (plant-derived products, also known as ‘Botanicals’, ‘Phytotherapies’, ’Phytomedicine’,
and some ‘biologically based therapies’) are sometimes used to affect health status through biological
activity within the body, and are most often sold as dietary supplements. Herbs are part of the broader
CHA group of approaches called ‘Natural Products’, which also include vitamins and minerals (which are
not plant-derived). The use of herbs for potential health benefit is sometimes called ‘Herbal medicine’ and
is part of many ‘Folk Medicine’ traditions indigenous to specific populations around the world.
Herbs are available for use as supplements, tinctures (alcoholic and non-alcoholic extracts), loose herbs
for making teas/infusions/decoctions, and are sometimes prepared as salves or ointments for topical use
(119, 120). Some traditional uses indicate the smoking of herbs for health benefit. However, this
dissertation does not specifically include the smoking of herbs and will avoid specific investigation of the
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herb Marijuana (Cannabis sativa, indica, and ruderalis) in this proposed project, due to pending legality
issues in the U.S. involving its growth, distribution, and use for recreational and health purposes. It is
possible that this omission may result in the under-ascertainment of herbal use prevalence. In this
research project, herbs will be referred to as “herbs”, “herbal supplements”, or “herbal medicine” (in lieu
of “herbal remedies”), depending on the specific aim of the project.
Herbal medicine is also used as a complement to or as a component of other CHA approaches, including
Ayurveda, folk medicine or traditional healing, naturopathy, Traditional Chinese Medicine, and to a lesser
degree, specialized diets such as the macrobiotic diet. However, because existing research does not
commonly discuss herbal use as a component of other CHA modalities, our aims will utilize and focus on
research which relates specifically to the definition set forth by the Center for Disease Control (CDC)
National Center for Health Statistics for ‘Nonvitamin, nonmineral dietary supplements’; specifically, the
latter are defined as herbs or other nonvitamin supplements (including those in pill, capsule, tablet, liquid
or other form) that have been labeled as dietary supplements. Whenever discrimination is possible, we
will limit our analyses to include only plant-based products (the NIH definition of ‘herbs’).
Because of the historical value placed on the sharing of herbal knowledge through ‘Folklore’ and
‘Folk Medicine’ in Appalachia (defined as a tradition of treating sickness by herbs, ethnic foods, prayers,
healing objects, magic and dance ceremonies (121)), these terms will be considered as herbal medicine use
in this project whenever it is clear that herbs were part of a healing regimen, to limit possible
misclassification bias. Plant materials used for making folk medicines include the roots, bark, wood, sap,
and leaves of plants (122).
Many of the top-selling herbs in the US have been subjected to clinical trials in Europe and are
currently recognized as beneficial for a range of health conditions by respected international health
authorities, including the World Health Organization, The European Scientific Cooperative on
Phytomedicine and the German Commission E. (123). However, the vast majority of herbs and their
components have yet to be studied; even among relatively well-researched herbs, specific active
components have yet to be identified, and potential interactions with other constituents of the herb, other
herbs, and pharmaceuticals remain largely unexplored. The US Food and Drug Administration (FDA)
does not regulate herbal products, and frequently, herbal products contain adulterants and manufacturers
make unsubstantiated (and sometimes illegal) claims regarding specific health benefits. However, herbs
remain a popular tool for the self-management of health among many people.

History and Prevalence of Herbal Medicine in the United States & Appalachia
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Although herbal medicines are considered a CHA in the West, herbal medicine remains a primary
source of medicine in many parts of the world, including present day China, India, and many countries in
South America and Africa (123). Since aboriginal times, more than one thousand plants have been used
for medicines in the United States and Canada. Native American exchanges with European settlers were
important contributions to folk medicine (122), and both groups believed that a plant existed for every
malady known to humankind (124). In the 1990s, specifically, Complementary and Alternative Medicine
(‘CAM’, the term used before CHA) gained increasing popularity in the United States (90, 91, 106, 125,
126). The prevalence of adults using herbs increased from 2.5% in 1990 to 12.1% in 1997 (106, 125) in
some of the earliest U.S. prevalence studies. Several groups also reported relatively high rates of herb and
supplement use, including women (125, 127-135), middle aged adults (125, 128, 134), Caucasians (125,
128, 129, 132, 133), Asians (125, 130, 136), and Latinos [106]. One study showed higher herbal
supplement use among minority populations (127).
Because we observed varied prevalence rates for herbal use, we conducted a preliminary
systematic literature review (Appendix C) assessing the herbal use in the United States general
population; our review was restricted to large studies (N≥500) of adults aged at least 18 years and
published between 2001-2012, and we excluded studies assessing specific conditions such as diabetes and
cardiovascular disease, among others. A total of 32 eligible studies were identified for inclusion.
Collectively findings indicated that rates of medicinal herb use averaged 18.1%, ranging from ~5% in a
group of physicians (137) to ~38.5% in a sample of Asian Americans (138). African Americans reported
the lowest rates of herbal use (15.3%), followed by Hispanics (19.4%) and Non-Hispanic Whites (19.9%)
(109, 116, 118, 137-165). Overall mean rates of herbal use were similar to the national prevalence rates
for nonvitamin, nonmineral dietary supplement consumption cited in 2002 (18.9%), 2007 (17.7%), and
2012 (17.7%); together, use of herbs and other supplements remains the most popular complementary
health approach in the U.S (166). Other gaps identified included a botanical use classification as either
too narrow or too broad to enable generalizability of results, in addition to confusing presentation of
results. Commonly cited suggestions for future studies included drug/botanical interactions, further
investigation of the concurrent utilization of other CHAs, and increased understanding of beliefs and
experiences which may act as enabling factors for herbal use.
Appalachia is a mountainous region in the eastern United States spanning southern New York to
northern Mississippi, including all of West Virginia and parts of 12 other states (167). It is one of the
most botanically diverse regions in the world (124); Appalachia’s many micro-habitats are home to some
2,500 plant species, of which some 1,100 have been reported to have medicinal properties (168). As
recent as the 1990s, there was written anecdotal evidence of medicinal plant and home remedy use in the
Appalachian region, particularly among the elderly population (169). These plants have a rich tradition in
oral history and folklore; while some plants are well-known only from older accounts, others have been
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and continue to be used in the preparation of pharmaceuticals. Digging for the herbs Ginseng (also known
as “sangin” or “digging sang”), wild cherry, goldenseal, sassafras (124), and other medicinal herbs was
noted as a general occupation as early as 1886 (170-172), and prior to WWII was a vital part of the local
economy of Southern Appalachia (124); several of these herbs continue to be harvested in WV (Image 1)
(120, 122, 173-178).
The Appalachian region remained the principal primary source of crude drugs (i.e., raw plant
material) (124) until the 1980s (179) and the advent of synthetic drugs (124); Appalachian forests
continue to provide the primary domestic source of wild native plants used in the American drug industry.
Much of the value of the plants harvested and used in the Appalachian region remain largely unknown and
often undocumented. However, much of the oral history of the area is destined to be irretrievably lost to
future generations unless it is collected in the very near future (121, 179). Rates of herbal use in the
Appalachian region have never, to our knowledge, been investigated, with the exception of one study in
2523 older North Carolina adults which reported a prevalence rate of 19.3% (141).
Historically, people living in remote, isolated regions of southeastern KY found it necessary to
formulate their own medicines, cures, and treatments for their self-diagnosed ills because of the scarcity
and inaccessibility of trained physicians, nurses, and hospitals (179). Most families kept a tonic on hand
for whenever someone felt “puny” (sluggish, weak), also known as the folk illness “low blood” (124)
(Figure 1). When engaging in research to assess herbal use, it is important for investigators to be aware of
self-diagnosed health conditions that may be part of folk illness tradition, rather than evidence-based
diagnoses made by physicians. Because herbs were traditionally self-administered, people may continue
to self-diagnose based upon folk illnesses; there has been contemporary practice of several widespread
and culturally significant systems of “traditional” or “folk” medicine in eastern regions of NC and VA
(108), and anecdotal evidence hints at its existence as far south as Alabama and potentially as far north as
West Virginia. A single plant, such as Sarsaparilla or Sassafras, could serve as a health tonic for some of
these folk illnesses, but often several plants were used (124). Qualitative analyses of patient sessions with
herbalists, lay midwives, and “root doctors” (who formed part of a traditional ethnomedical system
utilizing plant roots among African Americans, which in turn, influenced health behaviors among white
and Native Americans in the rural South) in various rural counties in the central Piedmont and eastern NC
from 1978-1991 demonstrated that individuals generally agreed herbal remedies worked effectively to
cure most minor, “natural” ailments, which are a type of folk disorder (Figure 1). Qualitative research on
folk medicine in Appalachia indicates a current revival of herbal medicine usage (Figure 2) (121, 180).
However, aside from a few very limited studies on specific patient populations, distributions, patterns, and
correlates have yet to be determined for herbal use in this particular region.
Physical barriers, as well as social and economic distinctions, have played a role in historical
Appalachian herbal usage. Herbal consumption by Appalachian populations has varied depending on the
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history and place; types of herbs consumed has largely derived from European and American herbal texts
of the nineteenth century, which were likely learned through European and Native American tradition
(179, 181). Herbal medicine appeared to be unevenly distributed in a North Carolina population study,
with one or two practicing herbalists in any given rural community (1978-1991). Herbalists still actively
practicing may treat hundreds or even thousands of people a year (182). Traditional herbalists have many
years of experience in collecting and preparing plants, know the properties of many different varieties and
species, and observe over time the empirical effects of their remedies on different illnesses. Traditional
herbalism, however, is a skill that appears to be dying out as existing practitioners grow older.
Traditional herbalists often understand the “proper” ways to prepare plants, and as their knowledge is lost
with time, the likelihood of negative side effects and toxicity among users may increase (108).
Although the landscape of healthcare has evolved through time, the rurality of the Appalachian
region, particularly in WV, may continue to contribute to the usage of herbal medicine. Isolation from
hospitals, doctors, and pharmacies have, and to some extent, continued to characterize many populations
resident in Appalachia today (122). It is not surprising that people facing these conditions of rurality may
rely on traditional remedies such as herbs, and/or folk practitioners, many of whom are both accessible
and willing to offer advice or treatment on short notice, often in their own homes (182).
Prevalence estimates of CHA use, including herbal use in WV, are largely unknown; a
crosssectional study among primary care clinics from nearly three decades ago (N=170) found that 73% of
patients used one or more folk medicine remedies, which are a CHA including herbs (mean= 4.5
remedies) (183). A more recent cross-sectional study on pregnant WV obstetrics patients (N=578)
showed 45.2% of the participants used herbal medications, with acquisition from a plethora of retailers:
grocery stores (40%), discount stores (21.8%), mail-order catalogs (11.3%), herbalists (7.0%), in-home
sales by friends and fellow church members (4.0%), and pharmacies (3.8%). Two percent of participants
grew and harvested their own herbal medicines (184). In lieu of largely absent prevalence rates for herbal
use in Appalachia, there is anecdotal evidence of Appalachian (185), specifically WV, herbal usage in
anthropological literature (175, 186-190). Within the last 40 years, WV was documented as having an
unusually strong tradition of folk medicine (191).

Herbal Medicine Use for Fibromyalgia Syndrome (FMS) and other Pain Conditions
Pain-related disorders are the most commonly reported conditions for which patients use CHA
approaches (86, 88, 93, 105, 106). A systematic review of the prevalence of CHA use in international
rheumatology patients, specifically FMS patients, indicated about two-thirds of patients who had FMS
were using at least one type of CHA by 1998 (192). Among the mixed study designs, three UK studies
indicated that 20% (N=78) (193, 194) and 35% (N=94) (194, 195) of Rheumatoid Arthritis patients used
11

herbal medicines, while 78% (N=90) (194, 196) of FMS patients used dietary supplements (including the
use of herbal supplements).
Results of a 2002 US national survey suggest that bodily pain, chronic conditions, and functional
impairment are associated with the use of CHAs among midlife and younger adults (156). The same
survey showed 3.3% of those with Arthritis, Gout, Lupus, and FMS used natural products (160). Another
study utilizing the same survey showed that those who worked less than full time were more likely to use
herbs compared with those who worked full time or more (116), which may indicate support for our
hypothesis that people with disabling diseases which keep them from working full time, such as FMS,
have an increased utilization of herbal supplements.
A U.S. study of CHA approaches among primary care patients receiving opioids (N=908) as a
primary treatment method for chronic pain showed that 6.8% used herbs and supplements, and that 44%
had used at least one CHA approach in the past year. CHA utilization was significantly related to age,
female gender, pain severity, income, pain diagnosis of neck and upper back pain, and illicit drug use
(93). Twenty-one percent of FMS cases used opioids, as well as herbs and dietary supplements (which
were not plant-derived) 42.9% (mean = 2.8 per person) of the time, compared to 23% (mean = 2.2 per
person) of the controls in a national case-control study (FMS = 434, Control = 198). Authors found no
evidence of FMS status being associated with any specific herb. This was a moderately strong study, but
limitations included lack of a random sample/significant differences on all demographic variables
between cases and controls, self-reported data, and a low sample size for controls using herbs, severely
limiting the statistical ability to compare herbal use between the two groups. Herbs used most often by
those with FMS were Ginkgo (3.7%), Garlic (3.0%), Ginseng (3.0%), Echinacea (2.5%), Evening
Primrose oil (2.3%), and Valerian (2.3%) (197). Although a number of studies have examined general
herbal use among specific populations, no population studies have asked pain patients about herbs used
specifically for pain. Additionally, whether opioids can be reduced by introducing herbal medications
remains to be studied.
Herbal Medicines used for Pain: a beneficial treatment for Fibromyalgia in Appalachia?

Pain-related disorders are the most commonly reported conditions for which patients use CHAs
(86, 104-106, 198). The history of Willow (Salix spp.) and other salicin-rich plants, which were
precursors to Aspirin, is an example of the role botanicals have played in the management of pain (123).
A meta-analysis of Capsicum (a compound extracted from the fruit of Chili peppers C. frutecens and
others) for the treatment of pain, reported that topical Capsaicin was superior to placebo for the treatment
of chronic pain due to neuropathic and musculoskeletal disorders (with trials of moderate to high quality);
12

the FDA has approved Capsaicin as an over-the-counter topical cream (199). There is a great deal of
historical evidence which reveals extensive use of botanicals for the relief of pain, and plants with
analgesic, anti-inflammatory and/or anti-spasmodic activities continue to be used (123). However, there is
a need for research regarding the use and efficacy of herbs that may benefit those with FMS and its
comorbidities, especially in the Appalachian region, where opioid prescription drug misuse and abuse
have skyrocketed, and safer, effective treatments aside from other existing pharmacological therapies for
those with FMS are clearly needed.
Existing Cochrane reviews and meta-analyses regarding herbal efficacy for chronic pain
syndromes often co-occurring with or similar to FMS (Appendix A) include Passiflora (200), Valerian
(201), and Kava (202) for anxiety disorders, compounds Qishe and Extractum Nucis Vomicae for chronic
neck pain (203), Feverfew for preventing migraine (204-206), St. John's Wort for major depression (207),
and mixed herbal medicine(s) for low back pain (208), irritable bowel syndrome (209), and rheumatoid
arthritis (210) (unless otherwise noted, Latin botanical names are omitted in this paper when source
identification is unclear; otherwise, they are denoted following their common name). Of these, sufficient
data are available only to evaluate Kava and St. John’s Wort, with Kava demonstrating a significant
treatment effect for anxiety (202), and St. John’s Wort demonstrating effects on depressive symptoms
superior to placebo and comparable to standard antidepressant treatments (207).
A practicing Canadian herbalist specializing in the treatment of FMS recommends groups of herbs
targeting various aspects of FMS, including muscle stiffness and pain, a lack of energy, pain and lack of
sleep, joint pain and inflammation, depression and digestive disturbance, and “brain fog” impaired
memory. Over 37 herbs are recommended (211), many of which have also been cited in qualitative
Appalachian herbal literature for the treatment of symptoms that overlap with FMS symptoms (FMS is not
cited in historical Appalachian herbal literature since it is a relatively new diagnosis, although the related,
older term “rheumatism” is used extensively) (Appendix B).
A qualitative study of rheumatism treatments used by a prominent Appalachian herbalist (first
located in Southern Appalachia, followed by residency in West Virginia) identified twenty-three different
plants used for rheumatism (212). Similar findings have been reported for various other illnesses, both in
contemporary field studies and in older regional collections of herbal texts (213-215). A literature review
of qualitative herbal literature (Appendix B) cites the anecdotal use of 101 herbs in the Appalachian
region for pain relief (121, 179, 180, 216-219) , rheumatism (121, 169, 178-180, 182, 191, 216-218), and
arthritis (121, 169, 178, 179, 191, 212, 217, 218), while 12 were used for inflammatory issues (121, 179,
180, 217, 218), 3 for alleviation of sleep troubles (121, 169, 179), and 4 for headache (179, 180, 217). It
is not clear if these herbs continue to be used for these conditions in Appalachia.
Herbs that have been used historically in the Appalachian region, and for which there is some
evidence of efficacy include: Willow (Salix sp.) for pain (220-223) and headache (224); Phytolodor herbal
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extract blend, which includes Ash bark (although a different Fraxinus species than that used in
Appalachia) for musculoskeletal issues (123); Black Cohosh (Cimicifuga racemosa) and chamomile
(Chamomilla recutita) for sleep (225-227); Hops (Humulus lupulus) for sleep (223, 228) and analgesia
(223, 229, 230); Evening Primrose (Oenothera biennis) for rheumatoid arthritis (231); Ginger
(Zingiber officinale ) for rheumatic pain and musculoskeletal disorders (223, 232, 233); and
Peppermint (Mentha piperita) for headache (223, 234, 235).
Herbs for which some evidence of efficacy for FMS symptoms or related conditions exist, but for
which no usage in the Appalachian region has been cited, include Chili pepper (C. frutecens and others),
Cat’s Claw (Uncaria tomentosa), Devil’s Claw (Harpagophytum procubens), Feverfew (Tanacetum
parthenium), St. John’s Wort (Hypericum perforatum), and Valerian (Valeriana officinalis) (123).
Despite the apparent promise of several herbs for relief of pain and related symptoms, there are few
population-based studies, high-quality trials, systematic reviews, and meta-analyses regarding the use and
efficacy of herbs that may benefit those with FMS and associated comorbidities. Therefore, further
research on herbs as a potential treatment for FMS is needed, specifically in the Appalachian region where
opioid use is epidemic.

Relationship of Herbal Medicines, Inflammation, and Chronic Pain

A common underlying mechanism in the generation and promotion of chronic pain is the presence
of inflammation at the site of the damaged or affected tissue (31); inflammatory responses in the
peripheral and central nervous systems may also play key roles in the etiology of chronic pain (32). When
the synthesis of prostaglandins is inhibited, inflammation may result, ultimately leading to pain.
Chronic inflammation is characterized by a proliferation of fibroblasts and formation of blood vessels
(angiogenesis), as well as an influx of chronic inflammatory cells, namely granulocytes (neutrophils,
eosinophils, and basophils), lymphocytes, plasma cells and macrophages (236). When macrophages
become activated, they produce cytokines and chemokines, some of which, in turn promote inflammation.
C-reactive protein (CRP), part of an acute response to underlying infection or tissue injury (237-239), is
now also believed to be a marker of chronic systemic inflammation (240). Because CRP levels have
neither seasonal nor diurnal variations and are not influenced by food intake (237-239), CRP assay is
commonly included as part of the diagnostic laboratory workup for many proinflammatory diseases,
including FMS.
Herbs with evidence of anti-inflammatory action (in vitro and in vivo) which have historically
been used in the Appalachian region (although exact rates of use are unknown) include Chamomile
(Chamomilla recutita) (225-227), Dandelion (Taraxacum officinale) (223, 241-243), Common Elder
(Sambucus canadensis) (223, 241, 244, 245), Eucalyptus (E. globulus) (223, 246), Hops (Humulus
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lupulus) (223, 243, 247), Mint (243), Watercress (243), Licorice (Glycyrrhiza glabra) (223, 248), Witch
Hazel (Hamamelis virginiana) (223, 249), Skullcap (Scutellaria baicalensis) (250-252), Willow (Salix
spp.) (223, 253, 254), and selected components of Skullcap (Scutellaria baicalensis) (255), Willow (Salix
spp.) (256), Ginger (Zingiber officinale) (233, 257-261), Ginseng (Panax quinquefolia) (262, 263), and
Horse Chestnut (Aesculus hippocastanum) (223, 264, 265). Leukocytes, which are associated with
cytokine production in both immune response and inflammatory processes, are mobilized by the herb
Echinacea (Echinacea spp.) as well (223, 266-268); moreover, in a 15-day experimental study in a female
rat model of arthritis, CRP values decreased significantly in those administered Echinacea, compared to
untreated animals (269). Oroxylin A, a natural flavonoid from Skullcap (Scutellaria baicalensis),
significantly attenuated expression of inflammatory mediators (i.e., iNOS and COX-2) and cytokines (i.e.,
TNF-alpha, IL-1beta, and IL-6), in an estrogen receptor-dependent manner, suggesting anti-inflammatory
effects (270).
Herbs for which some evidence of efficacy of anti-inflammatory action, but for which current
prevalence rates in the Appalachian region have, to our knowledge, never been measured, include the
ethanolic extract of Cat’s Claw (Uncaria tomentosa) (123), Thunder God Vine (Tripterygium wilfordii)
(123, 271), Stevia (243), Cinnamon (243) , Turmeric (243), Mate (243), Boswellia (Boswellia serrata)
(123), and Lavender (272), among others.
The relationship between many herbs and inflammatory markers may also be mediated in part by
the elucidation of related antioxidant activity. Oxidative damage to membrane lipids, DNA, proteins, and
lipoproteins, increases risk for several autoimmune and inflammatory diseases (273). Herbs are a rich
source of polyphenol compounds (274) and their antioxidant activities are several times higher than those
of vegetables (275) and fruits (276). Antioxidants contained in herbs may also suppress oxidative stress
and related damage in the gastrointestinal tract before being absorbed (273), and thus, could modulate the
level of oxidative stress by enhancing anti-inflammatory capacity (277, 278).
Because certain inflammatory cytokines are related to the development of contralateral
hyperalgesia (an extreme, exaggerated pain response) and allodynia (central pain sensitization following
painful, often repetitive stimulation) (33), which FMS patients experience (34), and because the
modulation of inflammation and oxidative stress by herbs can be beneficial (277), the possible links
between systemic inflammation and FMS, as well as herbal use and FMS, clearly warrant further
investigation.
Challenges in Herbal Medicine Research
Methodological issues specific to research on herbal medicines include misclassification,
ethnocentric, and recall biases. Areas in need of further exploration include the dialogue between
physicians and patients regarding herbal use, safety, and efficacy; specifically, patient under-reporting of
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herbal use to health providers should be examined. Studies utilizing biobehavioral approaches may help
bridge this gap, and aid in understanding/clarifying motivating factors in an individual’s decision to use
herbal medicine. Rigorous efficacy research on herbs remains sparse. Both rigorous population-based
epidemiologic studies and high quality clinical trials are needed; moreover, also needed is the
dissemination of evidence-based information that allows for clear interpretation regarding safety, efficacy,
and limitations.
The most universal and basic definition of an herb is ‘plant-derived material’. Herbs go by many
names, often creating confusion among researchers and the public, and can lead experienced researchers
to overlook research on plants of interest. Additionally, most available research is only available in the
Chinese language (279), which may result in an ethnocentric bias in herbs considered safe and efficacious
among differing populations.
Misclassification bias often exists, even in high-quality meta-analyses, due to the differences in
constituents between the same herbs grown in different locations, prepared or processed under differing
conditions, plant parts used, dose, and even plant variety. Therefore, the “pooling” of different products
to reach conclusions about the efficacy of a single herb is often difficult, if not impossible (123).
Additional misclassification bias exists due to the “lumping” of other biologically-based therapies with
herbs, such as vitamin or minerals, homeopathic supplements, fish oil supplements, and
prebiotics/probiotics.
In many traditional medical systems, combination herbal formulae are more the rule than the
exception. Many herbal practitioners individualize formulations and hold that combinations of plants may
work together in a synergistic fashion, although this area has not been the subject of much scientific
research (123). CHA users frequently use “bundles” of approaches rather than just one therapy in
isolation (107), which can result in potential misclassification bias among CHA users who participate in
poorly-designed observational studies, and clinical trials where exclusion criteria do not consider
polypharmacy of herbal products and other CHAs.
A regrettable aspect of most folk medicine sources is that they provide scant information on
dosage amount and intake regimen; dosing is often based on the number three or nine (times per day), and
dosage directions may be vague (e.g., stipulating only “a potent” or “a right smart amount” of herb) (124).
Recall bias in reporting specific herbs used may exist because of the more informal interactions which
occur when herbalist practitioners meet with patients, compared to those which occur in clinical settings
(182), where documenting procedures are more standardized. Additionally, preparation methods of herbs
can vary greatly, and are typically not described in literature focused on herbal preparations that are not
herbal supplements – and even for supplements, preparation and verification methods are not consistently
described.
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Not all physicians inquire about CHA use among their patients (137). A UK systematic review
indicated that, although patients believed CHAs to be effective, their doctors indicated skepticism about
the usefulness of CHA in rheumatology (192, 194). Commonly, there is miscommunication between
physicians and patients about CHA approaches for which potential safety concerns can arise. Patient care
may be improved if this miscommunication is addressed. This communication gap arises from differences
in cultures and belief systems: thus it requires a blend of intellectual flexibility and nonjudgmental
openness as it enables the physician to weave the patient’s “explanatory model”, which includes CHA use
as well as the application of their own understanding of geographically relevant folk illnesses [Figure 1]),
into the fabric of care (108).
There is a clear need for the utilization of behavioral theories in measuring factors related to
herbal use, as this can help to guide clinical practice. The reasoning behind current national trends in
herbal use are unclear; trends may be due to factors other than individuals’ willingness to follow
traditional remedies passed down through families or communities, often with accompanying
magicoreligious healing practices/folk healing. It is plausible that changes in environmental factors,
communication within families and communities, and in the health care system overall may have
contributed to an overall decline in the identification, preparation, and usage of traditional herbs in the
U.S. and in the Appalachian region; there has been variation in herbal trends since the large, population
studies of the 1990s (90, 106, 125, 280). Conversely, these or factors may have increased the usage of
already-prepared herbs in supplement form, which are often readily available from multiple sources (e.g.
Walmart) and promoted through various media (e.g. Dr. Oz television show, which attracts ~3.5 million
daily television viewers)(281). Additionally, it is important to note “no individual ever completely
replicates a single tradition” (108), which adds further complexity in understanding the reasoning for
changes in herbal use trends. In our preliminary systematic review on the prevalence of herbal use among
the general population in the US (Appendix C) (N=32 studies) (109, 116, 118, 137-165), only 7 studies
(~22%) documented using social, behavioral, or economic theories/models as a guide (116, 145, 150,
152, 153, 156, 163). These theoretical approaches included the Anderson-Newman Behavioral Model of
Health Services Utilization, the Socio-Behavioral Model of Healthcare Utilization, Grossman’s model of
Health Capital Investment, and Leventhal’s Self-Regulatory Model. By using behavioral theories such as
the Transtheoretical model and others, researchers and clinicians can begin to understand some of the
drivers for changes in out-of-pocket healthcare costs associated with CHAs, and may alter the dialogue
between patients and physicians to enable better treatment and ongoing, effective care for poorly managed
chronic pain syndromes such as FMS.
Lastly, the proof required by participants in folk-medical tradition is very different from that
demanded by medical researchers. For members of the former group, the efficacy of a home remedy, an
herbal cure, or a magical procedure can be verified through anecdotal or experiential evidence alone (182).
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Some treatments are presumed to depend on the unique characteristics of the healer and on features of the
healer-patient relationship (107). However, scientific research sometimes corroborates folk belief, as in
the case of foxglove (Digitalis purpurea), which was prescribed as a heart tonic by community herbalists
long before pharmacological studies confirmed its cardiotonic properties (182). There are many
differences in the information flow pathways of efficacy research to the ultimate use of an herbal product
versus a prescription (Rx) drug (Figure 3). The most obvious differences are: 1) Herbal use can occur
even in the face of no or minimal scientific evidence. This differs from patient and clinician expectations
regarding efficacy, and the ordered flow in prescription drug use, due to all constituents/ingredients
known in the beginning of the Rx life cycle; 2) Herbal use often originates from anecdotal/qualitative
literature. Therefore, the safety/efficacy is usually not known vs. a known safety/efficacy profile for Rx
drugs; 3) Social media, social networks, and industry largely control the flow of information regarding
evidence for herbal product use. Therefore, all information may be considered equally weighted evidence
of efficacy among many herbal consumers. During a person’s lifetime interaction with an herb, their
perceived safety and efficacy of the herb may change depending on which source is recommending the
herbal product. Although this may also occur with Rx drugs, it may be less likely due to more rigorous
efficacy research requirements from the FDA and other regulatory bodies; 4) Doctors and pharmacists act
as gatekeepers for Rx drug access, whereas there is no gatekeeper for herbal product access, since herbs
are unregulated and potential users often have multiple avenues of access (i.e. pharmacies, health food
stores, etc.). The current focus of herbal research is largely to identify constituents of herbs and their roles
in various physiological pathways (282); thus, there may be a long waiting period before rigorous clinical
research can verify the safety and efficacy of a wider variety of herbs, emphasizing the importance of
conducting primary- and secondary-data analysis. When RCTs cannot be conducted, however, or when
the results of RCTs may not be generalizable to the real world of CHA practice, it is necessary to use
other study designs (107). Based on this, and the differences noted in the efficacy research information
flow pathways of Rx drugs vs. herbs (Figure 3), epidemiological studies can play an important role for
consumers of herbal products. For these reasons, researchers in this field must pay special attention to
providing clear interpretations of their results for the public.

Summary
Complementary Health Approaches (CHAs) are frequently utilized to treat chronic pain
syndromes, however, rigorous observational and clinical studies of herbal medicine are largely lacking.
Additionally, no epidemiological studies have examined herbal use in Appalachian pain populations,
where opioid misuse and abuse is epidemic. There is limited evidence suggesting those with
Fibromyalgia Syndrome (FMS), a chronic pain syndrome with unknown etiology for which opioids are
often prescribed, frequently use herbal medicine to help with FMS symptoms. Further, the Appalachian
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region, particularly West Virginia, has a rich history of anecdotal herbal medicine use for many symptoms
overlapping with those of FMS. Understanding the correlates of herbal use in this population (including
pain level as a potential motivator for herbal use) as well as patterns of herbal medicine among pain
populations over time, will provide a window into patient health behaviors physicians may not be aware
of. Importantly, these studies will also lay the foundation for efficacy studies examining interactions and
synergistic effects of herbal medicine with opioids and other analgesic drugs. Further elucidation of the
relationship between inflammation and FMS is also necessary due to the inconsistency of existing studies;
understanding the potential role of inflammation in FMS is important since the presence of inflammation
is intrinsically tied to chronic pain, and many herbs are used for their antiinflammatory and analgesic
effects (Conceptual Model for this dissertation found in Figure 4).
Self-management of chronic pain is in the current translational focus of the National Institutes of
Health (NIH); additionally, the NIH Pain Consortium has stated that the understanding and treatment of
pain remains incomplete, thus, research with a theoretical underpinning is needed to determine the extent
for which specific CHAs, including herbs, are used in pain populations, specifically, FMS. Further
elucidation of the relationship between pain and inflammation is also essential. This research is critical,
since pain is poorly handled by current treatment methods.

Rationale
1)

Chronic pain management for FMS by conventional treatments is often

inadequate, perhaps contributing to the elevated use of CHAs such as herbal medicine
among chronic pain patients;
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2)

While the use of herbs, like certain other CHAs, is likely high among those with chronic pain,

little is known regarding herb use in specific chronic pain populations, including those who suffer from
FMS; 3) Increased understanding of the patterns, correlates, and determinants of herbal and other CHA
use is particularly important in chronic pain populations, given they are also likely to be on
pharmacological treatments, including opioids, with the potential for interaction and/or abuse;
4)

Appalachian adults, who reside in areas with some of the highest rates of opioid overdose

deaths in the US, may be more likely to consume herbs for health benefit, given their rich traditions of
herbal harvesting and consumption; and,
5)

Increased understanding of herbal medicine and other CHA use in this population may aid in

identifying new and potentially safer treatments for pain management, and help elucidate underlying
mechanisms.

Specific Aim 1
Investigate if elevated blood serum levels of pro-inflammatory C-reactive protein (CRP) are
associated with Fibromyalgia Syndrome (controlling for potential health factors, demographic
variables, and lifestyle factors).
Objective 1.1. Determine the association between CRP and FMS diagnosis.
Hypothesis 1.1. Those with a FMS will have significantly elevated blood serum levels of CRP
compared to those without FMS.

Specific Aim 2
To examine, in two nationally representative samples (2007 and 2012), potential associations
between herbal supplement use and FMS diagnosis (controlling for potential health factors,
demographic variables, and lifestyle factors) and potential changes in patterns of herbal use in this
population over time.
Objective 2.1. Determine if those with a diagnosis of FMS were more likely to use herbal
supplements than those without FMS in 2007 and 2012.
Hypotheses 2.1. Those with a FMS diagnosis will be more likely to use herbal supplements than
those without fibromyalgia syndrome in both 2007 and 2012.
Objective 2.2. Determine if the prevalence of herbal supplement use among those with FMS
diagnosis changed between 2007 and 2012.
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Hypothesis 2.2. Prevalence rates for herbal supplement use will increase over time among those
with FMS.

Specific Aim 3
Using a newly developed pain survey instrument, explore the patterns and correlates of herbal
medicine use in a sample of WV pain patients, including potential variation by pain status.
Objective 3.1. Assess potential correlates of herbal medicine and other CHAs used in northern West
Virginia (WV) pain patients, through the use of our recently established and pilot-tested pain survey
utilizing a theoretically-guided novel CHA/herbal medicine measurement tool
Hypothesis 3.1. Herbal medicine used for pain in Northern WV will be significantly associated with
a variety of demographic, lifestyle, and health factors, including the use of other complementary
health approaches and many health conditions.
Objective 3.2. Provide a list of patient-reported herbal identification, with accompanying
frequencies
Hypothesis 3.2. Northern WV pain patients will report a variety of herbs used for pain management

The three specific aims/studies listed above correspond to chapters two, three, and four. Chapter
5 presents a summary of key findings of these studies, strengths, limitations, potential public health
implications as well as potential direction and recommendations for future research.
To our knowledge, no research has investigated inflammation as a potential mediator between
herbal use and chronic pain, nor characterized varying levels of pain as a motivator for herbal medicine
use. Additionally, no research (to our knowledge) has attempted to quantify the herbs potentially used in
Appalachian folk medicine for pain
The Institute of Medicine stresses the importance of increased research into the translation of
effective treatments into practice and into the occurrence and cost of pain (6). Each aim of this
dissertation will use cross-sectional data to enhance our understanding of the prevalence, patterns, and
correlates of the herbal medicine use among those with chronic pain. This information will help inform
practitioners working with chronic pain populations, will lay the groundwork for additional exploration
regarding the role of inflammation in chronic pain, identify new and potentially safer treatments for pain
management, and may form the foundation for larger survey studies, future prospective studies, and
clinical trials.
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CHAPTER 2: The association of Fibromyalgia to serum C-reactive protein in a large
Appalachian population

Introduction

Chronic pain, defined as ongoing or recurrent pain that extends beyond the usual course of acute illness
or injury for at least three to six months, is debilitating and costly. Over 20% of adults experience chronic
pain at some point in their lives (3). Fibromyalgia syndrome (FMS) is a rheumatologic chronic pain
syndrome affecting approximately 0.5-5% of populations in developed countries (7), including 1.75% of
those in the U.S. (8). FMS is characterized by a constellation of somatic symptoms that are typically
present in addition to widespread pain (e.g., fatigue, sleep disturbance, memory, and mood problems), for
which no clear cause can be found (9). FMS is typically accompanied by morning stiffness, and
sensitivity to loud noises, bright lights, and temperature extremes; women with FMS often report painful
menstrual periods (13). Although FMS affects both sexes and people of all ages, the majority (80-90%)
have been Caucasian (13, 14) middle-aged women (13). Family members of FMS patients are at a higher
risk for FMS (15); the cause is unknown.
While the etiology of FMS remains poorly understood, the widespread pain of FMS is thought to
reflect abnormal central nervous system sensory information processing, with altered function in pain
pathways and neuroendocrine disturbance (9); Inflammatory processes may also play a significant role in
the pathogenesis of FMS (283). Although several MicroRNAs have been associated with FMS and
symptom severity (19), diagnosis of FMS remains challenging, and there are currently no definitive
diagnostic laboratory tests for the disease (18).
C-reactive protein (CRP), previously considered a biomarker of underlying infection or tissue
injury (237), is now also believed to reflect chronic systemic inflammation (240). CRP is considered a
reliable proinflammatory biomarker (237) and is often included as part of the diagnostic laboratory
workup for many rheumatological conditions (237). While CRP is often included in the diagnostic
workup for FMS, the relationship of CRP to FMS has not been clearly established.
Inflammation, as a characteristic reaction of tissues to injury or disease marked by physical
swelling, redness, heat, and pain upon clinical examination, is not a classical symptom of FMS (18).
Inflammatory cytokines promote the development of contralateral hyperalgesia (an extreme, exaggerated
reaction to pain) and allodynia (central pain sensitization following painful, often repetitive stimulation)
(33). FMS is typically characterized by both (34), and most (35-49), but not all recent studies (43, 50)
have suggested a possible link between systemic inflammation and FMS. Of these, five studies measured
CRP (44, 48, 49, 51, 284); four suggested a positive association between CRP and FMS (44, 48, 49, 284).
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However, to date, only one large, cross-sectional, population-based study has examined the association of
CRP to FMS (48). The study excluded women, and combined FMS with other pain syndromes, rendering
assessment of the specific relationship between CRP and FMS difficult.
Moreover, to our knowledge, no studies to date examining the association of CRP to FMS have
investigated the potential mediating effects of sleep or mood disturbance, factors linked to both elevated
CRP levels and FMS (285-288). Few have assessed the influence of elevated BMI (287,
289),comorbidities, and other correlates (290). This large, population-based study will fill the gaps in our
understanding of the potential influence(s) of mood, sleep, BMI, and comorbid conditions on the
relationship between CRP and FMS.
In this study, we investigated the relation of serum CRP levels to FMS in a large population of
Appalachian adults. We hypothesized that CRP serum levels would be significantly and positively
associated with diagnosed FMS after adjustment for potential confounding factors.

Methods

Data Source
This cross-sectional study used data from the C8 Health Project, which was conducted as part of
the settlement of a class-action lawsuit stemming from drinking water contamination by
Perfluorooctanoic Acid (PFOA) released from the DuPont Washington Works Plant near Parkersburg,
WV, USA (291). Data collection was conducted in 2005-2006 on individuals living or working in 6
PFOA-contaminated public water districts in West Virginia (WV) and Ohio (including those exposed to
contaminated private-well drinking water) since 1951; a total of 69,030 individuals participated in the
study, including 81% of eligible adults (291). Project data collection was administered by an independent
company, Brookmar, Inc. (Parkersburg, WV), and was conducted under the authority and supervision of
the Wood County, WV, Circuit Court. Participants completed a comprehensive health questionnaire and
volunteered a blood sample after completing individual consent forms for both. Demographic data and
health survey completion were verified by trained project staff (291). Project procedures, blood
processing and assay methods, along with quality-assurance measures, have been described in detail
elsewhere (291). Briefly, following collection of each blood sample, serum was separated from red blood
cells into single-use aliquots by centrifusion, and was refrigerated at individual data collection sites until
daily pickup from a large, independent, accredited clinical diagnostic laboratory (LabCorp, Inc.,
Burlington, NC, USA). Samples were transported to a regional processing center (LabCorp, Inc.,
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Columbus, OH) where they underwent analysis by latex immunoturbidimetry on a COBAS Integra 800
(Roche, Germany). The West Virginia University (WVU) IRB permitted access to the de-identified data
by WVU investigators. Demographic, lifestyle, and health characteristics were determined via self-report;
diagnoses of certain disorders, including diabetes and cardiovascular diseases, were further verified via
chart review.

Study Population
Our analysis excluded participants who were missing data on age or <18 years of age (n= 12471,
18.1%), pregnant (n = 640, 1.1%); those reporting a cancer diagnosis and receiving treatment for
diagnosed cancer other than non-melanoma skin cancer (n = 437, 0.77%) to eliminate potential bias
introduced by varied CRP levels as a result of chemotherapy treatment; those with service-related
disabilities (n= 710, 1.3%); and those who did not complete both the survey and blood work (n= 468,
0.83%). Participants with extreme body mass index (BMI) values (<10.5 and >60.0) were also excluded
to eliminate potential information bias (n= 94, 0.17%). Further exclusion of persons with missing data on
CRP and FMS (n = 40, 0.002%) and other covariates of interest (n = 1673, 3.1%), with the exception of
covariates for which missing data on >10% of participants occurred (for which a ‘missing’ category was
included in analysis), yielded a final study sample of 52,535, including 51,410 FMS-free controls and
1,125 adults with FMS (Figure 1).

Variables
Outcome Variable. Our primary, dichotomous outcome variable was FMS diagnosis, which was
ascertained via self-report response to the question “Have you ever been diagnosed with Fibromyalgia?”
Exposure Variable. Our primary exposure variable was serum level of inflammatory marker CRP
(mg/L). C8 Health Project coordinators recoded CRP values below the level of detection to 50% of the
lowest level (i.e., “<0.3”→0.15). Likewise, values above the level of detection were recoded to 50%
above the maximum level.
Covariates. In addition to age, gender, race, education, employment, marital status, income, alcohol or
tobacco use, and exercise program status, comorbid conditions were also selected a priori as covariates if
known or suspected to be associated with FMS and/or CRP. These included BMI (21), autoimmune
conditions (22), osteoarthritis (23), kidney (24), respiratory (25), cardiovascular (24), liver (26), and
endocrine (24) disease, diabetes (27), severe allergies (24) and sinus disease (28), stomach conditions (24,
26), and headache (29). PFOA serum level and reproductive factors (292) were also examined as
covariates.
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Potential mediating and modifying factors. Potential mediating and modifying factors included fatigue,
sleep impairment (26), mood disturbance (24, 26, 286), age (13), gender (13), obesity (289), tobacco use
(293), statin use (294), and reproductive factors (292).

Statistical Analysis
We conducted complete-case analyses using SAS 9.4 (Cary, NC, USA). Logistic regression
analyses were used to evaluate the independent association of CRP level to FMS status, and to assess the
influence of potential confounding, mediating, and modifying factors. The primary explanatory variable
of interest, CRP, was analyzed as a continuous and categorical variable (study population quartiles, with
the lowest percentile group used as the referent). Linear trends for CRP quartiles were assessed using
polynomial contrasts. Differences between participants missing any data were assessed using logistic
regression. Cox-Snell R2 values measured the predictive power of models. All p-values shown are
twosided.
All demographic characteristics, in addition to lifestyle factors significantly differing by FMS,
were controlled for in multivariate models. BMI was categorized using the National Institutes of Health
clinical classifications (scores of <25=‘Underweight or Normal weight’; 25 – 29.9=‘Overweight’; 30 –
34.9=‘Obese Class 1’; and, 35+=‘Obese Classes 2/3’) (295).
We evaluated the influence of both specific comorbid conditions and total number of comorbid
conditions on the relation of CRP to FMS. A comorbidity index was created based on number of chronic
comorbid conditions reported; these included: autoimmune disorders (defined as having any diagnoses of
immune disease, lupus, or rheumatoid arthritis), osteoarthritis, allergies or frequent sinusitis, kidney
disease, respiratory conditions (asthma, emphysema, chronic obstructive pulmonary disorder, bronchitis),
heart disease, liver disease, endocrine disorders (thyroid, Addison’s, or Cushing’s disease), diabetes, or
frequent headaches. This index was evaluated as both a continuous and categorical variable (‘none’, ‘1
comorbidity’, 2 comorbidities’, and ‘3+ comorbidities’).
We assessed potential mediating influences of sleep impairment and mood disturbance. A
composite sleep quality variable, with higher scores indicating poorer sleep quality, was derived from
responses to individual questions regarding the frequency of short sleep, fitful sleep, insomnia, and/or
daytime somnolence (scored as follows: 3=’frequently’, 2=’sometimes’, 1=’rarely’, and 0 =’never’, for
each). Mood disturbance was also assessed as a composite variable from responses to four individual
questions, with higher scores indicating frequent mood swings, irritability, fatigue, and/or inability to
concentrate (where 3=’frequently’, 2=’sometimes’, 1=’rarely’, and 0 =’never’).
Additionally, we assessed the potential modifying influence of age (<45 vs. >45 years), tobacco
use (‘current’/‘not currently using tobacco’), gender, obesity (BMI<30 vs. ≥30) current menstruation
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(yes/no), menopausal status (peri- or post-menopausal/premenopausal), statin use (yes/no), and sleep
impairment and mood disturbance (scores of <6 vs.>6, respectively) on the association between CRP and
FMS.
We also conducted separate ancillary analyses adjusting for statin use (yes/no), PFOA serum
level (ng/mL, evaluated as quartiles), and reproductive characteristics (women only) to determine the
potential confounding influence of these factors on any observed association between CRP and FMS.
Reproductive factors assessed included menopausal status (‘pre-menopausal,’ ‘peri-or post-menopausal,’
or ‘unsure’), parity (number of pregnancies), and age at menarche (‘16+ years of age’/‘other age or
unsure’).
The first regression model assessed the crude association of CRP levels to reported FMS
diagnosis. The second model was adjusted for demographic and lifestyle covariates, while additional
models adjusted for BMI and comorbid conditions, as well as sleep and mood disturbance (separately and
combined, respectively). We conducted additional analyses to evaluate the potential confounding
influence of statin use, PFOA serum level, and (in female participants) reproductive history (i.e.,
menopausal status, age at menarche, and parity).
The potential mediating effects of BMI and comorbid conditions, as well as sleep impairment and
mood disturbance were examined using separate logistic regression models. We also conducted ancillary
analyses excluding autoimmune disorders. To evaluate the potential modifying effects of age, smoking,
gender, obesity, current menstruation, menopausal status, statin use, sleep impairment, and mood
disturbance, we conducted multivariable analyses; interactions were assessed by including the
corresponding multiplicative-interaction term in the statistical models.

Results

Relative to participants with complete data, those with missing data on key covariates had a
higher number of comorbidities and were more likely to be poorly educated or to be retired, disabled, or
unemployed (p’s ≤.002), but did not differ in other factors. Demographic and lifestyle characteristics are
displayed in Table 1. Study participants were predominantly white (97.2%), female (52.4%), and married
or cohabitating (68.9%). Participant age ranged from 18.0 to 105.2 years, averaging 45.3 (SD = 16.1)
years. Most participants were employed or students (64.1%) and overweight (69.0% BMI>25, mean BMI
= 28.5, SD = 6.3), while nearly half did not currently consume alcohol (51.1%) and never smoked
(43.5%). CRP serum levels varied from 0.15 to 250.6 (mean CRP level = 3.79, SD = 7.2) mg/L.
FMS was present in 2.1% of the study population (n = 1125). After adjustment for demographic
and lifestyle factors, the odds of FMS increased 2% for every year-unit increase in age (Adjusted odds
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ratio (AOR) = 1.02, 95% confidence interval (CI): 1.02, 1.03 (Table 1)), with a significantly higher mean
age among FMS cases (M = 51.1, SD = 11.6) compared to controls (M = 45.1, SD = 16.2). Those aged
45-64 years were 8.3 times more likely (AOR = 8.28, CI 4.91, 13.95) than those in the age group 18-24
years to have FMS. Those with FMS were nearly 11 times more likely to be female (AOR = 10.68, CI
8.53, 13.37). Participants who were employed or students were less likely to have FMS than all others, as
were those with <12th grade education, compared to those with higher educational attainment. Relative to
participants who were married or cohabitating, those who were single were almost 40% less likely to
report a diagnosis of FMS (AOR = 0.63, CI 0.47, 0.84). Participants who reported current consumption of
alcohol were slightly less likely to report a diagnosis of FMS (35.8% vs. 49.2%, respectively; AOR =
0.86, CI 0.75, 0.98), and women who had experienced menopause were about 80% more likely to have an
FMS diagnosis compared to pre-menopausal women (AOR = 1.82, CI 1.49, 2.21).
Health characteristics of the study population are detailed in Table 2. Mean BMI was
significantly higher among FMS cases (M = 30.47, SD = 7.2) than controls (M = 28.49, SD = 6.3), and
was significantly and positively associated with FMS after adjustment for demographic and lifestyle
factors (AOR per unit BMI increase= 1.02, CI 1.01, 1.03). Relative to those with a BMI <25, participants
who were obese were significantly more likely to have FMS (AOR = 1.24, CI 1.02, 1.49; and, AOR =
1.43, CI 1.18, 1.74, for BMI 30-35 and BMI >35, respectively). There was a 60% increase in FMS
diagnosis for each additional comorbidity (AOR = 1.60, CI 1.54, 1.67 (Table 2); participants reporting a
diagnosis of 3 or more comorbidities were 10.5 times more likely to have FMS (AOR = 10.46, CI 7.90,
13.84) compared to those with no comorbidities. FMS was likewise strongly and positively associated
with most chronic conditions evaluated, including in order of decreasing magnitude osteoarthritis (AOR =
3.86, CI 3.34, 4.45), autoimmune disease (AOR = 3.43, CI 2.89, 4.06), allergies/chronic sinusitis (AOR =
2.91, CI 2.51, 3.38), frequent headaches (AOR = 2.03, CI 1.78, 2.31), and kidney (AOR = 1.72, CI 1.47,
2.01), respiratory (AOR = 1.89, CI 1.64, 2.17), endocrine (AOR = 1.82, CI 1.57, 2.12), and liver (AOR =
1.51, CI 1.06, 2.16) diseases.
FMS cases reported higher sleep (M = 7.3, SD = 3.3 vs. M = 3.9, SD = 3.5) and mood disturbance
scores (M = 7.3, SD = 3.4 vs. M = 4.5, SD = 3.7) than did controls (Table 2). After adjustment for
demographic and lifestyle factors, FMS remained strongly and positively related to scores for both sleep
(AOR = 1.23, CI 1.21, 1.25), and mood disturbance (AOR = 1.19, CI 1.17, 1.21).
Relation of CRP to FMS. Mean CRP (mg/L) was significantly higher among FMS cases (M = 5.54, SD
= 9.8) compared to controls (M = 3.75, SD = 7.2) (Table 3). CRP serum level showed a positive
association with FMS (unadjusted OR for highest vs. lowest quartile = 2.50, CI 2.10, 2.97; P for trend
<.0001); adjustment for demographic and lifestyle factors substantially attenuated but did not eliminate
this association (AOR for highest vs. lowest quartile = 1.35, CI 1.13, 1.62; P for trend <.0001). Analysis
of CRP as a continuous variable yielded similar findings, with odds of FMS increasing by 2% for each
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one mg/L of CRP rise (unadjusted OR = 1.02, CI 1.01, 1.02); adjustment for demographic and lifestyle
factors slightly attenuated this association (AOR = 1.01, CI 1.00, 1.01).
The addition of BMI and comorbidities to the model further weakened the relationship between
CRP and FMS (AORs for highest vs. lowest CRP quartile = 1.17 (CI 0.96, 1.42) and 1.10 (CI 0.92, 1.32),
for BMI and comorbidities, respectively; and, combined OR = 1.07 (CI 0.88, 1.30)) suggesting that these
factors may at least partially explain the observed associations (Table 3). The inclusion of mood
disturbance and sleep impairment, separately and combined, only slightly attenuated the association of
FMS to CRP after adjustment for demographic and lifestyle factors (AOR = 1.01, CI 1.00, 1.01) (Table
4). These findings suggest that any mediating effect of these factors was modest.
Additional adjustment for statin use, PFOA, and female reproductive characteristics (menopausal
status, age at menarche, and parity) did not appreciably change the relationship between CRP and FMS.
Similarly, exclusion of those with rheumatoid arthritis and other autoimmune conditions did not
appreciably affect risk estimates. Likewise, we found no evidence for a modifying effect of age, tobacco
use, gender, obesity, menopausal status, or other factors on the relationship between CRP and FMS.

Discussion

This is the first large, population-based investigation to examine the relationship between CRP
and FMS, to assess the potential influence of BMI and comorbid conditions on this relationship, and to
evaluate the potential mediating role of mood and sleep impairment. In this cross-sectional study of a
large Appalachian population, CRP serum level showed a positive association with FMS, which remained
significant after adjustment for multiple demographic and lifestyle factors, including age, gender,
education level, employment, marital status, alcohol, and tobacco use. Adjustment for BMI and comorbid
conditions substantially attenuated this relationship. These findings are broadly consistent with those
from a recent cross-sectional investigation of 5110 Norwegian men; cases with FMS/Chronic Pain
Syndrome showed a strong, positive relationship to high sensitivity-CRP level (OR for >10 mg/L vs. <1
mg/L = 2.6, 95% CI: 1.4, 4.6, p = .002; P for trend = .006) after adjustment for age, education, smoking,
and cholesterol medication (48). In contrast, as stated in the introduction, findings from smaller
casecontrol studies examining the association between CRP and FMS have been inconsistent (44, 46, 49,
51), perhaps due to varying sample sizes and differing selection criteria among controls; of the four
casecontrol studies published to date, only one reported significantly higher CRP levels in FMS patients
compared to healthy controls after adjustment for age, sex, and race (44).
As indicated above, the inclusion of BMI in our model substantially attenuated the association of
FMS to CRP, suggesting BMI may have largely explain the elevated CRP levels in FMS; this was second
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to the inclusion of comorbidities. Only one study to date has considered the potential contribution of BMI
to the profile of CRP in FMS, with a strong and positive correlation (44). Ours is the first study to assess
the contribution of multiple comorbidities on the relation of CRP and FMS. Additionally, in agreement
with our study, others have suggested a mediating effect of BMI on the relation between CRP and FMS;
FMS symptom improvement has followed weight loss among several FMS cases (296), and a
longitudinal study revealed regular exercise and maintenance of body weight lowered the risk of FMS
(297). Additionally, one case-control study found that after adjustment for demographic factors, BMI was
the only significant contributor in a model exploring the relation between CRP and FMS (r = .062, p <
0.001) (44).
Comorbidities characterized by pain may contribute to the development of FMS; shared pain
mechanisms between FMS and other conditions with a similar underlying pathophysiology (e.g., tension
headache) or as a comorbidity characterized by inflammation or ongoing peripheral damage (e.g.,
autoimmune disorders and osteoarthritis) and FMS have recently been explored (9, 23, 298). Our study
found that as the number of comorbidities increased, the odds of FMS increased as well.
Additionally, the presence of sleep impairment and mood disturbance modestly attenuated, but
did not eliminate, the association between CRP and FMS. No existing studies have examined the role of
sleep impairment on this relationship. We found no evidence supporting mood disorder as an effect
modifier, similar to a study finding where CRP level did not differ by psychiatric status among those with
FMS (47). The influence of sleep impairment and mood disturbance on the relation between CRP and
FMS in our study likely reflects a bidirectional relationship.
The prevalence rate of FMS in our study (2.1%) mirrored recent estimates for the U.S. population
(8, 299). Consistent with previous studies, we found the likelihood of FMS diagnosis was increased in
middle-aged females (8, 13). However, in contrast to findings from two large studies (8, 300), those who
were married or reported higher levels of education were more likely to report FMS. Females who had
experienced menopause were 1.8 times more likely to have FMS than those who had not; however, a lack
of epidemiological research exists in the topical area of sex hormones, neurotransmitters, and FMS. We
observed no significant association between age at menarche or parity and FMS, unlike a German
casecontrol study of 653 middle-aged women (FMS cases = 36) which found, after controlling for age,
those with FMS had significantly later menarche and were less likely to have ever been pregnant (301).
In agreement with previous cross-sectional and longitudinal studies (8, 297, 302), BMI was
strongly and positively related to reported FMS in this large Appalachian population. Additionally, higher
BMI has been associated with an increased risk of FMS after adjustment for mood and/or other health
factors (8, 297), including familial FMS diagnosis (302). Likewise, consistent with findings from a recent
cross-sectional study of a nationally representative sample of U.S. adults (N = 8446, FMS cases = 201)
(8) FMS showed significant positive associations to multiple comorbid conditions in our study after
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adjustment for demographic and lifestyle factors; these included cardiovascular disease, rheumatoid
arthritis and other autoimmune disorders, kidney, respiratory and liver diseases, and frequent headache.
Osteoarthritis was also associated with a nearly 4-fold likelihood of FMS, dissimilar from a large,
national analysis of U.S. electronic medical records (N = 587961, FMS cases = 4296) of only a
(unadjusted) 2-fold likelihood (303). In contrast to other large studies of U.S. adults (8, 303), diabetes
was not associated with FMS in this sample of Appalachian adults.
The strengths of this study were its high response rate, population-based design, and large sample
size; this was the largest comprehensive community study conducted to date in the Appalachian region.
We were able to control for a large number of potential confounders, including comorbid conditions.
Misclassification of CRP was unlikely due to standardized assay procedures used.
This study targeted a population of predominantly white Appalachian adults, potentially limiting
generalizability. Possible misclassification of FMS may have occurred depending on time the participant
was diagnosed and the physician’s awareness and use of the American College of Rheumatology
classification criteria for FMS first established in 1990. In particular, poor or incomplete recognition of
FMS by healthcare providers may have led to under-ascertainment (304). However, such
underascertainment would be expected to bias the observed associations toward the null. FMS, in addition
to most other assessed health conditions, was based on self-report, possibly leading to response or
misclassification bias. To our knowledge, no clinical validation study has assessed the agreement between
self-report and medical record-verified data on FMS.
Unmeasured confounding may have also contributed to our findings, although our ability to
control for a large number of both known and potential risk factors for FMS diminishes this possibility.
Our study also lacked specific information on certain conditions previously linked to FMS, including
sleep apnea and irritable bowel syndrome. Although contact with former residents of counties used for
study inclusion was attempted, some may not have participated in the study, possibly introducing
sampling bias. Lastly, we cannot draw any conclusions regarding causality due to the lack of a temporal
component in our cross-sectional study design.
Conclusion

In this large cross-sectional study of Appalachian adults we observed a significant, positive
association between serum CRP and diagnosed FMS, which was largely explained by elevated BMI and
chronic comorbid conditions. Adjustment for sleep and mood disturbance only modestly attenuated this
association, suggesting that BMI and chronic comorbid conditions may largely account for elevated CRP
levels among FMS patients over the presence of sleep and mood disturbance. Further prospective
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research is needed to determine the relation of CRP and other inflammatory markers to the development
and progression of FMS, and to clarify the potentially complex role of obesity and comorbidities, in the
potentially causal pathway between inflammatory markers and FMS.
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CHAPTER 3: Prevalence Trends and the Association between Herbal Supplement Use and
Fibromyalgia Syndrome in two National Samples (2007-2012)

Introduction

Fibromyalgia syndrome (FMS) is a rheumatologic chronic pain syndrome affecting
approximately 0.5-5% of populations in developed countries (7), including 1.75% of those in the U.S.(8).
FMS is characterized by a constellation of somatic symptoms that are typically present in addition to
widespread pain (e.g., fatigue, sleep disturbance, memory, and mood problems), for which no clear cause
can be found (9). Additionally, those with FMS also experience high rates of comorbidity, such as
autoimmune disease (22), osteoarthritis (23), kidney (24), respiratory (25), cardiovascular (24), liver (26),
diabetes (27), stomach conditions (24, 26), and headache (29). Although FMS affects both sexes and
people of all ages, the majority (80-90%) of cases occur in Caucasian (13, 14) middle-aged women (13).
Chronic pain, such as that accompanying FMS, is difficult to manage; this is partially due to
limited efficacy of conventional pharmaceutical therapies and the significant side effects associated with
these medications. In addition, although specific clinical criteria for FMS, first developed by the
American College of Rheumatology (ACR) in 1990, have been in effect for over 25 years, many
physicians remain unfamiliar with FMS and FMS treatment (305). Therefore, many FMS patients have
experienced difficulty in receiving diagnosis and consistent care for their symptoms, particularly before
less constrictive ACR criteria were introduced in 2010 (306), which additionally gauges impact of FMS
upon quality of life through the use of an impact score (17).
Although there is no evidence of efficacy for opioids as treatment for FMS (18, 75), more than
80% of FMS patients receive opioid therapy (63). Some physicians are reluctant to prescribe opioids (6),
while others overprescribe them (85), even though prescription drug overdose deaths involving opioids
(using age-adjusted data) have more than quadrupled since 1999 (84). People with FMS are also typically
treated with antidepressants (54), muscle relaxants (11), as well as other pain (54) and sleep medicines
(11). Drugs commonly used off-label to treat FMS include Gabapentin (56), Fluoxetine (57), Pramipexole
(57), Amitriptyline (54), and Tramadol plus Paracetamol (57), among others (307); all carry significant
side effects. Although three drugs (Anticonvulsant Lyrica/Pregabalin, and Serotonin-norepinephrine
reuptake inhibitors Cymbalta/Duloxetine (58, 59) and Savella/Milnacipran) have been approved by the
FDA for FMS treatment, they also carry significant side effects (57, 60, 61), and the mechanisms by
which these drugs alleviate FMS symptoms is unknown. For some FMS patients, these drugs are not
effective (11). Chronic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are also given as treatment for
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some pain symptoms (18), but likewise carry significant side effects for as many as 25% of long-term
users (62).
Complementary Health Approaches (CHAs) (formerly referred to as ‘Complementary and
Alternative Medicine’, or ‘CAM’ by the National Institute for Complementary and Integrative Medicine)
are medical and health care systems, practices, and are often used by those with chronic pain(308). The
ACR suggests people with FMS consider non-drug treatments in addition to their pharmaceutical
approaches, and that certain CHAs may be helpful in managing FMS symptoms. Many of these
treatments, including herbal dietary supplements, have not been well tested in FMS patients for safety
and efficacy (76-78). Although CHA use is popular in the U.S., patients often do not disclose their use of
CHAs to their physicians (97, 98), largely because the role of CHA in chronic pain management remains
controversial. Physicians disagree with one another and with their patients about the cost, validity, and
effectiveness of individual CHAs (99). The use of CHA use may reflect greater autonomy patient
populations who are less dependent upon conventional medicine and wish to direct their own health care
(88); some patients also use CHAs due to concerns over the safety of conventional medicine (100).
Compared with nonusers, CHA users tend to be women, white, middle-aged, of higher income, and
better-educated (90, 106, 110-116).
In the United States, 30-60% of the general population use CHAs (88), and in 2007, about $14.8
billion was spent on the purchase of non-vitamin, non-mineral, natural CHA products (109). According
to the 2012 National Health Interview Survey (NHIS), which included a comprehensive survey on the use
of CHAs in the U.S., 17.7% of adults had used a dietary supplement other than vitamins and minerals in
the past year, making these products the most commonly used CHA for which data were available (104);
these supplements included herbal products (Image 1) Consistent with these findings, systematic reviews
of population-based studies in U.S. adults (2001-2012) indicate 18.1% of the general population used
herbal medicine (109, 116, 118, 137-165). Echinacea, Ginseng, Ginkgo, and Garlic were the most
common natural products among adults in 2007 (161).
‘Herbs’ (plant-derived products also known as ‘botanicals’ or ‘biologically based therapies’) are
often sold as dietary supplements and are part of the broader CHA group of approaches called ‘Natural
Products’, which also include (non plant-derived) vitamins and minerals. The use of herbs for potential
health benefit is called ‘herbal medicine use’ or ‘phytomedicine’ and is part of many ‘folk medicine’
traditions. Many herbs have been documented to have anti-inflammatory action (in vitro and in vivo)
(123, 223, 225-227, 233, 241-265, 271), and anecdotal accounts demonstrate herbalists have
recommended many herbs for the treatment of FMS and/or related symptoms such as pain (121, 179, 180,
211, 216-219), rheumatism (121, 169, 178-180, 182, 191, 216-218), and arthritis (121, 169, 178, 179,
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191, 212, 217, 218); others have been used for non-specific inflammation (121, 179, 180, 217, 218), sleep
troubles (121, 169, 179), and for headache (179, 180, 217); it is not clear if these herbs continue to be
used by those with FMS. A 2009 case-control study (FMS = 434) showed nearly half (42.9%) of those
with FMS used herbs and other supplements; herbs used most often by those with FMS were Ginkgo
(3.7%), Garlic (3.0%), Ginseng (3.0%), Echinacea (2.5%), Evening Primrose oil (2.3%), and Valerian
(2.3%) (197).
Pain-related disorders are the most commonly reported conditions for which patients use CHAs
(86, 88, 93, 105, 106). Those in the US most frequently use CHAs for back pain, neck pain, joint pain,
and arthritis (161). However, investigations regarding the prevalence and correlates of herbal use in
chronic pain populations remains limited, and even fewer studies have examined the relation of FMS to
herbal use; one case-control study assessing this relationship combined herbal supplements with other
natural products (197). Further, only one large study examined herbal use in a pain population receiving
opioids (93), while UK population studies conducted over three decades ago examining similar chronic
pain syndromes to FMS used small sample sizes (N<100).
Further research on FMS and herbal use is clearly warranted given that FMS is poorly managed
by current treatment options, and there is a national opioid epidemic; while previous studies suggest CHA
use is popular, research regarding herbal use for pain remains limited, particularly before and after
implementation of updated FMS diagnostic criteria. We hypothesize that rates of herbal supplement use
will differ between time points among those with FMS, and those with FMS will be more likely to use
herbal supplements than those without FMS.

Methods

Data Sources
In two nationally nationally-representative samples of 23,501 and 34,525 U.S. adults (the
National Health Interview Surveys (NHIS), 2007 and 2012, respectively), we investigated if those with
Fibromyalgia Syndrome (FMS) were more likely to use herbal supplements than those without FMS, and
determined if prevalence rates for herbal supplement use among those with FMS significantly changed
over a 5-year time period. The NHIS is an annual national, cross-sectional household survey of the
noninstitutionalized US population and is administered by the Centers for Disease Control and
Prevention’s (CDC) National Center for Health Statistics. An additional supplement (Adult Alternative
Medicine) to the core individual, family, and household surveys in both years asked participants about
use of a broad range of CHAs, including herbal supplements. All questions were administered in a
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personal interview format. Adult response rates to the NHIS were 78.3% in 2007 and 79.7% in 2012,
respectively (309, 310).
The NHIS is the only national, public-use survey that includes comprehensive sets of questions
regarding herbal and other CHA use. Both 2007 and 2012 surveys used a stratified multistage probability
design weighted on age, sex, race/ethnicity; using 2000 and 2010 Census data for 2007 and 2012,
respectively. Both surveys oversampled Asian, Black, and Hispanic persons, and the minority elderly
population. Thus, each person in the covered population had a known non-zero probability of selection.
These probabilities of selection, along with adjustments for nonresponse and post-stratification (defined
as post-survey implementation stratification of the sample according to auxiliary information about the
sampled population, similar to direct standardization) were reflected in the sample weights and complex
survey procedures recommended by the CDC for our analyses. Additional project details have been
described elsewhere (310).

Study population
Our analysis excluded participants who were <18 years of age, pregnant, senile, had a stroke and used a
proxy to complete the interview, or had current cancer; those missing data on key covariates were also
excluded, as were participants with extreme values for exercise (>6,000 minutes per week) in order to
eliminate potential information bias; these were the only extreme values considered for exclusion. Further
exclusion of persons with missing data on FMS and herbal use (at 30 days, 12 months, or ever using
herbs) yielded final study samples of 20,127 and 30,672 adults for 2007 and 2012, respectively (Figure
1).

Variables
Outcome Variables. The main outcome variables for 6 separately run analyses were (in three models for
each of the two survey years) the use of herbal supplements within the previous 30 days, 12 months, and
having ever used herbal supplements (all dichotomous variables); these included herbs in the form of
pills, capsules, tablets (2007) or liquids (2012), and excluded herbal or green teas.
Exposure Variable. Our main exposure was Fibromyalgia Syndrome (FMS) diagnosis, a dichotomous
variable, which was self-reported as a previously diagnosed condition by a health professional.
Covariates. Demographics lifestyle factors, health conditions, and related factors known or suspected to
be associated with CHAs, herbal use, and/or FMS were considered a priori as potential covariates in
multivariable models. Demographic factors assessed included age, gender, race/ethnicity, education,
employment, income, marital status, geographic region, and place of birth. Additional related factors
included insurance status, family out-of-pocket medical costs in the past year, and delay of care due to
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concerns over cost. Lifestyle factors included smoking status, alcohol use, exercise, BMI (21), health
status, and substance abuse. Health conditions included self-reported history of physician diagnosed
diabetes (27), kidney disease (24), gastrointestinal disorder (24, 26), respiratory conditions (22),
dyslipidemia, liver condition, Rheumatoid arthritis, Cardiovascular disease (24), hypertension,
nonspecific arthritis (23), gout, migraines (29), mental health condition, insomnia, and previous cancer
diagnosis. These variables are described in greater detail below.
Potential Effect modifiers. Gender (Male/Female) and number of health conditions (0-1/2+) were
assessed for their potential influence on the relationship between FMS and herbal use.

Statistical Analysis

We conducted complete-case analyses using SAS 9.4 (Cary, NC, USA). We merged NHIS
Family, Person, Household, Sample Adult, and Adult Alternative health files for each year, and measured
sample characteristics, including frequencies and percentages/prevalence rates of herbal use (ever, past 12
months, and past 30 days) for 2007 and 2012, respectively (using PROC SURVEYFREQ and PROC
SURVEYMEANS); we extrapolated estimates to generate population frequencies using NHIS sampling
weights. Weighted t-tests (PROC SURVEYREG) and Rao-Scott Chi-square tests were used to determine
significant differences by herbal use status for three herbal use time points in both survey years;
significant factors were included in final models, for which we assessed the influence of potential
confounding factors. Weighted logistic regressions (PROC SURVEYLOGISTIC) were used to evaluate
the independent associations of FMS diagnosis to herbal use in the last 30 days, the last 12 months, or
ever. We also used a DOMAIN statement to keep our exclusions separate while maintaining the integrity
of sampling weights. We used Chi-square and t-tests to determine significant changes between 2007 and
2012 on weighted frequencies and means of all items, in addition to specific herbs used, herbal
practitioner visits, physician disclosure of herbal use, and use of other CHAs; we considered trends
between time points significant if there was no overlap in weighted percentage confidence intervals.
Differences between participants missing any data were assessed using logistic regression. All p-values
shown are two-sided at p < 0.05.
For 2007 and 2012, we examined crude associations between FMS and herbal use at 30 days, 12
months, and any previous use of herbs. Three additional models for each year adjusted for demographic
and related covariates, followed by six total models additionally adjusting for lifestyle factors. Last, we
additionally controlled for health conditions as well, in six (full) models.
Our models included demographic characteristics of age (evaluated as both continuous and in groups
18-24, 25-44, 45-64, 65-74, and 75+ years), sex (Male/Female), race (defined as ‘Non-Hispanic White,’
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‘Non-Hispanic Black,’ ‘Hispanic,’ ‘Asian,’ and ‘Other’), education (a categorical variable defined as
'<Some HS,’ ‘HS/GED,’ ‘Some college/AA/tech,’ and ‘Bachelor’s Degree+,’), employment (‘Employed
for pay,’ ‘Employed but not for pay,’ and ‘Unemployed,’), income ($1 - $24,999; $25,000 $44,999; $45,000 - $74,999; $75,000+; ‘Don't know’; and ‘Missing’), and geographic region
(‘Northeast,’ ‘Midwest,’ ‘South,’ and ‘West’), and place of birth (U.S.-born/other), which were controlled
for in a multivariate model first, as were related factors insurance status (separate categories ‘Uninsured,’
‘Medicaid,’ ‘Medicare,’ ‘disability,’ and ‘private’), family out-of-pocket medical costs in the past year
(aside from insurance premiums, deductibles, and/or co-pays) (‘None;’ <$500; $500-$1999; $2000$2999; $3000-$4999; $5000 and over; and, ‘Don't know’), and delayed access to care because “could not
afford” or “worried about cost” (yes/no). Marital status (evaluated as ‘married or co-habitating,’
‘divorced/separated/ widowed,’ and ‘single’) was additionally controlled for in 2012 models. Models also
controlled for lifestyle factors BMI (evaluated as continuous and categorical variables using the National
Institutes of Health clinical classifications scores of <18.5 – 25 =‘Underweight or Normal weight;’ 25 –
29.9=‘Overweight;’ 30 – 34.9=‘Obese Class 1;’ and, 35+=‘Obese Classes 2/3’) (295), tobacco use
(defined as ‘current smoker,’ ‘former smoker,’ and ‘never smoked’), alcohol use (‘None,’ ‘Light,’ and
‘Moderate to heavy’), substance abuse (other than tobacco or alcohol) in past year (yes/no), physical
activity of at least 10 minutes per week (continuous and dichotomous as ‘Any’/’None’), and self-reported
health status (‘Excellent/very good/good,’ ‘Fair,’ and ‘Poor’).
In our fully-adjusted models, we also evaluated the influence of both specific health conditions and total
number of health conditions on the relation of FMS to herbal use. A comorbidity index was created from
0-13 participant-reported conditions; these included history of 1) diabetes (27); 2) kidney disease (24); 3)
gastrointestinal disorder (including history of ulcers, inflammatory/irritable bowel disease or constipation
severe enough to require medication in the past year and/or (2012) abdominal pain, digestive allergy,
and/or heartburn in the past year) (24, 26); 4) respiratory conditions (history of asthma or emphysema,
and/or chronic bronchitis) (22); 5) dyslipidemia; 6) liver condition; 7) rheumatoid arthritis; 8)
cardiovascular disease (coronary heart disease, angina, and/or heart attack) (24); 9) hypertension; 10)
non-specific arthritis (23); 11) gout; 12) migraines (29); and, 13) mental health condition (depression,
phobias, and/or often anxious in past year, and/or ever having bipolar disorder). We categorized this
index as ‘No health conditions,’ ‘1 condition,’ 2 conditions,’ and ‘3 or more conditions’; Health
conditions were evaluated both collectively (as continuous and categorical variables) and individually;
insomnia in the past year or previous cancer diagnosis were also evaluated individually.
We assessed the potential modifying influence of gender and number of health conditions (0-1/2+) on
the association between FMS and herbal use at each outcome time point and for each survey year;
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interactions were assessed by including the corresponding multiplicative-interaction term in crude
statistical models.

Results

Relative to participants with complete data in both survey years, those employed and with higher
education were less likely to have missing data on key covariates (p’s ≤.0001). Those more likely to
have missing data were underweight, older, and with poor reported health status (p’s ≤.0001); in
2012, insured women were also more likely to have missing data (p ≤.0001). Participant age ranged from
18 to 85 years, averaging 47.5 (SE = 0.25) and 48.5 (SE = 0.18) years for 2007 and 2012, respectively.
In both survey years, study participants were predominantly white (72.2% and 69.5% for 2007 and 2012,
respectively), female (53.1% and 53.5%), and insured (84.3% and 84.2%); most (56.4% and 57.9%)
reported never smoking. Nearly one-third of participants were overweight (mean BMI for 2007 BMI =
27.3± 0.05; 2012 = 27.7± 0.04), and most (64% and 72.3%) reported at least one chronic health
condition, with the number of chronic health conditions increasing from a mean of 1.5± 0.02 in 2007 to
1.9± 0.01 in 2012.
Demographic and lifestyle characteristics are displayed in Tables 1a (any previous use of herbs),
2a (herbal use in past 12 months), and 3a (herbal use in past 30 days), while Tables 1b, 2b, and 3b display
health characteristics, respectively. Those reporting herbal use (ever, and past 12 months) significantly
decreased between 2007 and 2012 (p’s < .0001). Those with any herbal use (ever) comprised 27.1%
(2007 n = 5057) and 24.2% (2012 n = 7328) of population samples (Table 1a), with decreases in these
prevalence rates for recent use of herbs (12 months: 2007 PR = 19.1%; 2012 PR =
16.4%) (Table 2a); nearly 14% used herbs within the past 30 days (2007 PR = 13.9%; 2012 PR =
13.9%) in both survey years (Table 3a).
In 2012, fewer whites consumed herbs (ever, past 12 months) for health benefit compared to
2007, while the Hispanic population increased their use (p’s = < .0001). Herbal users exercised more and
smoked less in 2012 than in 2007 (p’s = < .0001). Additionally, herbal use was associated with a
significant increase in out-of-pocket costs in both survey years (p’s for trend = .0001; not shown);
specifically, there was a significant increase in out-of-pocket costs over $3,000 among herbal users
(ever, past 12 months) between time points. There was a significant decrease in privately-insured herbal
users (ever), and an increase in herbal users (past 12 months) with Medicaid (p’s < .0001). All herbal
users had significantly higher numbers of health conditions compared to non-herbal users in both 2007
and 2012 (p’s for trend = <.0001; not shown). Rates of chronic pain conditions (including migraines,
non-specific arthritis, gout, non-specific joint pain last greater than 3 months, and/or Rheumatoid
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arthritis) and mental health conditions among herbal users (past 12 months, past 30 days) was also
significantly higher in 2012 than in 2007 (p’s = <.0001) between time periods. Lastly, consumption of
natural products increased among all herbal users between time points, while significant decreases
occurred in those using herbs and reported ever using manipulative therapies/bodywork, as well as
alternative medical systems (Acupuncture, Ayurveda, homeopathy, naturopathy) (p’s < .0001).
Prevalence of diagnosed FMS also increased significantly from 1.3% of adult participants in 2007 to
1.7% in 2012 (p<.0001) (Table 4). However, consistent with overall trends in herbal use (Table 1a-3a),
herbal use (ever) among adults diagnosed with FMS declined significantly from 2007 to 2012, decreasing
from 57 to 41% (p <0.0001); however, there were no significant differences in the proportions of those
with FMS using herbs in the past 12 months (42% to 31%) or 30 days (33% to 25%) (Table 4). There
were no changes between time points in herbal use disclosure rates to physicians (64.6% within the past
30 days in 2007 to 71.4% within past 12 months for “top herbal supplements used”) and number of
different of herbal supplements taken in the past 30 days (2007 Mean = 0.99, SE = 0.20 vs. 2012 Mean =
1.1, SE = 0.38; p = .89) among those with FMS.

Relation of FMS to Herbal use. Nearly 60% of those with FMS had previous/current use of herbs
(ever), while 42% used herbs in the past 12 months, and 33% used herbs in the past 30 days.
Approximately 3% of herbal users (ever, past 12 months, past 30 days) had FMS in 2007 and 2012; this
rate did not differ between time points (Table 5). Relative to those without FMS, participants diagnosed
with FMS were over three times as likely to use herbs for any length of time in 2007. After adjustment
for demographic, lifestyle, and health factors, those with FMS were 2.7 times more likely to ever use
herbs than those without FMS (Adjusted odds ratio (AOR) = 2.66, 95% confidence interval (CI): 1.85,
3.82); this positive association remained when examining the association between FMS and recent herbal
use as well (12 month and 30 day AOR’s = 2.25 (CI: 1.51, 3.35) and 2.34 (CI: 1.55, 3.52)). Likewise,
FMS was significantly associated with all herbal use outcomes in 2012, although the magnitude of the
associations were comparatively attenuated (2012 AOR’s: herbal use (all) = 1.59 (CI: 1.25, 2.03); 12
month = 1.57 (CI: 1.21, 2.04); 30 days = 1.51 (CI: 1.15, 2.00)).
As illustrated in Table 6, we found evidence of a modifying effect of comorbidity only for the
relationship between ever using herbs and FMS in 2007; the magnitude of the association of herbal use
to FMS was significantly greater in those with 0-1 comorbid health condition than in those with 2 or
more health conditions (OR’s, respectively= 4.67 (CI: 2.22, 9.81) vs. 2.80 (CI: 1.99, 3.92; p for
interaction = .008); we found no evidence of a modifying effect of multiple comorbidities for either
year, even after controlling for age. Additionally, we found no evidence for a modifying effect of
gender on the relation between FMS and herbal use in either year.
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Discussion

Our study was the first large, population-based study to examine the relation of herbal use to
FMS in any population, while controlling for a wide array of potential confounders and examining the
modifying influence of comorbid conditions; it is also among the first rigorous studies to investigate the
relation of herbal use to any chronic pain condition in a large sample. Relative to adults without FMS,
those with FMS were significantly more likely to use herbs at 30 days, 12 months, or ever, in both 2007
and 2012 survey years; these positive associations remained highly significant even after controlling for
a broad array of demographic, lifestyle, and health-related factors.
In our study, 60% of those with FMS had ever used herbs, while 42% used herbs in the past 12
months, and 33% used herbs in the past 30 days. Studies assessing herbal use in FMS have not
examined relationships as we did, but only reported frequencies of use; these ranged from 6.8% (in a
large sample of Wisconsin primary care patients receiving opioids) to 78% (among 90 FMS patients in
the UK) (93, 196, 197). However, these studies were limited by combining herbs with other natural
products (14, 93, 196, 197, 311) in proportion estimates, and the wide variation in proportions likely
arise from using different definitions for herbs and supplements. When examining herbal use in
rheumatoid arthritis populations, 20% - 35% used herbal medicine; however, these small (N=78 and N
= 94) studies were conducted over three decades ago (193-195).
Prevalence of diagnosed FMS was significantly higher in 2012 compared to 2007 (1.7% vs.
1.3%), which is slightly less than national estimates (1.75% of those in the U.S. (8)) but fits within
prevalence ranges (0.5-5%) of developed countries (7); this apparent rise is likely due in part to increased
recognition of FMS by physicians after updated 2010 ACR criteria, potentially enabling shorter patient
waiting times to diagnoses than before.
In contrast, we found reported herbal use among adults with FMS to decline significantly from
2007 to 2012; this decrease may in part reflect the modest but significant reduction in overall herbal use
observed between survey time periods. Additionally, the decrease in odds of herbal use in FMS may
also reflect the availability of FDA-approved FMS treatments that became available in 2007, 2008,
2009 shortly following implementation of the 2007 NHIS survey.
It remains possible that both the increase in FMS diagnoses and the decrease in odds of herbal
use for FMS over time are also in part perhaps the result of corporate promotion for FMS drugs,
increased off-label use of other drugs for FMS, and potentially, increased opioid use for FMS. Between
2007 and 2012, the mean number of different herbal supplements used by those with FMS did not
differ, and both means (2007 mean = 0.99; 2012 mean 1.07) were lower than that of a 2009 North-

40

American case-control study (FMS = 434, Control = 198) which showed those with FMS took ~ 2.8
per person; however, this average was also combined with the use of all other natural products (197).
Ours is the first study to document the rates of FMS in herbal users, which remained consistent at ~3%
in both 2007 and 2012.
The magnitude of the association between herbal use (ever) and FMS was significantly greater
in those with 0-1 comorbid conditions in 2007 but not 2012. Although the possibility remains that this
finding may indicate those diagnosed with FMS before 2007 were more likely to have used herbs in an
attempt to exercise control over their health, since no FDA-approved treatments existed before 2007
data collection (312). While it remains possible those with FMS managed their illness more successfully
with herbs, resulting in fewer FMS comorbidities before FDA-approved treatments were made
available, these findings should be interpreted with caution.
Our ability to examine associations between herbal use and FMS in nationally representative
samples that spanned two time periods comprehensive data on herbal use, as well as on many potential
confounders, including demographic, lifestyle, health-related, and other factors, are major strengths of
our study.
However, there were some limitations, including inadequate capture of certain herbal products.
No data were available on consumption of herbal teas used for health purposes or on other herbal
products not labelled as a “dietary supplement”, including traditionally prepared herbal creams,
tinctures/extracts, and powders, or products (with different labelling than that specified by the NHIS)
that are sometimes recommended by herbalists over widely-available supplements due to quality and
processing concerns. Additionally, many of the CHAs were only assessed in NHIS if they were
administered by a practitioner (e.g., massage therapy, deep breathing only as part of other guided
meditation practice, etc.). Our estimates for herbal use and other CHAs are likely underestimated due
to misclassification of herbal use by the additional inclusion of non-herbal products including
coenzyme Q-10, fiber, SAM-e, fish oil, and prebiotics/probiotics in the NHIS.
Additionally, the 2012 questionnaire differed substantially from 2007. Based on cognitive testing
and input from expert panels, the definitions of certain modalities were modified between years to reduce
false-positive responses (313), which may have affected findings. However, these changes were
relatively minor and are unlikely to impact our estimates.
Given the high prevalence rates of those with FMS using herbs (as indicated through positive
associations with all herbal use outcomes), additional observational studies are needed to explore
potential impacts of herbal use on a variety of chronic pain conditions, in order provide rationale for
clinical trials on potential herbal therapies for other poorly-managed chronic diseases. Future
observational research should continue to examine patterns of herbal use, and clinical research should
also examine the safety and efficacy of herbs.
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Conclusion

In this large cross-sectional study of two nationally representative samples of US adults,
reported diagnosis of FMS was strongly and positively associated with any duration of herbal use in both
2007 and 2012 after adjustment for demographic, lifestyle, and health factors; As a result of this study,
we have an increased understanding of the patterns of herbal use prior to and following the
implementation of an update to FMS diagnostic criteria and increased availability of treatments for a
disease characterized by chronic pain. Rigorous prospective studies are needed to confirm these
findings, to further explore the patterns and determinants of herbal use in other chronic disease
populations.
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CHAPTER 4: Correlates of Herbal Use and other Complementary Health Approaches among
Appalachian Pain Patients
Introduction

Over 20% of adults eventually experience chronic pain (2, 3), and as many as 100 million
individuals are affected in the United States alone (4). The International Association for the Study of
Pain (IASP) defines pain as chronic if it persists beyond normal tissue healing time of 3 months (314).
Unrelieved pain results in decreased function, longer hospital stays, and increased rates of
rehospitalization and outpatient visits, leading to lost employment, income, and insurance coverage (5).
Chronic pain costs the U.S. more than $635 billion annually in medical costs and lost productivity, which
equates to approximately $2,000 per person (3).
The Institute of Medicine stresses the importance of increased research regarding the translation
of effective treatments into practice and regarding the prevalence and costs associated with pain (6).
While many pain measurement tools exist (315-324), some instruments incorporate frequency and
intensity criteria, while others do not; this adds to variation in prevalence estimates (1-3, 325). Recently,
pain physicians and researchers gathered to create a more standardized measurement tool for pain
assessment, the Global Pain Scale (GPS) which incorporates elements of existing pain measurement tools
and measures various clinical and quality of life factors (315).
Poor pain management frustrates patients and their caregivers; poor symptom management often
prolongs pain treatment, and many of these treatments carry significant side effects (326). The
identification of superior management options for chronic pain is difficult, likely due to the multiple
complex mechanisms and signaling pathways through which chronic pain is generated (30, 31); many
chronic pain patients thus experience poor treatment outcomes (2). Chronic pain is challenging to
manage, partially due to limited efficacy and negative side effects from conventional medical therapies,
but also because some physicians are reluctant to prescribe opioids (6), while others overprescribe them
(85).
Over the past decade, the worrisome trend of increased prescription and utilization of opioids for
the treatment of chronic nonmalignant pain has emerged (83), even though opioids cause physical and
psychological dependence in users. Additionally, there is no concrete evidence opioids are effective in
treating some chronic pain conditions for which they are prescribed (18, 75). Opioid pain relievers—also
called prescription painkillers—such as Oxycodone, Hydrocodone, Fentanyl, and Hydromorphone, were
responsible for three-fourths of all prescription drug overdose deaths in the United States in 2010 (84).
Nationally, deaths involving opioids (using age-adjusted data) have more than quadrupled since 1999
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(84). However, non-opioid medications such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) carry
significant side effects for as many as 25% of long-term users (62).
Opioid treatment for chronic pain management presents a great challenge in the unique
demographic of Appalachia. In particular, West Virginia, the only state situated entirely within
Appalachia, ranks among the highest in the nation for several health disparities, including opioid pain
medication misuse and abuse. West Virginia’s overdose death rate has been climbing (28.9 per 100,000
population in 2010, compared to 35.5 per 100,000 in 2014), and was more than double the national rate,
which has also been rising over time (12.4 per 100,000 population, compared to 16.1 per 100,000,
respectively) (86, 327).
Understanding the patterns of usage and efficacy of other, safer forms of chronic pain treatment
are necessary, and may include Complementary Health Approaches (CHAs) such as herbal medicine.
Some patients choose CHAs because of concerns over the safety of conventional medicine (100);
Painrelated disorders are the most commonly reported conditions for which patients use CHAs (86, 88,
93, 105, 106); CHAs encompass therapeutic approaches not customarily prescribed by medical doctors to
treat chronic pain, such as natural products (e.g., herbs, probiotics, fish oil) and Mind-body practices (e.g.,
yoga, meditation, etc.), as well as Ayurvedic medicine, Traditional Chinese Medicine, Naturopathy,
homeopathy, and other practices. Most people use CHAs with conventional treatments (90, 95, 96), but
patients often do not disclose the use of CHAs to their physicians (97, 98). CHA use is popular in the
United States, with 30-60% of the general population estimated to use CHAs (88). In 2007, about $14.8
billion was spent on the purchase of non-vitamin, non-mineral, natural CHA products in the United States
(e.g., herbs, fish oil, etc.) (109). The most comprehensive systematic review to date (28 trials meeting
quality criteria and presenting an economic evaluation) concluded that substituting a complementary and
integrative medicine (a.k.a. self- or practitioner-administered CHA) care component in place of usual care
had better health outcomes and lower costs than usual care alone for a variety of chronic health conditions
(328). However, comparative research is largely lacking, as is research regarding the overlap of CHA use
and/or conventional treatments among those with pain conditions (329).
Herbs (plant-derived products also known as ‘botanicals’, ‘biologically based therapies’, and
‘herbal medicine’) are sold as food and dietary supplements in the United States. In 2012, 17.7% of U.S.
adults had used a dietary supplement other than vitamins and minerals in the past year, making these
products the most popular CHA (104).
Herbal medicine is also part of many ‘folk medicine’ traditions. Anecdotal accounts suggest that
many herbs have been recommended by herbalists for the treatment of pain, rheumatism, and related
symptoms (121, 179, 180, 211, 216-219). The history of Willow (Salix spp.) and other salicin-rich plants,
which are pre-cursors to the NSAID Aspirin, is an example of the role herbs have played in pain
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management (123). A meta-analysis of Capsicum (a compound extracted from the fruit of Chili peppers
C. frutecens and others) for the treatment of pain, reported that topical Capsaicin was superior to placebo
for the treatment of chronic pain from neuropathic and musculoskeletal disorders (with trials of moderate
to high quality); the FDA approves Capsaicin as an OTC medicine as topical cream (199). There is also
extensive anecdotal evidence indicating widespread use of botanicals for the relief of pain. Based on
current anecdotal evidence, plants with analgesic, anti-inflammatory and/or anti-spasmodic activities
continue to be used as well.
However, there are relatively few population-based studies assessing the prevalence and/or
correlates of herbal use in pain populations. A large cross-sectional study among Wisconsin primary care
patients receiving opioids as a primary treatment method for chronic pain showed that 6.8% used herbs
and supplements (93). However, a cross-sectional study of primary care patients with chronic pain
conducted in 12 academic medical centers demonstrated a higher prevalence rate (15%) for herbal use
(95). Additionally, two studies indicated herbal use prevalence among U.K. Rheumatoid Arthritis patients
varied from 20% (N=78) (193, 194) to 35% (N=94) (194, 195) of used herbal medicines, while 78%
(N=90) (194, 196) of U.K. FMS patients used dietary supplements (including herbal supplements).
The history of folk medicine in Southern Appalachia is much better known in some areas than
others; more research has been conducted in western NC, eastern TN, and eastern KY. Comparable
research has been conducted more recently in other areas, particularly northern Georgia, southwestern
VA, mid-TN, western KY, and northern Alabama (124). West Virginia has a known anecdotal history of
herbal medicine use, and some of it is specific to folk illnesses as part of Appalachian folk medicine (169,
217); however, no epidemiological studies on herbal use have been conducted in WV pain populations.
There are many methodological problems attending the gathering of information on the use of folk
medicine, including small sample sizes, misclassification bias (investigators have failed to distinguish
between past and present herbal medicine usage), and failure to account for contextual factors influencing
use, including concurrent use of conventional medicines (124).
In a comprehensive literature review of herbal texts and qualitative studies of herbal use in
Appalachia (Appendix B), we found anecdotal evidence for the historical use of 101 herbs for pain relief
(121, 179, 180, 216-219), rheumatism (121, 169, 178-180, 182, 191, 216-218), and arthritis (121, 169,
178, 179, 191, 212, 217, 218); 12 herbs for non-specific inflammation (121, 179, 180, 217, 218); 3 for
alleviating sleep troubles (121, 169, 179); and 4 for headache (179, 180, 217). It is not clear if these
herbs continue to be used for these conditions in Appalachia. Unfortunately, rigorous observational
studies and high-quality trials regarding the use and efficacy of herbs for chronic pain syndromes remain
sparse and little is known regarding the correlates and motivators of herbal use, including pain level and
prescription drug use. Clearly additional research is needed, particularly in Appalachia, where prevalence
of chronic pain disorders (such as arthritis (330)) is high and opioid misuse is epidemic.
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In this study, we examine potential motivators of herbal and CHA use by using a Transtheoretical
Model-guided tool to better understand the underpinnings of short-term and long-term use. The
Transtheoretical Model (TTM) is a behavioral theory which proposes that changes in a health behavior
consist of movements between sequences of discrete, qualitatively distinct stages, characterized by
distinct mindsets. As individuals move between these stages, specific social-cognitive factors influence
stage progression (331); stage progression occurs through 6 separate ‘Stages of Change’ (Figure 1):
Precontemplation (a person has no intention to change a health behavior), Contemplation (they begin to
consider changing a health behavior), Preparation (they intend to change this behavior), Action (initiation
of the new health behavior), Maintenance (execution of the health behavior for more than 6 months)
(332), and the newly added Termination (desired health behavior complete) (333) . The ‘Stage of
Change’ construct is the central organizing dimension of the TTM (334); this construct has demonstrated
success in measuring various stages of health behavior change in cross-sectional research on the topics of
diet (335, 336), the use of health care proxies (337), exercise in pain patients (338), physical activity and
body satisfaction (339), and measuring health-promoting behaviors for cancer prevention in a healthy
population (340). However, the TTM Stages of Change construct has never been applied to measure the
health behavior of herbal use, nor other CHAs.
Current and future public health research calls for the use of theoretical models to better
understand motivators of health behaviors (341) such as herbal medicine use; social/biobehavioral
underpinnings in research are critical to understanding the processes and motivators of health behavior
change. The use of a theoretical underpinning/conceptual framework, such as the TTM Stages of Change
construct, in assessing the correlates of herbal medicine use (and the use of other CHAs) can help
elucidate the reasoning and potential motivators behind an individual’s decision-making process
regarding the use of these approaches.
The use of herbs and other CHAs may signal a patient is actively engaged in a potentially positive
health behavior, but may carry a risk of potentially negative interactions with other treatments. Gaps in
existing research highlight a need to examine correlates of herbal use, as well as use of a variety of
CHAs, to better understand if pain and other factors may influence individuals to engage in these health
behaviors. Additionally, gaps exist with regard to identification of herbs used in Appalachia for pain, for
which knowledge of potentially superior pain treatments may be lost; further investigation is also needed
regarding the relation of herbal and other CHA use to demographics, lifestyle characteristics, pain and
other health conditions, and other health-related factors, including prescription drug use. By employing a
new, comprehensive instrument for measuring pain and CHA use and incorporating questions regarding a
broad range of potential correlates, this cross-sectional study was designed to help address these gaps.
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Methods

Scope of Project
This cross-sectional survey study was conducted from June 2014 – March 2016 in a sample of
301 English-speaking adult (>18 years) patients in four Northern West Virginia pain and rheumatology
clinics. We conducted primary data collection using a new measurement tool, the Complementary
Approaches for Pain Survey (CHAPS) (Appendix D), using consecutive sampling (Response rate across
clinics = 88.0%), in order to investigate the associations between a variety of demographic, lifestyle,
health, and pain correlates with herbal use and other CHAs for pain in an Appalachian pain patient
population. Details regarding survey development and content, study population, and survey
administration are given below.

Survey Development
Development. The CHAPS included 2 closed-ended items regarding past and present chronic
pain; demographics and lifestyle (10 and 6 items, respectively); 24 health conditions (including nine
known to cause pain) and other health factors (3 items); the Shortened-Form Global Pain Scale (SF-GPS)
pain assessment (20 items), and, open-ended questions regarding specific herbs and other CHAs (2
items). Additionally, we assessed the usage of 12 separate CHAs, including Herbs/Botanicals, following
the definition of ‘Herbs’ from the National Institutes of Health’s (NIH’s) National Center for
Complementary and Integrative Medicine (NCCIM), which consider herbal products a CHA falling into
the subgroup of ‘Natural products’. Natural products listed on our survey instrument included
‘Herbs/botanicals,’ ‘Vitamins and minerals,’ ‘Probiotics,’ and ‘Other Natural products;’ accompanying
examples (e.g., “Herbs/Botanicals (such as Echinacea, Black Cohosh, etc.)”), were also included to
minimize misclassification bias among users who may have been confused. These questions were asked
how long they had used each CHA; length of time corresponded to Stage of Change (334, 341); for each
CHA, this included: “I do not know what this is;” “No, and I do not intend to within the next 6 months
(Precontemplation stage);” “No, but I intend to within the next 6 months (Contemplation stage);” “No,
but I intend to within the next 30 days (Preparation stage);” “Yes, and I have for less than 6 months
(Action stage);” “Yes, and I have for more than 6 months (Maintenance stage);” and, “If Yes, how
effective is it in managing your pain?”. Twelve optional, nested questions regarding the efficacy of CHAs
(if used) were also included.
Stage of change questions were constructed based on previous surveys measuring health
behaviors by the TTM Stages of Change framework (334, 341). Researchers have indicated that projects
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applying TTM should include investigation of problem severity (341). Our approach to measuring
problem severity among this WV pain populations was through the use of the SF-GPS (315).
The SF-GPS (315) was adapted from the pre-validated Global Pain Scale (GPS) by its original
authors, and was used in this research; The GPS was created to meet the need for a simplified instrument
for use by both clinicians and researchers, incorporating key elements of many existing pain assessments.
The GPS uses a variation of the Visual Analog Scale (VAS); numbers are spaced equidistant from one
another on a horizontal line, both ends are defined as the extreme limits of the parameter measured (pain
severity, etc.), and orientation is from the left (best) to the right (worst), indicating the impact each
measure has had in a participant’s life. The SF-GPS contains 5 items each on pain, feelings, clinical
outcomes, and activities; it addresses the ceiling, floor, and average pain over the past week, as well as
current pain state; screens for depression, anxiety, fear, hopelessness, and energy level, while exploring
the effect of pain on respondents’ quality of sleep, comfort, medication consumption, mood,
independence, energy, work interference, perceived control over pain, health care utilization, and
satisfaction with health care received. Finally, it also assesses how pain affects respondents’ ability to
complete a variety of activities.
A cover page was attached to every survey, indicating that the study was open only to patients
over the age of 18 years, ensuring anonymity, and indicating the intent of the research study (Appendix
D); returning of the survey served as implied informed consent. The CHAPS was designed to require no
more than 15 minutes to complete, and the average time for survey completion among clinic patients was
~12 minutes.

Pre-testing/Pilot period. Following initial development of CHAPS and after obtaining provider
permissions and IRB approval, we piloted the survey in a convenience sample of pain patents attending
the WVU Medicine Pain clinic in Morgantown, WV (June 2014 – March 2015). We visited the clinic
waiting room in person to solicit patient participation in the survey. In addition, we also placed a stack of
surveys, pens, and a survey drop box in the waiting room; during the following 9 months, we visited
every 2-3 weeks to collect surveys, and ensure surveys and pens were replenished. A total of 66 patients
completed surveys during this period, including 28 during our in-person visit.
A preliminary version of the CHAPS was also pre-tested in 10 patients by two independent
investigators in order to assess comprehension, recall, identification of strong and weak points, and
through gauging sensitive/controversial elements (342); our investigators gauged this through the
assessment of 13 pre-determined questions. Wording of the survey was designed to be at a ninth grade
reading level or below.
Based on responses to and feedback on this preliminary survey, and after learning more about the
patient experience through a 20-hour clinical immersion (accompanying a lead physician in patient rooms
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at the WVU Medicine Pain clinic), we made minor formatting changes to the CHAPS to improve clarity,
and included an additional question about (each) prescription use, CHA efficacy (if respondent used a
CHA), and military status. We then pre-tested the final survey version in 11 additional patients at the
same clinic location.
Final Version. Minor alterations were made to the final version of the CHAPS by September 2015. This
89-item self-administered survey required 10-12 minutes to complete. The survey included questions
regarding use of a variety of CHAs, including herbs, in a manner consistent with surveys utilizing a
Stages of Change approach (335, 337-339, 343). The CHAPS also included the 20-item SF-GPS(315);
questions regarding a variety of demographic, lifestyle, and health factors (10, 6, and 25-items,
respectively); and, 4 open-ended questions regarding additional CHA use, diagnoses, and prescriptions
used for pain. There were no differences in CHA/herbal use outcomes by survey version (Fisher’s p =
.102 and .690, respectively) or (pilot) test period (Fisher’s p = .879 and .678). Based upon the similarity
of the preliminary and final CHAPS surveys, data from these surveys were pooled in our primary
analyses.

Data Collection

Target study population and Identification of Sampling Locations. Our target study population
comprised adult chronic pain patients attending a WV pain management or rheumatology clinic within a
100 mile radius of Morgantown, WV. Pain and rheumatology clinics were identified by conducting an
internet search utilizing the Bing search engine; an online White Pages directory (www.whitepages.com);
and, online healthcare specialist directories (www.healthgrades.com; www.RA.com; and,
www.vitals.com) with search terms “Rheumatology,” “Rheumatology clinic,” or “Pain clinic,” and
“WV,” or “West Virginia” and (for internet specialist directories) using the ‘Physician locator’ function
to search for rheumatologists within 100 miles of the CHAPS office (May – July 2015).
Of the 15 and 91 rheumatology and pain management practices identified, respectively, non-pain
specializing physicians were excluded, as were multidisciplinary practices that included specialties other
than pain or rheumatology (Figure 2); also excluded were eye doctors, podiatrists, neurosurgeons,
chiropractors, acupuncturists, and weight centers, leaving 9 and 30 eligible rheumatology and pain
clinics, respectively. After exclusion of duplicates and those not meeting location criteria, we made
phone calls to all remaining clinics (6 and 9, respectively) to verify address and purpose of the business,
asking “Is this a rheumatology/pain management clinic, and do a majority of patients seek care in your
facility for pain?”. Following a positive response from rheumatology and pain clinic personnel, we
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engaged clinic managers or lead physicians from each facility in an effort to describe the study and secure
permission to administer the survey to their patients. When clinic managers were not available to speak
by phone or email, we attempted to follow up 3 times. A total of 4 eligible clinics (1 rheumatology and 3
pain management) located in 4 different WV counties agreed to participate. Managers from each
participating clinic signed a consent form which: briefly described the study purpose, stated that study
investigators would neither disrupt clinic practice nor provide any medical advice; and, provided the IRB
number and the primary contact information for the CHAPS study coordinator. Our resources allowed 24
total clinic visits throughout the study.
Clinic visits. Although our presence was not specifically advertised in clinics, we chose our seating in
strategic areas of clinic waiting rooms (corners and/or areas located close to the entrance) so that we
could utilize table space to hold our equipment (a number of clipboards, pens, and a stack of surveys).
While we dressed nicely (i.e., no jeans or sneakers), we omitted the use of uniforms or formal business
attire because we did not want to draw attention to our non-patient status. During clinic visits, a member
of our team consecutively approached every patient (with the exception of one, who was on a stretcher
with his face covered) by (in order) verifying patient status, giving a self-introduction and description of
the study purpose, and asking for their participation as an anonymous respondent. When approaching
someone in obvious pain, we added "I understand if you are in too much pain, or if you are not interested
in filling out a survey." If they agreed to participate, we handed them a clipboard, survey, and pen; we
thanked them regardless of decision. All surveys were self-administered with the exception of 14 (4.7%),
which were completed by a proxy; we also assisted with personal interview format requests (n =6, 2.0%).
Upon submission to a CHAPS team member, all surveys were marked with date and clinic location,
folded to conceal any written information, and placed in a bag beneath our sitting area for delivery to the
CHAPS office for analysis. All surveys were placed in a locked filing cabinet in our research
coordinator’s office when not in use by the CHAPS team. All data entry and compilation of a master
codebook was completed by TF; data were checked periodically for data entry errors by visual
examination, assessment of the distribution of each variable, and by examining the consistency of related
variables.
During all phases of CHAPS research, we also engaged with clinic administrative staff, ensuring
they were familiar with our study objectives; this enabled the return delivery of surveys taken back into
the patient rooms. We used phones and other technology only minimally in waiting rooms, engaged in
dialogue with patients when prompted, and kept a record of distance traveled and participant refusals.
Public notification was not given for this study.
No participant incentives were used for this research study. Approval for the study was obtained
from West Virginia University Institutional Review Board (IRB# 1403248198).
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Variables
Outcome Variables. The main, dichotomous outcome variables for these analyses are 1) Current herbal
use for pain (defined as ‘Action [<6 months] or Maintenance [>6 months] stage of herbal use’ or ‘Does
not use herbs’); and, 2) Current use of other CHAs for pain (defined as the ‘Action or Maintenance stage
of CHA use’ or ‘Does not use CHAs’), which included the use of vitamins and/or minerals, probiotics,
other natural products (excluding herbs), acupuncture, massage therapy, spinal
manipulation/Chiropractic, Tai Chi, yoga, meditation, other relaxation practices, and/or movement
therapies.
Independent Variables. We examined relationships between the outcomes with a variety of
demographic, lifestyle, and health exposure variables in separately run models for each exposure.
Demographics: variables included age, gender, race/ethnicity, education, marital status, household
Income, body mass index, and employment status.
Lifestyle factors: Smoking status, alcohol use in past year, and exercise were included as lifestyle factors.
Health factors: The SF-GPS score was our overall indicator variable for pain. Additionally, twenty-three
comorbidities were assessed, as was past/current prescription medication use for pain management.
Covariates. We adjusted for education, age, exercise, SF-GPS, and health conditions in models, when
sample sizes allowed.

Statistical Analysis

We conducted analyses using SAS 9.4 (Cary, NC), and measured means/frequencies of sample
characteristics, including outcomes CHA/herbal use by each length of time used (Stage of Change). We
manually coded the answers to open-ended questions describing specific herbs used for pain and
generated frequencies for each. Next, we examined relationships between CHA/herbal use and a variety
of demographic, lifestyle, and health factors among pain patients; we also assessed the potential influence
of education and other significantly associated covariates from crude, individual models on CHA/herbal
use for pain.
Demographic variables included age (continuous and 18-49/50+ years), gender (Male/Female),
race/ethnicity (Non-Hispanic White/Other Race), education (‘<HS/GED;’ ‘Some College/Associate/
Technical training;’ ‘>Bachelor’s degree’), marital status (‘Single;’ ‘Divorced/Separated/Widowed;’
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‘Married/Cohabitating’), and household Income (ordinal and in categories ‘<$50,000’/‘$50,001+’).
Additionally, Body Mass Index (BMI, calculated as weight (pounds) x 703/height in inches 2) was
evaluated as continuous and categorical, using the National Institutes of Health clinical classifications
(BMI scores of <25 = “Underweight or Normal weight;” 25 – 29.9 = “Overweight;” 30 – 34.9 = “Obese
Class 1;” and, 35+ = “Obese Classes 2/3”) (295), as was employment status (a categorical variable
defined as ‘employed,’ ‘not employed and not disabled,’ ‘disabled,’ and ‘retired’). Lifestyle factors
included smoking status (defined as Current/former/Never), alcohol use in past year (None/any), and
exercise (categorical as None/Any, and continuous, in 30-minutes per week increments).
Health factors included SF-GPS score, as well as comorbidities. The total SF-GPS score was our
overall indicator variable for pain. As stated before, the SF-GPS contains 5 items each on pain, feelings,
clinical outcomes, and activities; the total score is the sum of these subscales, and ranges from 0 -100,
where 0 = pain generally doesn’t affect life and 100 = pain causes great distress in life) (315).
Additionally, twenty-three comorbidities (a continuous index from 0-23, in addition to dichotomous
variables: ‘Pain syndromes,’ which incorporated diagnoses of spine/back/neck pain, migraines, tension
headaches, rheumatoid arthritis, osteoarthritis, temporomandibular jaw disorder, non-specific knee pain,
fibromyalgia, and/or gout; ‘Mental Health conditions,’ including depression and/or anxiety; ‘Injury,’
including broken bones and/or musculoskeletal injury/tissue trauma; and, ‘Other conditions,’ for which
hypertension, heart disease, irritable bowel disorder, renal disorder, asthma, chronic bronchitis, diabetes,
cancer, stroke, and/or chronic fatigue syndrome were included). Past and current prescription medication
use for pain management was manually recoded (None/any Rx) and examined as an exposure variable as
well.
Additionally, we assessed the association of herbal use to concurrent use of other CHAs. Thus,
we examined as independent variables CHA use (Current user of any CHA except herbs/None), Dietary
supplement use (current use of Vitamins/Minerals, Probiotics, and/or other natural products excluding
herbs/None), Mind and Body practices use (current use of Meditation, Relaxation, Yoga, and/or Tai
Chi/Qi Gong/None), and, use of Acupuncture, Manipulative treatments, Massage, and/or Movement
therapies (current user/None) in separate models. All CHA exposures were further examined in separate
models by Action (short-term use, defined as <6 months) and Maintenance (long-term use, defined as >6
months) Stages of Change for each respective CHA.
All multivariable models were adjusted for demographic and lifestyle factors that did not have a
substantial proportion of missing values (>10%) and were associated (p < .10) with herbal/CHA use in
the unadjusted analyses, such as education, chosen due to its established associations with herbal (144)
and CHA use (95, 144). Additionally, we controlled for variables significantly associated with either
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respective outcome in crude models; these variables included age, exercise, SF-GPS, and health
conditions, when adequate sample sizes for power allowed.

Sensitivity Analysis of Missing Data
As we had over 10% missing data on certain variables, including CHA use, herbal use, BMI,
alcohol consumption, and income, we conducted additional sensitivity analyses using the fully
conditional specification (FCS) method of multiple imputation (PROC MI/MIANALYZE); FCS was
chosen because it allowed us to incorporate both dichotomous outcomes and all categorical/continuous
predictors (with missing values ranging from 5.0% – 53.5%, for SF-GPS and those missing any of the 11
other CHA use questions, respectively) using a total of 250 imputed datasets. Prior to performing multiple
imputation analyses, we first verified that data were missing at random by conducting regression tests on
missing data for all variables of interest, followed by an assessment of missing data patterns to further
verify data were missing at random (PROC MI). After imputation, we compared the unadjusted odds
ratios between our imputed and original datasets; because no differences were detected, we have
presented the results from our original dataset in the Results section.

Results

Response rates were high overall (88% ± 4.1%) ranging from 84 to 94%. Common reasons for
refusal to participate included hand pain, visual impairment (e.g., forgot glasses), or a reluctance to fill
out paperwork. The average one-way travel time for patients across all locations was 74 minutes (ranging
from 34 to and 129 minutes for pain clinics in Elkins and Morgantown, respectively). Results from our
preliminary survey indicated very high internal consistency for the SF-GPS (Cronbach’s alpha = .919);
the internal reliability of each (5-question) subscale was also high (Cronbach’s alpha for the Pain subscale
= .888; Feelings subscale = .874; Clinical Outcomes subscale = .804; Activities subscale = .904).
Coefficients for the total sample were similar, likewise indicating high internal reliability of the SF-GPS
(Cronbach’s alpha overall= .931; Pain subscale= .892; Clinical outcomes subscale = .830; Activities
subscale= .908 Feelings subscale = .865).
Relative to participants with complete data, those missing data on any survey item were more
likely to be older (Odds Ratio (OR) for age = 1.04, 95% CI 1.02, 1.07), prescribed opioids (OR = 3.41, CI
1.39, 8.38), and have a lower SF-GPS score (OR for lowest vs. highest SF-GPS quartile = 3.46, CI 1.62,
7.39). Those missing data on outcome variables CHA/herbal use were also older (OR = 1.04, CI 1.02,
1.06 and OR = 1.04, CI 1.01, 1.07, respectively) and more likely to use opioids (OR = 2.59, CI 1.24, 5.42
and OR = 5.42, CI 1.92, 15.30) over no drugs. Although there was no difference in herbal use by clinic
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location (Fisher’s p = .656), there was a borderline significant difference in CHA use by location
(Fisher’s p = .05), with the lowest use of CHAs (other than herbs) found among rheumatology clinic
patients in our sample (4.0%), compared to the highest proportion of other CHA use in the Morgantown
pain clinic (78.5%). There was no difference between those using a proxy/personal interview vs.
selfadministered format (Fisher’s p = .857) by herbal use; however, there was a difference in survey
format by CHA use (Fisher’s p = .034), with a lower CHA use proportion among those using a proxy or
personal interview format (4.0%) compared to those self-administering surveys (96.1%).
Demographic and lifestyle characteristics are displayed in Table 1. Study participants were
predominantly white (92.0%), female (56.9%), and married or cohabitating (57.5%). Participant age
ranged from 22 to 88 years, averaging 55.6 (SD = 13.6) years. Over 40% of participants were disabled
(43%) and/or obese (44%, mean BMI=33.4±31.5), and over 55% reported no exercise during the last
month. Nearly half did not consume alcohol within the past year (46.8%).
Health characteristics are displayed in Table 2. As expected, the majority of study participants
were experiencing chronic pain (93.4%). Average GPS scores were high (mean=50.9 ±20.6), with 44% of
participants reporting opioid use for pain management. The mean number of pain syndromes/conditions
was 2.3 (SD = 1.6), and prevalence of comorbidity was high, with 93% reporting at least 2 health
conditions (mean=5.4±3.1).

Herbal Use
Table 3 displays frequencies for the use of CHAs, including herbal use. Eight percent of
participants (n = 24) used herbs for pain, with the majority using herbs for 6 months or more
(Maintenance stage) (4.3% of sample). Nineteen specific herbs used for pain management were reported;
of these, the most commonly reported were ginger (41.7%), lavender (33.3%), peppermint (29.2%), black
cohosh (16.7%), marijuana (12.5%), and turmeric/curcumin (12.5%). The mean age for those using herbs
was 49.5 (SD = 12.2) years, with nearly half of herbal users reporting at least a Bachelor’s degree (45.8%).
Those using herbs had a mean of 6.1 health conditions (SD = 3.5) and a SF-GPS score of 56.9 (SD = 18.2).
Eighty-four percent of herbal users were using or had used prescriptions for pain; 63.2% of herbal users
had used opioids (not shown). Nearly all herbal users were also using other CHAs (95.8%), with the highest
proportion using other dietary supplements (91.7%). Over half of herbal users also reported using
Acupuncture, Manipulative treatments, and/or Movement therapies (60.9%), as well as Mind - Body
practices (56.5%).

Relation of herbal use to demographic, lifestyle, and health factors (including other CHAs). Age
showed a marginally significant inverse association with herbal use which persisted after adjustment for
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education (adjusted odds ratio (AOR) = 0.97, 95% confidence interval (CI) 0.94, 1.01). After adjustment
for age, those with the highest education level were approximately five times as likely to use herbs than
those with the lowest education level (AOR = 4.94, CI 1.59, 15.29) (Table 4). While herbal use was
significantly and positively related to household income in the unadjusted model (OR = 1.59, CI 1.07,
2.37 per $25,000-unit income increase), this association was eliminated after adjustment for age and
education (AOR = 1.25, CI 0.81, 1.93). There were no significant differences in herbal use by other
demographic or lifestyle factors.
Although there was no difference in herbal use by prescription medication, those using CHAs
other than herbs were 11.5 times more likely to concomitantly use herbs compared to those not using
CHAs (AOR = 11.46, CI 1.49, 87.93); specifically, in order of decreasing magnitude, those more likely to
consume herbs included those using: Dietary supplements (OR = 12.26, CI 2.82, 53.38), Acupuncture,
manipulative treatments, massage, and/or movement therapies (OR = 5.15, CI 2.11, 12.60), followed by
Mind-body practices (OR = 3.83, CI 1.59, 9.23). Adjustment for age and education only modestly
attenuated these associations (Dietary supplements AOR = 10.25, CI 2.31, 45.47; Acupuncture,
manipulative treatments, massage, and/or movement therapies AOR = 3.99, CI 1.55, 10.23; and, MindBody practices AOR = 2.44, CI 0.94, 6.30). Short-term (<6 months) dietary supplement users were 4.7
times more likely to use herbs than those not using dietary products for under 6 months (AOR = 4.46, CI
1.76, 11.32); long-term (> 6 months) dietary supplement use was not associated with concomitant herbal
use (AOR = 1.83, CI 0.75, 4.49) (not shown). Additionally, short-term users of Acupuncture,
manipulative treatments, massage, and/or movement therapies were 3 times as likely to use herbs (AOR =
2.97, CI, 1.09, 8.07), although long-term use of these CHAs was not associated with concomitant herbal
use (AOR = 2.38, CI 0.84, 6.70) (not shown). Conversely, longer-term users of Mind-Body practices
were over 3 times more likely to use herbs than those not using mind and body practices long-term (AOR
= 3.21, CI 1.23, 8.37), while no significant association existed between short-term use of Mind-Body
practices with herbal use (AOR = 0.50, CI 0.10, 2.45) (not shown).
Other CHA use
CHAs other than herbs were used by the majority of survey participants (58.8%, n= 177), with
47% of survey participants in the long-term/Maintenance (>6 months) stage of use; an additional 32% of
participants were in the Contemplation or Preparation stage (i.e., had an intention to use within 6 months).
Most commonly reported CHAs used were dietary supplements (53.6% of participants), followed by
Mind -Body practices (28.9%) and Acupuncture, manipulative treatments, massage, and/or movement
therapies (28.1%).
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Relation of CHA use (excluding herbs) to demographic, lifestyle, and health factors. Relative to
participants with a high school diploma or less, those with higher education levels were significantly
more likely to use CHAs other than herbs than those with the lowest education levels (Crude OR’s for
>Bachelor’s degree and some college/Associate’s degree/tech training = 2.55 (CI 1.21, 5.40) and 2.11
(CI 1.17, 3.79), respectively); adjustment for age, exercise, health conditions, and GPS strengthened these
associations (AOR for the highest vs lowest education level = 2.68, CI 1.13, 6.39). CHA use was
significantly and inversely associated with age (OR = 0.98, CI 0.96, 0.99) in the unadjusted model,
although adjustment for education and exercise eliminated this association (AOR = 0.99, CI 0.96, 1.01).
(Table 5).
Exercise was strongly associated with CHA use in both crude and adjusted models, with a 14%
increase in the odds of CHA use per 30-minute increase in exercise per week, after adjustment for age,
education, GPS, and health conditions (AOR = 1.14, CI 1.01, 1.29). Relative to those reporting no
exercise, participants indicating engagement in physical activity were over twice as likely to use CHAs
(fully adjusted OR =2.34, CI 1.29, 4.22). Reported SF-GPS, which includes pain severity, was also
positively related to CHA use (OR adjusted for age, education, exercise, and health conditions=1.02 (CI
1.00, 1,03) per unit GPS increase).

Sensitivity Analyses. Missing data was unrelated to specific patient characteristics, suggesting that
missing data likely occurred due to inability to complete the survey while with a physician, or the
wording/layout of the CHAPS, rather than a patient misunderstanding of what specific CHAs were. In
addition, risk estimates for herbal/CHA use calculated using imputed data did not differ appreciably on
any variable from those derived using the original CHAPS data set, suggesting that missing data are
unlikely to account for our findings. Further, exclusion of participants in the pilot phase did not
appreciably alter our findings.

Relation of specific CHA groups (excluding herbs) to demographic, lifestyle, and health factors. We
examined the relationships between all covariates and: dietary supplements (other than herbs) (Table 6);
Mind-body practices (Table 7); and Acupuncture and other approaches (Table 8). After controlling for
demographic, lifestyle, and health factors, education level remained significantly and positively
associated with all CHA categories, with Mind-body practices showing the strongest relationship (AOR
for Bachelor’s degree or higher= 6.45, CI 2.71, 15.37). In addition, exercise remained significantly
associated with dietary supplements (AOR = 2.42, CI = 1.41, 4.14) and Mind-body practices (AOR =
2.31, CI 1.22, 4.39) after adjustment for other covariates, while associations with age were largely
eliminated (Mind and body practices AOR = 0.98 (CI 0.95, 1.00); Acupuncture and other approaches
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AOR = 0.98 (CI 0.96, 1.01)). Those who were morbidly obese (BMI >35) were 70% less likely to use
Acupuncture, manipulative treatments, massage, and/or movement therapies relative to normal or
underweight individuals (AOR = 0.32, CI 0.12, 0.82) (Table 8); likewise, morbid obesity showed an
inverse, although more modest association with use of dietary supplements other than herbs (AOR = 0.40,
CI 0.16, 1.02) (Table 6).
Concomitant use of other CHAs was significantly and positively associated with all CHA
categories; these associations persisted after adjustment for demographic, lifestyle, and health factors,
with AORs ranging from 2.5 (1.2, 5.2) for dietary supplements (Table 6) to 3.3 (1.6, 6.7) for Acupuncture
(and other manipulative/bodywork/movement approaches) (Table 8). Dietary supplement use was
positively related to the number of health conditions (OR for total number of health conditions adjusted
for demographic and lifestyle factors= 1.1, CI 1.01, 1.22) and specifically to pain syndromes and injuries
(partially adjusted OR’s = 1.25 (CI 1.04, 1.51) and 1.52 (CI 0.99, 2.34), respectively); these associations
were modestly attenuated by the addition of SF-GPS to the model (Table 6).

Discussion

This was the first study to examine correlates of herbal use and other CHAs specifically used for
pain in a chronic pain population, and among one of the first to examine correlates of herbal use and other
CHAs in an Appalachian population, while controlling for a variety of potential confounders. To our
knowledge, correlates of overall herbal use have only been assessed in the general population; unadjusted
bivariate comparisons are seen more often in the literature, and many do not separate herbs from other
natural products.
A wide variety of herbs were reported as having been used for pain management, some of which
have at least preliminary evidence of benefit for pain, and/or have been anecdotally used for pain
symptoms in Appalachian herbal texts and qualitative literature. Herbal users (and those using all other
CHAs) had higher education levels, and were significantly more likely to concomitantly use a variety of
CHAs; the strongest association was found between herbal use and short-term use of other dietary
supplements. Other CHAs were used by almost 60% of participants; dietary supplements (excluding
herbs) were the most commonly used CHA, followed by an approximately equal proportion of those
using either Acupuncture (including manipulative or movement therapies, and/or massage), or, Mind and
body practices. Additionally, CHA use was marginally associated with increased SF-GPS scores.
Exercise was associated with the use of all individual CHAs, with the exception of herbal use.

The

8% prevalence of herbal use in our study was higher than that reported in a recent study of primary care
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patients using opioids for pain management (93) and another U.S. study of chronic pain patients (95), but
substantially lower than that reported in prior European (193-195). However, these differences may be
due to the differing classification of our outcome of herbal use specifically for pain, rather than herbs
used for a variety of purposes. The lower rates of herbal use reported in our study population may reflect
the modest decline in the national use of herbs over the last decade (125), and/or differences in
methodology, time period, and/or study population. For example, in their cross-sectional study of 463
chronic pain primary care patients sampled from multiple U.S. academic medical centers, Rosenberg et
al. used an open-ended item administered with a personal interview format to assess herbal use; this may
have allowed a broader capture of herbs and herbal preparations in their study (35). Two of the three
European investigations assessing use of herbs for pain conditions were conducted 3 decades ago;
including two U.K investigations indicating 20 (193, 194) to 35% (194, 195) of Rheumatoid Arthritis
patients used herbal medicines; one more recent (1996) survey study in another U.K. population
suggested high prevalence of herbal use in FMS patients (194, 196, 197), although the authors did not
distinguish herbal from other dietary supplements, rendering comparisons with our findings challenging.
Only two prevalence studies have assessed herbal use in non-pain Appalachian populations, including a
2003 prevalence study on 578 WV pregnant women which showed that 45.2% used herbs (184);
however, this included soft drinks, cocoa butter for external use, and other products not counted as herbs
in our study, while in 1999-2004, 19.3% of 2523 rural NC adults over 45 years of age used herbs and
other natural products, with garlic (4.9%) and cayenne (1.8%) the most widely reported (141).
In contrast, the reported prevalence of CHA use other than herbs was higher in our sample
(58.8%) than that reported in prior studies of U.S. chronic pain populations (93). For example, in a large
sample of Wisconsin primary care patients using opioids for chronic pain, participants reported lower
usage of several CHAs; the most striking contrast was the difference between supplement use in our
sample (53.6%) compared to that of the Wisconsin sample (6.8% for herbs/supplements) (93, 95).
Likewise, observed CHA use in our population also higher than that of reported by a sample of chronic
pain primary care patients from academic medical centers in the US, although differences were more
modest (58.8% vs. 52%) (95).
Our preliminary systematic review on herbal prevalence among the general U.S. population
(Appendix C) showed the majority of large cross-sectional studies frequently lumped herbs and dietary
supplements together, resulting in uncertainty regarding true herbal prevalence rates; this was often due to
misclassification of herbal use with other natural products (such as fish oil, etc.) in national surveys
(primarily, the NHIS, which was used for a majority of these studies). Many studies assessing potential
correlates of herbal use have used inconsistent definitions as well, often combining herbs with other
dietary supplements (141, 143, 144, 146, 147, 155, 156, 159, 161, 165, 344) or other approaches (139,
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145, 152, 154); few have kept the outcome herbal use separate from other CHAs (138, 157, 160, 162,
345); our study separately classified herbal products from other dietary supplements.
Two herbs used in the Appalachian region and for which both evidence of anti-inflammatory and
pain management exist were also reported in our sample; these were Ginger (223, 232, 233, 257-261) and
Peppermint (223, 234, 235, 243) (41.7% and 29.2% of herbal users, respectively). Although not for pain,
18% of 578 WV pregnant women used peppermint in a 2003 study (184). Lavender has at least
preliminary evidence of efficacy for pain management (346-348), and anti-inflammatory (272) effects as
well; our study is the first to report its use in an Appalachian sample. Herbs used most often by a
U.S./Canadian sample of 434 with Fibromyalgia syndrome (FMS) were Ginkgo (3.7%), Garlic (3.0%),
Ginseng (3.0%), Echinacea (2.5%), Evening Primrose oil (2.3%), and Valerian (2.3%) (197). With the
exception of Ginkgo and Ginger, these were not reported by our participants; however, this was due to a
difference in the assessment of herbal use for management of pain (in our sample) vs. herbal use for a
variety of conditions.
Compared with nonusers, CHA users in the general population tend to be women, white, middle
aged, better-educated, and of higher income (90, 106, 110-116). CHA use was not associated with female
gender or race, and a borderline association between CHA use and (younger) age was eliminated when
controlling for education, exercise, SF-GPS, and health conditions. Similarly, a study of 463 primary care
patients with chronic pain also found no association between female gender, race, and age, after
controlling for a variety of factors. It is plausible the demographic makeup and likelihood of CHA use
differs in populations experiencing pain, compared to populations with a greater variety of health
characteristics. Other CHA use was significantly associated with higher levels of education in our sample
of pain patients, particularly mind and body practices; herbal use was as well.
Both CHA and herbal use in our sample were significantly and positively associated with higher
education levels, consistent with previous studies, including two large 2002 studies which found those
with a higher education were more likely to use CHAs (95, 144) and natural products (144).After
adjustment for other factors, income was not associated with herbal use or other CHAs, unlike a study of
over 900 chronic pain patients using opioids (93). Although an income effect (349) may influence CHA
use (i.e., higher-wage individuals are more likely to invest in health because they perceive higher benefits
associated with improved health, including an increase in productive days and less sickness-related
income loss), Bhargava et al. recently proposed that a substitution effect may also be present among those
with higher incomes (i.e., higher wages may also increase the opportunity cost of time used for producing
health, thus discouraging time spent on health care) (116). This may, perhaps, apply to CHAs use among
those with higher incomes in pain populations; alternately, the impact of pain may influence individuals
(regardless of income) to try approaches outside of or alongside conventional medicine. However, neither
of our outcomes was associated the SF-GPS subscale, which incorporated pain severity as a component,
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even after controlling for income and other factors; this contrasts a cross-sectional study which found an
adjusted (age, gender, race, pain sites, and illicit drug use) association between CHA use and pain
severity without the use of the SF-GPS (93).
Overall, CHA users had higher odds of exercise and a marginal inverse association with higher
BMI, associations of BMI and exercise were particularly pronounced with dietary supplement and
Acupuncture (and manipulative/movement approaches) users. These findings are consistent with those
from a study using 2012 NHIS data which indicated a significant, positive association of exercise to use
of Chiropractic, Massage, herbs, and yoga (116). Herbal and CHA use was not associated with specific
health conditions (such as both neck/upper back and multiple sites of pain), in contrast to findings
reported in previous studies, including a larger study also controlling for demographic, health, and
lifestyle factors similar to ours (93). Neither CHA nor herbal use was associated with prescription drug
use in the CHAPS, similar to a large sample of primary care patients with chronic pain using opioids (95).
In addition, CHA use differed by those using a proxy or personal interview format, while no
difference was found for herbal use. Thus, there may be a possibility that those lacking skills to complete
the survey on their own may have limitations, perhaps disability and/or cognitive impairment, preventing
them from using CHAs which require either physical movement or frequent practitioner visits – however,
this may not prevent them from engaging in self-administered CHAs such as herbal use. Only one study
has compared differences between self- and practitioner-administered CHA use, for which
disability/cognitive impairment factors were not assessed (116).
This the first study to assess correlates of both herbal use and other CHAs in an Appalachian pain
patient population. We pilot-tested and employed a newly developed survey instrument, the CHAPS.
Incorporating pain items adapted from a previously validated pain measurement tool (315), the CHAPS
included comprehensive information on a range of factors and constructs, yet required only 12 minutes to
complete, and may thus be appropriate for use in future population- and clinic-based survey studies of
pain populations. Survey response rates were high and we exceeded our target sample size, despite
limited resources and other challenges including clinic lockdown, suspension of physician licensure, and
inclement weather. In addition, our high reliability estimates for the SF-GPS also support further use of
this measurement tool in pain populations.
Despite these strengths, there were also some limitations. Due to limited data regarding the use
of CHAs in an Appalachian population with pain, we powered our study based on herbal prevalence
rates reported in the literature for the general population (18%); given that CHA use is known to be
further elevated in chronic pain populations, we assumed that herbal use would be at least as high in our
sample of Appalachian chronic pain patients. However, due to the lower than expected rates of herbal
use in survey participants, we did not have sufficient power to examine associations by specific Stages
of Change regarding herbal use, or to determine with confidence the prevalence of use of specific herbs.
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Many of our confidence intervals were wide, suggesting estimates should be interpreted with caution.
Notably, some factors had relatively high rates of missing data, including the outcome herbal use
(18.3%), BMI (11.6%), alcohol use (11%), and income (12.3%). However, we used multiple imputation
procedures to account for missing data in order to obtain appropriate estimates of uncertainty associated
with missing variables, assess for and minimize potential bias, and maximize the use of available
information in our CHAPS dataset,; notably, estimates using imputed data did not differ appreciably
from those derived from the original data, suggesting that missing data are unlikely to account for our
findings. As there were no systematic patterns associated with missing data, and risk estimates did not
appreciably change, we have confidence that estimates obtained from our data provided reasonably
reliable measurements regarding the correlates of CHAs, including herbal use, in northern WV pain
patients.
As in many studies using self-report data, there is a possibility of recall bias. While the
misclassification of outcomes was unlikely, specific herbs or prescriptions listed in open-ended items
may have suffered from misclassification bias, potentially resulting in underascertainment. For example,
we overheard a proxy interviewer ask a respondent, "Do you want to list your prescriptions?” to which
the respondent replied, "No, it would take too long.". Additionally, we did not incorporate specific
questions about marijuana due to concerns regarding the sensitivity of this issue. Nonetheless, marijuana
use for pain was still reported by 12.5% of herbal users in our open-ended item, a figure that likely
substantially underestimates true prevalence.
Selection bias may have been present since this study utilized a convenience sample. However,
our consecutive sampling approach minimized this possibility; in addition, response rates were very
high, reducing the likelihood of non-response bias. Researchers wishing to implement the CHAPS or
similar surveys should explore barriers to survey implementation present at specific clinics, including
the physical space made available to them; one clinic was gracious enough to offer our coordinator a
workstation behind their check-in window during data collection days, and although all patients were
solicited for participation, this site had the lowest overall response rate (84.1%) of all clinics.
Additionally, much remains unknown about the health behavior habits of opioid users with regard
to CHA use. Our measurement of CHAs, particularly herbal use, was hindered by a high proportion of
missing responses among those using opioids, which comprised nearly half of our population, potentially
leading to an underestimate for herbal use. Other issues surrounding the use of our survey instrument
include a lack of data on specific reasoning to use herbs and other CHAs. This was the result of our
decision to keep the CHAPS as brief as possible; however, future studies may wish to incorporate more
contextual elements of herbal use and CHAs, including specific reasons for use, concomitant use of
medications, spirituality and/or prayer, access to CHAs, and disclosure of CHA use to physicians.
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Additional considerations should be made for the capture of information in future iterations of the
CHAPS, or for similar surveys. These include additional questions regarding e-cigarettes and other
forms of tobacco, capture of previous use of CHAs beyond the 6-month time point assessed in our study,
and reformatting CHA questions with equally-spaced bins on multiple pages with adequate visual cues
and space for nested efficacy questions.

Conclusion

Our study was the first to assess concomitant CHA use in a pain population and to document specific
herbs used within this population. Although the majority of patients in our sample did not use herbs for
pain, their use was reported 8% of the time and through the use of 19 unique herbs, and was strongly and
positively associated with the use of other CHAs. The majority of our sample used at least one CHA for
pain. Investigation of factors associated with herbal medicine, other CHAs, and their concomitant use in
pain populations will help inform physicians concerned about potential interactions. Additional studies
are needed to further explore the patterns and determinants of herbal and other CHA use in chronic pain
populations, to assess perceived efficacy of these approaches, and to lay the foundation for future clinical
efficacy studies on herbal and other CHA approaches for managing chronic pain.

CHAPTER 5: Discussion
Summary of Key Findings
Inflammation is often a component of chronic pain, yet its potential role in fibromyalgia
syndrome (FMS) remains inconclusive. FMS is a complex chronic pain condition affecting ~2% of the
population; management is challenging and treatment options remain limited. Many herbs contain antiinflammatory properties, and herbs indicated for analgesia and rheumatic conditions have traditionally
been used in Appalachia. Despite the popularity of herbs in the US, determinants and patterns of herbal
use in FMS and other chronic pain populations have not been well studied, particularly in Appalachia,
where prevalence of chronic pain and related comorbid conditions is high. Likewise, prevalence, patterns
and correlates of other CHA use remain little studied in Appalachian chronic pain populations, or in
adults with certain pain conditions, including FMS. This series of 3 studies are designed to help fill these
knowledge gaps; the overall objectives of these investigations were to investigate: 1) the association of
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FMS to a marker of inflammation, serum C-reactive protein (CRP) in a large Appalachian population; 2)
the demographic, lifestyle, and health-related correlates of herbs and other complementary health
approaches (CHAs) used for pain in a sample of WV chronic pain patients, using a newly developed
survey instrument; and, 3) the relation of herbal supplement use to FMS in two nationally representative
samples of U.S. adults (NHIS 2007 and 2012), as well as trends in patterns of herbal use over time.
Although we found herbal use was associated with concurrent use of other CHAs in WV pain
patients, it was not associated with pain level, the use of prescription medications, or the number of pain
conditions. Results of these studies suggest the following 1) FMS is positively associated with serum
CRP; this association was largely explained by obesity and comorbidity, suggesting the role of
inflammation in FMS may be complex 2) CHA use in chronic pain patients in northern WV is high,
although reported use of herbs for pain appears low. Herbal use for pain was strongly associated with use
of other CHAs, but was unrelated to pain severity or use of prescription medications. 3) Use of herbs and
other CHAs is strongly and positively associated with FMS diagnosis in U.S adults.
Strengths of the Dissertation
All studies had high response rates and population-based designs. Sample sizes for two of the
three studies were large. The C8 Health Project, from which we drew data for Chapter 2, was the largest
comprehensive community study conducted to date in the Appalachian region; Chapter 3 was conducted
using two nationally representative samples of US adults. Chapter 4, the CHAPS, was the first to assess
correlates of CHAs and herbal use in an Appalachian pain population and to employ a newly developed
comprehensive survey instrument for measuring herbal and other CHA use, pain severity, and a wide
range of demographic, lifestyle, and health-related factors (see below). With the exception of analyses
regarding correlates of herbal use in the CHAPS, we were also able to control for a broad array of
potential confounders, including health conditions, which diminished the possibility of unmeasured
confounding. We were also able to assess the influence of a variety of potential mediators and/or effect
modifiers in our analyses.
In Chapter 4, we employed our newly developed survey instrument, the CHAPS, in over 300 pain
patients, utilizing independent investigators to conduct quality assessment, and incorporating pain items
adapted from a previously-validated pain measurement tool (315). Although allowing for capture of
information on a wide array of health-related information, the CHAPS required only 10-12 minutes to
complete; reliability of the CHAPS was also excellent overall, indicating high internal reliability
estimates and further supporting the use of this instrument for observational research in chronic pain
populations. We exceeded our target sample size, even though we faced significant obstacles to data
collection including clinic lockdown, inclement mountain weather, and temporary withdrawal of
physician licensure which limited our access to patients. In addition, we conducted a sensitivity analysis
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using imputation procedures to verify our estimates against those without missing data, which enabled us
to interpret our findings with confidence.

Limitations of the Dissertation
Although our studies had many strengths, there were several limitations. Most important
conclusions regarding causality cannot be drawn due to the lack of a temporal component in our
crosssectional study designs. Two of our studies targeted populations of predominantly white
Appalachian adults, potentially limiting the generalizability of findings to other populations. Moreover,
our original study in a sample of WV chronic pain patients was underpowered to assess herbal use based
on the TTM Stages of Change as originally envisioned. Given the often poor recognition of FMS in the
medical community, particularly prior to 2010, misclassification is also possible and may have led to
underascertainment. Nearly all health conditions, and all herbal/CHA use measurements in our studies
were based on self-report, possibly leading to response or misclassification bias.
Additionally, neither NHIS dataset captured the use of herbal products other than supplements,
likely leading to underestimates of herbal use. Likewise, many of the CHAs were only assessed in the
NHIS if they were administered by a practitioner, likely resulting in underestimates, which may have
impacted our ability to measure concurrent CHA and herbal use accurately. Additionally, we were
unable to incorporate an additional year of the NHIS (2002) due to a lack of specific information
regarding FMS diagnosis.

Potential Public Health Implications and Future Recommendations
FMS, a disease with largely unknown etiology, has higher odds of comorbid conditions compared to
non-FMS populations; this includes inflammatory-mediated diseases such as autoimmune disease (22).
However, the potential shared role of inflammatory markers between FMS and specific comorbidities
remains largely unexplored by population studies. Because we were only able to assess the role of CRP as
an overall measure of systemic inflammation, however, we remain unaware of specific dynamics
regarding inflammatory response, or interplay, between other cytokines (and related markers) in those
with FMS, in the presence of obesity and comorbidities such as autoimmune disease.
Although it is possible inflammation is not associated with FMS, given the results of our first
study, further large, population-based research is still needed to replicate our findings while assessing for
a variety of inflammatory markers while controlling for a variety of factors and assessing potential
mediators as we did; based on established knowledge of the anti-inflammatory effects of some herbs
(123, 223, 225-227, 233, 241-268, 270-272), and, given FMS was positively associated with herbal use in
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our second study, future research should also compare a variety of inflammatory measures among those
using herbs (ideally, with known anti-inflammatory benefit) by FMS status; based on sensitivity analysis
results from our second study as well, the role of comorbidities in research on herbal use in FMS
populations should be further explored.
As a result of our second study, we have a better understanding of the patterns of herbal use
prior to and following the implementation of updated FMS diagnostic criteria and increased
availability of FDA-approved treatments for FMS. It remains possible that both the increase in FMS
diagnoses and the decrease in odds of herbal use for FMS over time are also in part perhaps the result
of corporate promotion for FMS drugs, increased off-label use of other drugs, and, opioid use for
FMS. Additional research should continue to monitor FMS trends, in addition to herbal use trends over
time for a variety of diseases; all trend studies should continue to consider changes in diagnostic
criteria as well as the changing availability of treatments for respective diseases.
Whether opioids can be reduced by introducing herbal products remains to be examined. Our second
and third studies offer information regarding the patterns and correlates of complementary health
practices in specific chronic pain populations in WV and nationally. Although efficacy studies for such
approaches, including herbs, are largely lacking, our research may encourage a more open dialogue
between physicians and patients about potential opioid alternatives at a time when there is a public
health epidemic of opioid misuse and abuse (86). However, studies regarding perceived or
demonstrated efficacy of herbs for FMS and other pain syndromes remain sparse; unfortunately, we
were unable to adequately measure efficacy on a number of CHAs due to low sample size.
Nonetheless, clinical studies should ideally examine aspects of CHA and herbal efficacy in pain
populations rather than observational research; with the inclusion of a larger sample size, the CHAPS
will be a useful tool in identification of potential herbs and other CHAs of interest. Future observational
and clinical studies should, however, capture concurrent dietary supplements and medication intakes,
including opioids, to enable assessment of potential herb-drug interactions in populations with disease.
Neither CHAs nor herbal use were strongly associated with the SF-GPS subscale in our third
study; however, 8% of pain patients still reported using herbs specifically for pain. Due to lack of a
standard definition for herbal products, true herbal prevalence rates for pain are unknown. Moving toward
an international consensus regarding a widely-used definition for herbal products will only improve the
quality of research by enabling a greater degree of comparison between studies. Other CHAs were used
by 58.8% of participants in our sample; again, the comparability of our results to other studies is greatly
hampered by the lack of standardized CHA definitions.
Herbs reported as used for pain management in our third study included ginger and peppermint, which
have at least preliminary evidence of benefit for pain and/or inflammation, and have been anecdotally
used for pain in Appalachian herbal texts and qualitative literature (223, 232-235). Our study was the first
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to report pain patient use of lavender, an herb for which some evidence of anti-inflammatory mechanism
exists (272); lavender was used specifically for pain in our sample. While ethnobotanical studies are
important in documenting herbal preparations in a variety of populations for health purposes, our
epidemiological approach to quantifying the use of herbs is also useful; this approach lays the foundation
for understanding differences regarding a variety of factors associated with herbal use in subpopulations,
while enabling our ability to draw estimates for measures of association. Replication of the CHAPS in a
larger population may yield additional information about the correlates of specific herbs; these future
studies may inform differences in herbal use by a variety of demographic, lifestyle, and health factors, to
lay the foundation for clinical studies or when clinical studies are not feasible.

Conclusion

Our studies, collectively, demonstrate a need for further clarification regarding the relationships
between herbal use, FMS, and inflammation. Our main findings suggest that: inflammation in FMS may
be partially accounted for by factors including BMI, comorbidities, and other factors; those with FMS are
significantly more likely to use herbs; and, although herbal use (specifically) for pain may be strongly
associated with concurrent use of other CHAs for pain, their use may not be associated with pain level,
but other factors. Future observational and longitudinal studies must replicate our studies with specific
improvements: correct classification of herbal use as plant-based products consumed in a variety of
formats; multiple, concurrent, inflammatory marker measurement; ascertainment of FMS diagnosis
timing; and, for CHAPS, larger samples to obtain more precise estimates regarding correlates of herbal
use for pain.
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Tables
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Table 1: Characteristics of an Appalachian adult population by Fibromyalgia (FMS) status,
Adjusted for Demographic and Lifestyle factors, C8 Health Project, 2005-2006
Characteristic
Total
Age (years)
Age
18-24 (ref)
25-44
45-64
65+

Total Population

FMS

Non-FMS

Adjusted Odds Ratioa
OR (CI), p-value

52535
45.25 (16.14)

N (%) / Mean (SD)
1125 (2.1%) 51410 (97.9%)
51.14 (11.58)
45.12 (16.20)

6540 (12.5%)
20178 (38.4%)
19098 (36.4%)
6719 (12.8%)

16 (1.4%)
6524 (12.7%)
300 (26.7%) 19879 (38.7%)
689 (61.2%) 18409 (35.8%)
120 (10.7%) 6599 (12.8%)

25002 (47.6%)
27533 (52.4%)

90 (8.0%) 24912 (48.5%)
1035 (92.0%) 26498 (51.5%)

51092 (97.2%)
1443 (2.8%)

1098 (97.6%)
27 (2.4%)

49994 (97.2%)
1416 (2.8%)

1.09 (0.73-1.62), .683
---

6261 (11.9%)
22353 (42.6%)
17081 (32.5%)
6840 (13.0%)

106 (9.4%)
445 (39.6%)
442 (39.3%)
132 (11.7%)

6155 (12.0%)
21908 (42.6%)
16639 (32.4%)
6708 (13.1%)

--1.57 (1.25-1.96), .0001*
2.22 (1.75-2.82), <.0001*
1.91 (1.42-2.56), <.0001*

33682 (64.1%)
9057 (17.2%)
3357 (6.4%)
5979 (11.4%)
460 (0.88%)

482 (42.8%) 33200 (64.6%)
144 (12.8%) 8913 (17.3%)
252 (22.4)
3105 (6.0%)
233 (20.7%) 5746 (11.2%)
14 (1.2%)
446 (0.9%)

--1.44 (1.16-1.79), .0008*
5.70 (4.73-6.87), <.0001*
1.50 (1.26-1.78), <.0001*
2.23 (1.28-3.88), .004*

36198 (68.9%)
8729 (16.6%)
7608 (14.5%)

836 (74.3%) 35362 (68.8%)
60 (5.3%) 8669 (16.9%)
229 (20.4%) 7379 (14.4%)

--0.63 (0.47-0.84), .002*
0.85 (0.71-1.01), .058

5335 (10.2%)
12308 (23.4%)
14326 (27.3%)
13559 (25.8%)
7007 (13.3%)

92 (8.2%) 5243 (10.2%)
288 (25.6%) 12020 (23.4%)
301 (26.8%) 14025 (27.3%)
291 (25.9%) 13268 (25.8%)
153 (13.6%) 6854 (13.3%)

0.85 (0.66-1.10), .217
--1.03 (0.86-1.24), .759
1.05 (0.86-1.29), .619
1.09 (0.85-1.39), .514

26847 (51.1%)
25688 (48.9%)

722 (64.2%) 26125 (50.8%)
403 (35.8%) 25285 (49.2%)

--0.86 (0.75-0.98), .023*

22859(43.5%)

567 (50.4%)

--1.02 (1.02-1.03), <.0001*
--3.89 (2.30-6.56), <.0001*
8.28 (4.91-13.95), <.0001*
4.37 (2.50-7.64), <.0001*

Gender
Male (ref)
Female

--10.68 (8.53-13.37), <.0001*

Race/Ethnicity
Non-Hispanic White
Other Race (ref)

Education
<12th grade (ref)
HS/GED
Some College
Bachelor’s degree+

Employment
Employed/Student(ref)
Retired/Unemployed
Disabled
Homemaker
Other

Marital Status
Married/Cohabitating (ref)

Single
Divorced/Sep/Widow

Household Income
Don’t know/Missing
<$20,000 (ref)
$20,000-40,000
$40,001-70,000
$70,000+

Alcohol
Don’t drink (ref)
Currently Drink

Tobacco User
Never (ref)

22292 (43.4%)

---
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Current
Former

16691 (31.8%)
12985 (24.7%)

274 (24.4%)
284 (25.2%)

16417 (31.9%)
12701 (24.7%)

36113 (68.7%)
16422 (31.3%)
10526 (38.2%)

762 (67.7%) 35351 (68.8%)
363 (32.3%) 16059 (31.2%)
631 (61.0%) 9895 (37.3%)

0.91 (0.78-1.07), .243
1.06 (0.91-1.23), .441

Exercise Program
No regularity (ref)
Regular exercise

Menopause occurred

----1.82 (1.49, 2.21), <.0001*

Note: Column Percentages shown a Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level,
White Race, and Household Income; Also adjusted for lifestyle covariates Tobacco Use and Current Alcohol consumption

Table 2: Health Characteristics of an Appalachian adult population by
Fibromyalgia (FMS) status, Adjusted for Demographic and Lifestyle factors,
C8 Health Project, 2005-2006
Characteristic

Total
Population
28.53 (6.31)

BMI+
< 24.99 (ref)
25.5-29.99
30 – 34.9
35+

Number of
Comorbidities
Comorbidity Index
None (ref)
1
2
3+

Autoimmune disorder
Osteoarthritis
Allergies or Chronic
Sinusitis
Kidney disorder
Respiratory disease
Cardiovascular
disease
Liver disease
Endocrine Disorder
Diabetes
Frequent Headache
Sleep Impairment
Scores
Mood Disturbance
Scorem

FMS

Non-FMS

N (%) / Mean (SD)
30.47 (7.22)
28.49 (6.28)

Adjusted Odds Ratioa
OR (CI), p-value
1.02 (1.01-1.03), .001*

16258 (31.0%)
18200 (34.6%)
10704 (20.4%)
7373 (14.0%)
1.29 (1.27)

279 (24.8%)
320 (28.4%)
251 (22.3%)
275 (24.4%)
2.78 (1.59)

15979 (31.1%)
17880 (34.8%)
10453 (20.3%)
7098 (13.8%)
1.25 (1.24)

16778 (31.9%)
16999 (32.4%)
10535 (20.1%)
8223 (15.7%)
2192 (4.2%)
4093 (7.7%)
24470 (46.6%)

58 (5.2%)
177 (15.7%)
301 (26.8%)
589 (52.4%)
220 (19.6%)
411 (35.5%)
893 (79.4%)

16720 (32.5%)
--2.38 (1.77-3.21), <.0001*
16822 (32.7%)
5.16 (3.88-6.86), <.0001*
10234 (19.9%)
7634 (14.9%) 10.46 (7.90-13.84), <.0001*
3.43 (2.89-4.06), <.0001*
1972 (3.8%)
3.86 (3.34-4.45), <.0001*
3782 (7.1%)
23577 (45.9%) 2.91 (2.51-3.38), <.0001*

5202 (9.9%)
7385 (14.1%)
4661 (8.9%)

226 (20.1%)
342 (30.4%)
148 (13.2%)

4976 (9.7%)
7043 (13.7%)
4513 (8.9%)

1.72 (1.47-2.01), <.0001*
1.89 (1.64-2.17), <.0001*
1.25 (1.03-1.51), .027*

684 (1.3%)
4083 (7.8%)
4778 (9.1%)
10105 (19.2%)
4.00 (3.56)

38 (3.4%)
264 (23.5%)
157 (14.0%)
439 (39.0%)
7.32 (3.29)

646 (1.3%)
3819 (7.4%)
4621 (9.0%)
9666 (18.8%)
3.93 (3.53)

1.51 (1.06-2.16), .022*
1.82 (1.57-2.12), <.0001*
.978 (.813-1.18), .810
2.03 (1.78-2.31), <.0001*
1.23 (1.21-1.25), <.0001*

7.25 (3.40)

4.53 (3.68)

1.19 (1.17-1.21), <.0001*

4.59 (3.70)

--1.11 (.932-1.31), .248
1.24 (1.02-1.49), .028*
1.43 (1.18-1.74), .0003*
1.60 (1.54-1.67), <.0001*

Note: Column Percentages shown
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a

Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household Income;
Also adjusted for lifestyle covariates Tobacco Use and Current Alcohol consumption
S Sleep impairment derived from responses to four individual questions regarding the frequency of short sleep, fitful sleep, insomnia and/or
daytime somnolence; higher
score indicates increased frequency of impairment m Mood disturbance derived from responses to four individual questions regarding
frequent mood swings, irritability, fatigue and/or inability to
concentrate; higher
score indicates increased frequency of disturbance

Table 3: Model Statistics assessing the association between Fibromyalgia (FMS) and blood serum Creactive Protein (CRP) quartile adjusting for BMI and Comorbidity index in an Appalachian adult
population, 2005-2006 (N=52,535)
Characteristic

NonFMS
Total

Models

FMS
Crudee
N (%) / Mean (SD)

CRP level (mg/L)

3.79 (7.22)

CRP Quartile 1a

14516
(27.6%)
12221
(23.3%)
12755 (24.3%

(ref)

Quartile 2b
Quartile 3c
Quartile 4d
Wald X2, p for trendt

13043
(24.8%)

5.54 (9.77)

3.75 (7.15)

192
(17.1%)
214 (19.0%)

14324
(27.9%)
12007
(23.4%)
12458 (24.2%

297 (26.4%)
422 (37.5%)

12621
(24.6%)

Odds Ratio (CI) (p-value)
Adjusted for
Model 1 +
Model 1 +
Demographic
BMIg
comorbiditiesh
and Lifestyle
Factors
(Model 1)f

1.02 (1.011.02)
(<.0001*)
--1.33 (1.09-1.62)
(.004*)
1.78 (1.48-2.14)
(<.0001*)
2.50 (2.10-2.97)
(<.0001*)
118.42,
(<.0001*)

1.01 (1.001.01) (.004*)
--1.13 (0.92-1.38)
(.243)
1.23 (1.02-1.48)
(.032*)
1.35 (1.13-1.62)
(.0009*)
17.48,
(<.0001*)

1.01 (1.001.01) (.059)
--1.07 (0.881.32) (.473)
1.12 (0.921.37) (.244)
1.17 (0.961.42)
(.120)
4.02, (.045*)

1.00 (.997-1.01)
(.267)

Model 1 +
BMI &
comorbiditiesr

1.00 (.997-1.01)
(.279)

---

---

1.04 (0.85-1.28)
(.686)
1.08 (0.89-1.30)
(.452)
1.10 (0.92-1.32)
(.310)
3.44, (.064)

a C-reactive

1.03 (0.84-1.27)
(.750)
1.06 (0.87-1.29)
(.576)
1.07 (0.88-1.30)
(.510)
1.23, (.269)

protein .15-.80 mg/L b
C-reactive protein .81-1.80 mg/L c
C-reactive protein 1.81-4.20 mg/L d
C-reactive protein 4.21-250.6 mg/L
t Linear trend e (R2==.003) f Full Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household
Income; Also adjusted for
lifestyle covariates Tobacco Use and Current Alcohol consumption (R 2= .031)
g (R2=.031)
h Model adjusted for Comorbidity index; index included diabetes, other endocrine disorders (thyroid, Addison’s, and Cushing’s disease), kidney
disease, respiratory
conditions (asthma, emphysema, chronic obstructive pulmonary disorder, bronchitis), osteoarthritis, heart disease, liver disease, autoimmune disorders (defined as having
any diagnoses of immune disease, lupus, or rheumatoid arthritis), sleep apnea, irritable bowel syndrome, allergies or frequent sinusitis, or frequent recurrent headache
(R2=.041)
r (R2=.041)
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Table 4: Model Statistics assessing the association between Fibromyalgia (FMS) and blood serum
C-reactive Protein (CRP) quartile adjusting for Sleep impairment and Mood disturbance in
an Appalachian adult population, 2005-2006 (N=52,535)
Models
Crudee

Odds Ratio (CI) (p-value)
Adjusted for
Model 1 + Moodg Model 1 + Sleeph
Demographic and
Lifestyle Factors
(Model 1)f

1.02 (1.01-1.02)
(<.0001*)
---

1.01 (1.00-1.01) (.004*)

1.01 (1.00-1.01) (.021*)

1.01 (1.00-1.01) (.035*)

---

---

---

Quartile 2b

1.33 (1.09-1.62) (.004*)

1.13 (0.92-1.38) (.243)

1.12 (0.91-1.36) (.287)

1.10 (0.90-1.35) (.357)

Quartile 3c

1.78 (1.48-2.14) (<.0001*)

1.23 (1.02-1.48) (.032*)

1.20 (1.00-1.45) (.056)

1.18 (0.98-1.43) (.083)

2.50 (2.10-2.97) (<.0001*) 1.35 (1.13-1.62) (.0009*)

1.28 (1.07-1.53) (.007*)

1.26 (1.05-1.51) (.011*)

118.42, (<.0001*)

11.06, (.0009*)

10.40, (.001*)

CRP level (mg/L)
CRP Quartile 1a

Model 1 +
Mood & Sleepr

1.01 (1.00-1.01)
(.031*)
---

(ref)

Quartile 4d
Wald X2, p for trendt

17.48, (<.0001*)

1.10 (0.90-1.34)
(.363)
1.18 (0.97-1.42)
(.093)
1.24 (1.03-1.48)
(.021*)
8.25, (.004*)

a C-reactive

protein .15-.80 mg/L b
C-reactive protein .81-1.80 mg/L c
C-reactive protein 1.81-4.20 mg/L
d C-reactive protein 4.21-250.6 mg/L
t Linear trend e (R2==.003) f Full Model adjusted for demographic covariates Age, Gender, Marital Status, Employment, Education level, White Race, and Household
Income; Also adjusted for lifestyle covariates Tobacco Use and Current Alcohol consumption (R 2= .031)
g Mood disturbance derived from responses to four individual questions regarding frequent mood swings, irritability, fatigue and/or inability to concentrate (R2=.035)
h Sleep impairment derived from responses to four individual questions regarding the frequency of short sleep, fitful sleep, insomnia and/or daytime somnolence
(R2=.037)
r (R2=.038)
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Table 1a: Demographic and Lifestyle Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by Herbal use (previous or current use of herbal products)
2007 (N = 20,127)

2012

Herbal use

P

Yes
Characteristic
Total

N (%)
5057 (27.1)

95% CI
(26.2, 27.9)

Weighted
population
estimate*
23057602

No

Yes

N (%)

N (%)

15070 (72.9)

(N=30, 672)

Herbal use

7238 (24.2)

P

Overall P

W

No
95% CI
(23.5, 25.0)

Weighted
population
estimate**
21914809

N (%)
<.0001

23434 (75.8)

Age in years
18-24
25-44
45-64
65-75
75+
Mean (SE)
Gender
Male
Female
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Asian
Other Race/ethnicity
Education

<.0001

397 (8.4)

(7.2, 9.7)

1943145

1756 (12.0)

507 (7.3)

(6.4, 8.2)

1600475

2521 (11.5)

1700 (33.5)

(31.9, 35.0)

7717572

5664 (36.2)

2400 (32.5)

(31.0, 33.9)

7112702

8254 (34.1)

1992 (39.4)

(37.8, 41.0)

9088019

4736 (31.7)

2846 (39.5)

(38.1, 40.9)

8653969

7695 (32.5)

591 (11.3)

(10.3, 12.3)

2597876

1470 (9.6)

953 (13.7)

(12.8, 14.6)

3002082

2565 (11.3)

377 (7.4)

(6.6, 8.3)

1710990

1444 (10.5)

532 (7.1)

(6.3, 7.8)

1545581

2399 (10.6)

48.35 (0.33)

(47.71, 48.99)

49.44 (0.28)

(48.90, 50.00)

<.0001

<.0001

0.001

0.0158

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<12th grade
HS/GED
Tech Training/some College
>Bachelor’s degree
Employment
Employed for pay
Employed but not for pay
Unemployed
Income
$1 - $24,999
$25,000 - $44,999
$45,000 - $74,999
$75,000 and over
Don't know
Missing
Marital Status
Married/Cohabitating
Never married
Divorced/Sep/Widow
Insurance status
Uninsured
Medicaid
Medicare
Disability
Private insurance
Out of pocket costs, past year$
None
<$500
$500-$1999
$2000-$2999
$3000-$4999
$5000+
Don't know
Delayed Care because could not
afford/worried about cost
Geographic location
Northeast
Midwest
South
West
Place of birth
US born
Physical Activity R

47.14 (0.28)

0.0009

48.2 (0.20)

<.0001

2187 (44.0)

(42.4, 45.6)

10145502

6992 (48.0)

3136 (43.4)

(41.9, 44.9)

9516692

10770 (47.5)

2870 (56.0)

(54.4, 57.6)

12912100

8078 (52.0)

4102 (56.6)

(55.1, 58.1)

12398117

12664 (52.5)

<.0001

3771 (82.0)

(80.9, 83.2)

18915344

8364 (68.5)

5226 (78.5)

(77.4, 79.7)

17213880

13390 (66.6)

523 (7.7)

(6.9, 8.6)

1782620

2618 (13.9)

681 (7.7)

(7.0, 8.5)

1697535

3890 (13.7)

516 (6.8)

(6.1, 7.5)

1567155

3202 (13.4)

839 (8.9)

(8.2, 9.7)

1961358

4579 (14.8)

141 (1.8)

(1.5, 2.2)

426139

505 (2.3)

266 (2.7)

(2.3, 3.1)

593743

905 (2.9)

106 (1.6)

(1.3, 1.9)

366344

381 (1.9)

226 (2.0)

(1.7, 2.3)

448293

670 (2.1)

<.0001

411 (7.3)

(6.5, 8.1)

1687140

3168 (17.4)

576 (6.6)

(5.9, 7.4)

1456473

4261 (15.7)

1147 (22.3)

(20.9, 23.6)

5138228

4491 (30.4)

1409 (19.0)

(17.9, 20.1)

4161460

6494 (27.2)

1682 (33.3)

(31.8, 34.9)

7680535

4030 (28.0)

2547 (35.4)

(33.9, 36.9)

7764858

6925 (30.3)

1817 (37.1)

(35.5, 38.7)

8551699

3381 (24.2)

2706 (38.9)

(37.4, 40.5)

8532018

5754 (26.8)

NoneS
Low/Moderate
High
Mean (SE) (weekly)(min)

Tobacco Use
Never
Former
Current
Alcohol Use
None
Light
Moderate to heavy
Substance Abuse
Use of other Complementary
Health Approaches t

<.0001

3125 (62.3)

(60.7, 63.9)

14359042

8882 (59.0)

4287 (59.3)

(57.8, 60.8)

12989605

12871 (55.3)

211 (4.6)

(3.9, 5.3)

1056194

416 (3.0)

309 (4.5)

(3.8, 5.1)

979184

621 (2.8)

1721 (33.1)

(31.6, 34.6)

7642366

5772 (38.0)

2642 (36.3)

(34.8, 37.7)

7946020

9942 (41.9)

Other Natural Products a
Mind-bodyb
Manipulative/Bodyworkc
Energy healing/Reiki
Spiritual practices d
<.0001

Alternative medical systems e

1170 (23.4)

(22.0, 24.8)

5392332

3360 (22.1)

1608 (21.8)

(20.6, 22.9)

4772787

5248 (21.4)

107

831 (16.8)

(15.6, 18.0)

3878888

2290 (15.5)

1185 (16.4)

(15.3, 17.5)

3586770

3384 (14.4)

678 (13.5)

(12.3, 14.7)

3115599

1443 (10.3)

1038 (14.6)

(13.6, 15.6)

3192245

2492 (11.4)

455 (9.4)

(8.4, 10.4)

2163806

744 (5.4)

741 (11.0)

(10.1, 11.9)

2412850

1525 (7.4)

192 (3.7)

(3.1, 4.2)

843187

881 (5.4)

230 (2.9)

(2.5, 3.4)

646373

1062 (4.5)

1731 (33.2)

(31.5, 35.0)

7663790

6352 (41.3)

2436 (33.3)

(31.9, 34.7)

7303784

9723 (41.0)

0.118

0.0002

<.0001

2699 (52.4)

(50.7, 54.2)

12086329

7711 (51.1)

3780 (52.1)

(50.5, 53.7)

11421411

11439 (49.1)

1030 (21.4)

(19.9, 22.9)

4937934

3480 (23.1)

1577 (22.4)

(21.1, 23.8)

4915172

5813 (25.0)

1328 (26.2)

(24.8, 27.6)

6033339

3879 (25.7)

1881 (25.5)

(24.2, 26.7)

5578226

6182 (25.9)

716 (13.5)

(12.6, 14.4)

3108438

2788 (16.5)

<.0001

1089 (13.8)

(12.9, 14.7)

3025400

4406 (16.5)

<.0001

<.0001

237 (4.2)

(3.6, 4.8)

971775

1428 (7.8)

<.0001

412 (4.7)

(4.1, 5.2)

1021071

2611 (9.6)

<.0001

<.0001

1061 (20.6)

(19.2, 22.0)

4749125

3191 (22.1)

0.058

1654 (22.9)

(21.6, 24.1)

5011748

5545 (24.1)

0.1

<.0001

86 (1.9)

(1.3, 2.4)

426800

142 (0.89)

<.0001

130 (1.8)

(1.4, 2.2)

394974

239 (1.0)

<.0001

<.0001

3572 (72.5)

(71.1, 73.9)

16717518

9176 (64.6)

<.0001

4826 (69.0)

(67.5, 70.4)

15115629

13148 (59.9)

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

424 (8.0)

(7.1, 8.9)

1842858

2017 (12.0)

674 (8.6)

(7.8, 9.4)

1879476

3620 (14.2)

1763 (34.6)

(33.1, 36.1)

7972887

6205 (40.2)

2406 (31.9)

(30.6, 33.2)

6989608

8967 (37.5)

1739 (34.4)

(33.0, 35.9)

7935523

4252 (28.9)

2340 (33.2)

(32.0, 34.4)

7272642

6407 (28.1)

467 (9.4)

(8.4, 10.3)

2165805

1017 (7.4)

722 (10.3)

(9.5, 11.2)

2267715

1857 (8.6)

296 (5.9)

(5.2, 6.7)

1368788

612 (4.4)

528 (7.9)

(7.3, 8.6)

1737660

1129 (5.0)

305 (6.3)

(5.7, 7.0)

1460678

552 (3.9)

501 (7.1)

(6.4, 7.8)

1557788

1075 (5.0)

63 (1.3)

(0.91, 1.8)

311063

415 (3.1)

67 (0.96)

(0.70, 1.2)

209920

379 (1.6)

856 (17.3)

(16.1, 18.5)

3991358

1712 (11.5)

1273 (16.9)

(15.9, 17.9)

3703456

3169 (12.9)

<.0001

<.0001

763 (15.6)

(14.1, 17.2)

3600700

2561 (17.6)

993 (13.8)

(12.5, 15.1)

3029506

4094 (18.7)

1213 (26.0)

(23.6, 28.4)

5992975

3279 (24.8)

1610 (26.0)

(24.2, 27.7)

5690774

4793 (23.1)

1703 (32.5)

(30.2, 34.8)

7491580

5824 (38.3)

2033 (29.7)

(27.6, 31.7)

6503257

9156 (39.5)

1378 (25.9)

(24.0, 27.8)

5972347

3406 (19.3)

2602 (30.5)

(28.8, 32.3)

6691272

5391 (18.8)

<.0001

21012787

11808 (84.7)

<.0001

6287 (89.3)

(88.5, 90.2)

(24.4, 27.4)

5970320

6972 (43.7)

<.0001

1552 (20.5)

(19.4, 21.7)

(62.0, 65.4)

14689791

6647 (46.1)

<.0001

(44.1, 47.7)

10581806

4537 (32.7)

<.0001

4971 (69.9)
3705 (52.7)

(68.6, 71.2)
(51.2, 54.2)

11550005

4472 (91.1)

(90.3, 91.9)

1371 (25.9)
3155 (63.7)
2240 (45.9)

18616 (83.2)

<.0001

4500886

8662 (35.5)

<.0001

<.0001

15313768

12295 (53.9)

<.0001

<.0001

9036 (40.1)

<.0001

<.0001

19578199

108

275.56 (8.87) (258.10, 293.02)

<.0001

192.0 (6.28)

310.63 (8.6)

(293.79, 327.47)

237.8 (4.8)

<.0001

2696 (51.8)

(50.2, 53.5)

11951861

9175 (58.0)

4087 (56.0)

(54.7, 57.4)

12277432

13966 (58.6)

1438 (28.5)

(27.1, 29.9)

6570756

2921 (20.9)

1974 (28.0)

(26.8, 29.3)

6141595

4846 (21.7)

923 (19.7)

(18.2, 21.1)

4534985

2974 (21.0)

1177 (16.0)

(14.9, 17.0)

3495782

4622 (19.7)

<.0001

Note: Column Percentages shown

<.0001

0.0046

<.0001

<.0001

<.0001

<.0001

1405 (26.4)

(24.9, 27.9)

6088296

6559 (40.9)

1974 (25.0)

(23.7, 26.3)

5471701

9377 (37.2)

2438 (47.6)

(46.0, 49.2)

10973974

5911 (40.4)

3477 (48.8)

(47.4, 50.3)

10701511

9611 (42.4)

1214 (26.0)

(24.5, 27.5)

5995332

2600 (19.1)

1787 (26.2)

(24.9, 27.5)

5741597

4446 (20.3)

39 (0.80)

(0.52, 1.1)

182916

87 (0.60)

0.189

78 (1.2)

(0.85, 1.5)

252648

148 (0.65)

0.0008

<.0001

4990 (98.8)
4672 (92.8)

(98.5, 99.1)
(91.9, 93.6)

22775084
21394190

12699 (84.8)
8902 (61.5)

<.0001

6996 (97.0)
6747 (93.8)

(96.6, 97.4)
(93.1, 94.4)

21258408
20545840

16050 (70.4)
14274 (62.8)

<.0001

<.0001

<.0001

<.0001

<.0001

2577 (52.0)

(50.5, 53.5)

11983152

2914 (20.8)

<.0001

2646 (37.9)

(36.5, 39.4)

8310751

2738 (12.5)

<.0001

<.0001

2730 (55.3)

(53.7, 56.9)

12753689

3448 (24.8)

<.0001

3584 (50.4)

(49.0, 51.9)

11051380

5274 (23.7)

<.0001

<.0001

260 (5.3)

(4.6, 6.1)

1230209

95 (0.61)

<.0001

286 (4.1)

(3.6, 4.6)

894463

77 (0.32)

<.0001

<.0001

3267 (63.7)

(62.0, 65.4)

14681433

8704 (56.0)

<.0001

813 (11.9)

(11.0, 12.7)

2603754

548 (2.4)

<.0001

<.0001

1094 (21.6)

(20.2, 23.0)

4972413

900 (5.9)

<.0001

1281 (17.8)

(16.8, 18.9)

3910655

987 (4.2)

<.0001

<.0001

* Adjusted for age, sex, race/ethnicity
**Adjusted for age, sex,
based on 2000 Census data race/ethnicity based on 2010 Census data

a. Supplements other than herbs, including Vitamins/Minerals, probiotics (past 30 days), fish oil (past 30 days), chelation therapies
b. Tai Chi/Qi Gong, Yoga, guided imagery, progressive relaxation, deep breathing exercises, Meditation (for which singular term "meditation" is used in 2007; was expanded in 2012 to include mantra, and mindfulness meditation),
Stress-management class and support group (2007), mindfulness meditation: including

mindfulness-base stress reduction and congitive therapy (2012)

Biofeedback, hypnosis c. (Ever) Practitioner-based massage,

chiropractic/osteopathic manipulation, Sobador visit
d. Prayed for one's own health (2007) or centering prayer/contemplative meditation (2012); and/or, visit with espiritista (2007 only), cuarandero, shaman, and/or Native American healer e. Acupuncture,
Ayurveda, homeopathy, naturopathy
$ family costs aside from deductibles, premiums, copays
R. Defined as >10 min per week
W. p-values obtained by comparing weighted estimates

Table 1b: Health Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by ever using herbal products
2007 (N = 20,127)

2012 (N = 30, 672)

Herbal use

P

Yes
N (%)
Body Mass Index (BMI)
<24.9
25-29.9
30-35
35+

95% CI

Weighted
population
estimate*

Herbal use

No

Yes

N (%)

N (%)

P

Overall P W

No
95% CI

Weighted
population
estimate**

N (%)

0.125

1929 (38.6)

(37.0, 40.1)

8889846

5698 (38.8)

2663 (37.6)

(36.3, 39.0)

8244907

8433 (36.5)

1739 (34.2)

(32.8, 35.6)

7883150

5382 (35.6)

2524 (34.5)

(33.2, 35.8)

7562183

8109 (34.8)

871 (17.1)

(15.9, 18.4)

3944736

2474 (16.0)

1209 (16.6)

(15.6, 17.6)

3633769

4119 (17.3)

518 (10.1)

(9.1, 11.2)

2339870

1516 (9.6)

842 (11.3)

(10.5, 12.1)

2473950

2773 (11.4)

27.47 (0.10)

(27.27, 27.67)

27.70 (0.08)

(27.55, 27.86)

0.158

<.0001

0.735

0.0743

<.0001

<.0001

<.0001

<.0001

Mean (SE)

Comorbidity Indexa
0
1
2
3+
Mean (SE)

Chronic Health Conditions
Diabetes
Kidney disease
GI diseaseaa
Chronic Respiratory
conditionsb

27.31 (0.06)

0.182

27.73 (0.05)

CVDc
Hypertension
Dyslipidemia
Liver disease
Chronic pain conditions d

<.0001

1331 (26.3)

(24.9, 27.7)

6056905

6119 (39.6)

1372 (18.7)

(17.7, 19.7)

4095224

7251 (30.6)

1268 (25.6)

(24.3, 27.0)

5911165

3490 (23.5)

1614 (22.2)

(21.1, 23.4)

4873381

5321 (22.9)

919 (18.2)

(17.0, 19.4)

4199183

2231 (15.2)

1405 (19.5)

(18.5, 20.5)

4265489

3921 (17.1)

1539 (29.9)

(28.5, 31.3)

6890349

3230 (21.6)

2847 (39.6)

(38.2, 41.0)

8680715

6941 (29.4)

1.82 (0.03)

(1.76, 1.88)

2.25 (0.03)

(2.20, 2.31)

Mental health conditions e
Insomnia
History of Cancer
Perceived health status
Excellent/very good/good
Fair
Poor

1.42 (0.02)

<.0001

1.80 (0.02)

109

442 (8.2)

(7.3, 9.0)

1885710

1505 (9.5)

0.007

806 (10.7)

(9.8, 11.5)

2337648

2755 (11.1)

0.388

<.0001

85 (1.8)

(1.3, 2.1)

397934

261 (1.6)

0.621

126 (1.6)

(1.3, 1.9)

352738

471 (1.9)

0.128

<.0001

830 (16.7)

(15.5, 17.9)

3848711

1456 (10.1)

<.0001

2907 (40.8)

(39.4, 42.1)

8936761

6747 (29.0)

<.0001

<.0001

875 (17.2)

(16.0, 18.4)

3957352

1884 (12.9)

<.0001

1331 (18.3)

(17.2, 19.4)

4015034

3416 (14.8)

<.0001

<.0001

359 (6.9)

(6.1, 7.7)

1597503

976 (6.8)

0.09

517 (7.2)

(6.5, 7.8)

1569346

1705 (7.3)

0.674

<.0001

1594 (30.8)

(29.3, 32.3)

7107125

4306 (28.5)

0.01

2439 (33.5)

(32.2, 34.8)

7336612

7585 (32.1)

0.067

<.0001

1608 (31.5)

(30.1, 33.0)

7274054

3528 (24.0)

<.0001

2468 (33.8)

(32.4, 35.2)

7408479

6041 (26.2)

<.0001

<.0001

74 (1.5)

(1.1, 1.9)

345579

178 (1.1)

0.06

123 (1.6)

(1.3, 1.9)

345528

316 (1.3)

0.135

<.0001

2561 (50.8)

(49.2, 52.4)

11715342

5215 (35.6)

<.0001

3928 (55.0)

(53.6, 56.4)

12047659

9033 (38.9)

<.0001

<.0001

1189 (23.9)

(22.4, 25.3)

5506796

2266 (15.1)

<.0001

2249 (30.8)

(29.6, 32.1)

6758368

5279 (22.2)

<.0001

<.0001

1331 (26.4)

(24.9, 27.8)

6082197

2502 (17.0)

<.0001

1957 (26.8)

(25.6, 28.0)

5874097

4259 (18.1)

<.0001

<.0001

488 (9.8)

(8.9,10.7)

2258274

968 (7.2)

<.0001

740 (10.5)

(9.6, 11.3)

2293335

1868 (8.6)

<.0001

<.0001

<.0001

<.0001

0.002

4402 (87.5)

(86.5, 88.5)

20170533

12893 (86.2)

6335 (88.6)

(87.8, 89.5)

19423622

19897 (86.2)

520 (10.0)

(9.1, 10.9)

2305743

1624 (10.2)

713 (9.0)

(8.2, 9.7)

1962675

2734 (10.6)

135 (2.5)

(2.0, 3.0)

581326

553 (3.7)

190 (2.4)

(2.0, 2.8)

528512

803 (3.2)

**Adjusted for age, sex,
* Adjusted for age, sex, race/ethnicity
Note: Column Percentages shown

race/ethnicity based on 2010
based on 2000 Census data
Census data

a. Includes diabetes, kidney disease, Gastrointestinal disorder (including ulcer and/or abdominal pain, digestive allergy, heartburn), respiratory conditions (Asthma, emphesema, and.or chronic bronchitis), dyslipidemia, liver condition, Rheumatoid
Arthritis, CVD, hypertension, non-specific arthritis, gout, migraines, mental health condition
aa. Includes: bowel conditions and ulcers (2007); past 12 month abdominal pain, digestive allergy, heartburn, and ever having ulcer (2012) b. Asthma,
emphysema, and/or chronic bronchitis
c. Myocardial Infarction, Heart Disease, Angina pectoris
d. Migraines (past 3 months), nonspecific arthritis, gout, non-specific joint pain for 3+ months, Rheumatoid Arthritis
e. Depression, bipolar disorder, phobias, often anxious in past year
W. p-values obtained by comparing weighted estimates

Table 2a: Demographic and Lifestyle Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by herbal use in the last 12 months
2007 (N = 20,127)
Herbal use
Characteristic

Yes
N (%)

Total
Age in years
18-24
25-44
45-64
65-75
75+
Mean (SE)
Gender
Male
Female
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Asian
Other Race/ethnicity
Education
<12th grade
HS/GED
Tech Training/some
College
>Bachelor’s degree
Employment
Employed for pay
Employed but not for pay
Unemployed
Income
$1 - $24,999
$25,000 - $44,999
$45,000 - $74,999
$75,000 and over
Don't know
Missing
Marital Status
Married/Cohabitating
Never married
Divorced/Sep/Widow
Insurance status

3582 (19.1)

95% CI
(18.4, 19.8)

Weighted
population
estimate*
16270972

2012 (N=30,672)
Herbal use

P
No

Yes

N (%)

N (%)

16545 (80.9)

5490 (16.4)

P

95% CI
(15.8, 17.1)

Weighted
population
estimate**
16713004

269 (8.2)

(6.8, 9.6)

1332833

1884 (11.7)

391 (7.4)

(6.3, 8.4)

1231081

2637 (11.1)

1169 (31.9)

(30.1, 33.7)

5193487

6195 (36.3)

1775 (32.1)

(30.4, 33.7)

5358304

8879 (34.1)

1414 (39.8)

(37.9, 41.7)

6476821

5314 (32.3)

2162 (39.1)

(37.5, 40.8)

6542615

8379 (33.1)

462 (12.6)

(11.4, 13.7)

2044193

1599 (9.5)

741 (14.0)

(12.8, 15.1)

2332396

268 (7.5)

(6.5, 8.5)

1223638

1553 (10.2)

421 (7.5)

(6.6, 8.4)

1248608

49.06 (0.35)

(48.38, 49.75)

49.58 (0.33)

(48.93, 50.23)

<.0001

48.24 (0.19)

(41.3, 45.1)

7028291

7644 (47.8)

2341 (42.8)

(41.1, 44.5)

7153927

11565 (47.3)

2047 (56.8)

(54.9, 58.7)

9242681

8901 (52.2)

3149 (57.2)

(55.5, 58.9)

9559077

13617 (52.7)

<.0001

13487880

9419 (69.6)

3979 (78.8)

(77.5, 80.1)

13163299

<.0001

<.0001

<.0001

0.2794

<.0001

<.0001

<.0001

<.0001

2510 (10.3)

1535 (43.2)

(81.7, 84.1)

<.0001

2777 (11.4)

0.0001

2716 (82.9)

W

N (%)
25182 (72.4)

<.0001

47.09 (0.27)

Overall P

No

14637(67.4)

110

Uninsured
Medicaid
Medicare
Disability
Private
insurance
Out of pocket costs, past
year$
None
<$500
$500-$1999
$2000-$2999
$3000-$4999
$5000+
Don't know
Delayed Care because could
not afford/worried about cost
Geographic location
Northeast
Midwest
South
West
Place of birth
US born
Physical ActivityR
None
Low/Moderate
High

329 (6.9)

(6.0, 7.8)

1121133

2812 (13.5)

513 (7.6)

(6.7, 8.4)

1266927

4058 (13.3)

360 (6.7)

(5.9, 7.5)

1091895

3358 (12.8)

622 (9.0)

(8.1, 9.8)

1496127

4796 (14.4)

99 (1.8)

(1.4, 2.2)

297318

547 (2.3)

196 (2.6)

(2.2, 3.0)

438850

975 (2.9)

78 (1.7)

(1.3, 2.0)

272746

409 (1.8)

180 (2.1)

(1.7, 2.4)

347801

716 (2.1)

<.0001

272 (7.0)

(6.1, 7.8)

1131795

3307 (16.5)

417 (6.4)

(5.7, 7.2)

1076502

4420 (15.1)

808 (22.3)

(20.7, 23.8)

3624376

4830 (29.6)

1043(18.4)

(17.2, 19.6)

3078409

6860 (26.8)

1185 (33.4)

(31.6, 35.2)

5436406

4527 28.5)

1317 (37.4)

(35.4, 39.3)

6078395

3881 (25.4)

1924 (35.3)
2106 (39.9)

(33.6, 36.9)
(38.1, 41.6)

5896361
6661732

7548 (30.7)
6354 (27.4)

Mean (SE) (weekly)(min)

Tobacco Use
Never
Former
Current
Alcohol Use
None
Light
Moderate to heavy
Substance Abuse
Use of other Complementary
Health Approaches t

<.0001

2189 (61.6)

(59.8, 63.3)

10016152

9818 (59.5)

3301 (60.2)

(58.5, 61.9)

10065089

13857(55.4)

162 (4.8)

(4.0, 5.6)

784425

465 (3.1)

227 (4.3)

(3.7, 5.0)

725979

703(3.0)

1231 (33.6)

(31.9, 35.3)

5470395

6262 (37.4)

1962 (35.4)

(33.7, 37.1)

5921936

10622 (41.7)

Other Natural Products a

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

0.009

<.0001

<.0001

<.0001

<.0001

<.0001

0.451

<.0001

<.0001

<.0001

<.0001

<.0001

Mind-bodyb
c

Manipulative/Bodywork
Energy healing/Reiki
Spiritual practices d
Alternative
medical
systemse

820 (23.4)

(21.8, 25.1)

3809168

3710 (22.2)

1186 (21.0)

(19.8, 22.3)

3512363

5670 (21.6)

576 (15.7)

(14.3, 17.1)

2553714

2545 (15.9)

894 (16.3)

(15.1, 17.5)

2727946

3675 (14.5)

478 (13.5)

(12.2, 14.9)

2203952

1643 (10.6)

803 (14.9)

(13.7, 16.0)

2490180

2727 (11.5)

341 (10.0)

(8.8, 11.1)

1622926

858 (5.6)

583 (11.4)

(10.4, 12.5)

1912903

1683 (7.5)

129 (3.6)

(3.0, 4.2)

578665

944 (5.3)

189 (3.2)

(2.6, 3.8)

538020

1103 4.3)

1238 (33.8)

(31.9, 35.7)

5502547

6845 (40.4)

1835 (33.1)

(31.6, 34.6)

5531592

10324 (40.5)

0.088

1903 (52.0)

(50.0, 53.9)

8453944

8507 (51.4)

2865 (52.1)

(50.2, 53.9)

8703339

12354 (49.4)

710 (21.0)

(19.2, 22.7)

3411156

3800 (23.1)

1206 (22.8)

(21.2, 24.4)

3813588

6184 (24.7)

969 (27.1)

(25.5, 28.7)

4405872

4238 (25.6)

1419 (25.1)

(23.7, 26.5)

4196077

6644 (25.9)

505 (13.4)
155 (4.0)
786 (21.6)
63 (2.0)
2537 (72.6)

(12.4, 14.5)
(3.3, 4.6)
(20.0, 23.2)
(1.3, 2.7)
(70.9, 74.3)

2185136
645744
3519561
321398
11813273

2999 (16.2)
1510 (7.6)
3466 (21.7)
165 (0.96)
10211 (65.3)

790 (13.0)
287 (4.4)
1277 (23.3)
111 (2.1)
3736 (70.2)

(12.0, 13.9)
(5.2, 10.5)
(21.8, 24.8)
(1.7, 2.5)
(68.7, 71.8)

2168607
735478
3892141
346117
11739270

4705 (16.5)
2736 (9.3)
5922 (23.9)
258 (1.1)
14238 (60.2)

<.0001
<.0001
0.623
<.0001
<.0001
<.0001

<.0001

<.0001

286 (7.8)

(6.8, 8.8)

1272433

2155 (11.7)

483 (8.1)

(7.3, 9.0)

1358939

3811 (13.9)

1249 (35.0)

(33.3, 36.8)

5700791

6719 (39.6)

1780 (31.3)

(29.7, 32.9)

5230362

9593 (37.3)

1236 (34.1)

(32.4, 35.8)

5549126

4755 (29.5)

1809 (33.8)

(32.4, 35.1)

5641914

6938 (28.3)

111

333 (9.3)

(8.3, 10.3)

1512573

1151 (7.7)

554 (10.3)

(9.3, 11.3)

1717635

2025 (8.7)

217 (6.2)

(5.3, 7.1)

1008834

691 (4.5)

420 (8.3)

(7.5, 9.1)

1391128

1237 (5.1)

222 (6.4)

(5.6, 7.2)

1039327

635 (4.1)

396 (7.3)

(6.5, 8.1)

1219938

1180 (5.1)

39 (1.2)

(0.74, 1.6)

187888

439 (2.9)

48 (0.9)

(0.63, 1.2)

153088

398 (1.6)

621 (17.6)

(16.2, 19.0)

2867318

1947 (12.0)

964 (16.7)

(15.6, 17.9)

2794500

3478 (13.2)

<.0001
<.0001

541 (15.5)

(13.8, 17.2)

2526830

2783 (17.4)

762 (13.9)

(12.5, 15.3)

2324064

4325 (18.3)

850 (25.6)

(23.1, 28.1)

4161206

3642 (25.0)

1230 (26.2)

(24.2, 28.1)

4374539

5173 (23.3)

1190 (32.2)

(29.7, 34.7)

5232720

6337 (37.8)

1506 (29.2)

(26.8, 31.7)

4886374

9683 (38.9)

1001 (26.7)

(24.6, 28.9)

4350216

3783 (19.8)

1992 (30.7)

(28.6, 32.7)

5128027

6001 (19.6)

<.0001

<.0001

<.0001

<.0001

<.0001

3164 (91.0)

(90.1, 91.9)

14807161

13116 (85.4)

<.0001

4791 (89.8)

(88.9, 90.7)

15010846

20112 (83.5)

<.0001

915 (24.6)
2298 (65.3)
1613 (46.5)

(22.9, 26.3)
(63.3, 67.3)
(44.5, 48.5)

4001744
10629710
7571196

7428 (42.2)
7504 (47.5)
5164 (33.8)

<.0001

(17.7, 20.1)
(69.5, 72.2)
(53.0, 56.3)

3158655
11841154
9136857

<.0001

<.0001

<.0001

<.0001

<.0001

198.45 (6.00)

<.0001

325.00 (9.77)

(305.77, 344.24)

9136 (34.8)
13429
(54.8)
9817
(40.6)
239.65 (4.63)

<.0001

<.0001

1078 (18.9)
3837 (70.8)
2924 (54.7)

<.0001

0.003

<.0001

<.0001

<.0001

<.0001

0.0003

<.0001

283.09 (10.23)

(262.96,
303.22)

<.0001

<.0001

1894 (51.2)

(49.2, 53.2)

8330263

9977 (57.6)

3114 (56.3)

(54.8, 57.9)

9413789

14939 (58.3)

1067 (30.3)

(28.7, 31.9)

4930987

3292 (21.2)

1539 (28.6)

(27.3, 30.0)

4788193

5281 (22.0)

621 (18.5)

(16.7, 20.3)

3009722

3276 (21.2)

837 (15.0)

(13.8, 16.2)

2511022

4962 (19.6)

<.0001

1006 (26.7)

(25.1, 28.4)

4349888

6958 (39.0)

1454 (24.0)

(22.5, 25.5)

4012831

9897 (36.6)

1740 (47.9)

(46.1, 49.7)

7794610

6609 (41.0)

2662 (49.6)

(48.0, 51.3)

8292892

10426 (42.7)

836 (25.4)

(23.6, 27.1)

4126474

2978 (19.9)

1374 (26.4)

(24.9, 27.9)

15263475

4859 (20.7)

30 (0.81)
3539 (98.9)

(0.52, 1.1)
(98.6, 99.3)

132414
16094998

96 (0.62)
14150 (86.2)

62 (1.3)
5357 (97.9)

(0.89, 1.6)
(97.5, 98.4)

210988
16369136

164 (0.66)

<.0001

3331 (93.4)

(92.4, 94.4)

15192940

10243 (64.4)

<.0001

5215 (95.5)

(94.9, 96.2)

15965914

17689 (72.1)
15806 (64.5)

<.0001

<.0001
<.0001

1870 (53.2)

(51.5, 55.0)

8659604

3621 (23.6)

<.0001

2094 (39.7)

(38.0, 41.4)

6633294

3290 (13.9)

<.0001

<.0001

2034 (58.4)

(56.5, 60.3)

9496114

4144 (27.1)

<.0001

2783 (51.7)

(50.0, 53.4)

8634942

6075 (25.3)

<.0001

<.0001

218 (6.1)
2334 (64.6)

(5.2, 7.0)
(62.7, 66.5)

997157
10512222

137 (0.89)
9637 (56.5)

<.0001

(3.8, 5.1)
(11.4, 13.5)

747014
2081886

123 (0.47)
718 (2.9)

<.0001

<.0001

<.0001

240 (4.5)
643 (12.5)

<.0001

<.0001

858 (23.8)

(22.1, 25.5)

3867268

1136 (6.9)

<.0001

1037 (19.0)

(17.8, 20.2)

3180077

0.157

<.0001

<.0001

1231 (4.9)

<.0001

**Adjusted for age, sex,
Note: Column Percentages

* Adjusted for age, sex, race/ethnicity

race/ethnicity based on 2010
shown

based on 2000 Census data

Census data
a. Supplements other than herbs, including Vitamins/Minerals, probiotics (past 30 days), fish oil (past 30 days), chelation the rapies
b. Tai Chi/Qi Gong, Yoga, guided imagery, progressive relaxation, deep breathing exercises, Meditation (for which singular term "meditation" is used in 2007; was expanded in 2012 to include mantra, and mindfulness meditation),
Stress-management class and support group (2007), mindfulness meditation: including mindfulness-base stress reduction and congitive therapy (2012) Biofeedback, hypnosis c. (Ever) Practitioner-based massage,
chiropractic/osteopathic manipulation, Sobador visit
d. Prayed for one's own health (2007) or centering prayer/contemplative meditation (2012); and/or, visit with espiritista (2007 only), cuarandero, shaman, and/or Native American healer e.
Acupuncture, Ayurveda, homeopathy, naturopathy
$ family costs aside from deductibles, premiums, copays
R. Defined as >10 min increments
Table 2b: Health Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by herbal use in the last 12 months
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2007 (N = 20,127)
Herbal use
Yes
Characteristic
Body Mass Index (BMI)
<24.9
25-29.9
30-35
35+
Mean (SE)
Comorbidity Indexa
0
1
2
3+
Mean (SE)
Chronic Health Conditions
Diabetes
Kidney disease
GI diseaseaa
Chronic
Respiratory
conditionsc b

N (%)

95% CI

Weighted
population
estimate*

No

Yes

N (%)

N (%)

Insomnia
History of Cancer
Perceived health status
Excellent/very
Fair
Poor

P

95% CI

Weighted
population
estimate**

(37.3, 40.8)

6348273

6243 (38.7)

2057 (38.6)

(37.0, 40.1)

6448785

9039 (36.3)

1246 (34.5)

(32.7, 36.2)

5605830

5875 (35.4)

1916 (34.4)

(32.9, 36.0)

5757553

8717 (34.8)

614 (17.2)

(15.8, 18.6)

2793014

2731 (16.1)

903 (16.3)

(15.1, 17.4)

2718245

4425 (17.3)

338 (9.4)

(8.3, 10.5)

1523855

1696 (9.9)

614 (10.7)

(9.8, 11.6)

1788421

3001 (11.6)

27.37 (0.11)

(27.15, 27.60)

27.54 (0.09)

(27.36, 27.72)

0.887

W

N (%)

1384 (39.0)

27.35 (0.56)

Overall P

No

0.016

CVD
Hypertension
Dyslipidemia
Liver disease
Chronic pain conditions d
Mental health conditions e

2012 (N = 30, 672)
Herbal use

P

27.77 (0.05)

<.0001

0.031

<.0001

0.024

0.2305

<.0001

0.0001

<.0001

<.0001

918 (25.6)

(23.9, 27.3)

4164042

6532 (38.4)

1035 (18.7)

(17.5, 19.8)

3117059

7588 (29.8)

912 (26.0)

(24.4, 27.5)

4225414

3846 (23.7)

1218 (22.3)

(20.9, 23.6)

3721577

5717 (22.9)

662 (18.4)

(16.9, 19.8)

2987313

2488 (15.5)

1083 (19.6)

(18.4, 20.8)

3272605

4243 (17.2)

1090 (30.1)

(28.4, 31.7)

4894203

3679 (22.4)

2154 (39.5)

(37.8, 41.2)

6601763

7634 (30.2)

1.83 (0.03)

(1.77, 1.90)

<.0001

2.23 (0.03)

(2.17, 2.29)

314 (8.2)

(7.2, 9.1)

1331587

1633 (9.4)

0.021

596 (10.2)

(9.3, 11.2)

1709992

2965 (11.2)

0.106

<.0001

57 (1.6)

(1.2, 2.1)

263373

289 (1.6)

0.713

91 (1.5)

(1.2, 1.8)

250872

506 (1.9)

0.047

<.0001

590 (16.9)

(15.5, 18.3)

2752405

1696 (10.8)

<.0001

2186 (40.4)

(38.9, 41.9)

6744109

7468 (29.9)

<.0001

<.0001

615 (16.9)

(15.6, 18.2)

2745606

2144 (13.4)

<.0001

985 (18.0)

(16.8, 19.3)

3015703

3762 (15.1)

<.0001

<.0001

257 (7.0)

(6.1, 7.9)

1142025

1078 (6.8)

0.607

393 (7.1)

(6.3, 7.9)

1186819

1829 (7.3)

0.621

<.0001

1136 (31.1)

(29.4, 32.9)

5064154

4764 (28.7)

0.017

1856 (33.4)

(31.8, 35.0)

5582424

8168 (32.2)

0.165

<.0001

1159 (32.2)

(30.5, 34.0)

5246236

3977 (24.6)

<.0001

1881 (33.9)

(32.2, 35.6)

5659527

6628 (26.8)

<.0001

<.0001

54 (1.5)

(1.1, 1.9)

244387

198 (1.2)

0.138

91 (1.6)

(1.2, 2.0)

271510

348 (1.3)

0.146

<.0001

1836 (51.6)

(49.8, 53.3)

8390744

5940 (36.9)

<.0001

3018 (55.2)

(53.9, 56.9)

9263106

9943 (39.9)

<.0001

<.0001

832 (23.8)

(22.1, 25.6)

3874783

2623 (16.0)

<.0001

1674 (30.4)

(28.9, 31.9)

5084683

5854 (22.9)

<.0001

<.0001

948 (26.9)

(25.2, 28.7)

4383811

2885 (17.8)

<.0001

1488 (26.8)

(25.4, 28.2)

4472612

4728 (18.8)

<.0001

<.0001

355 (10.1)

(9.0, 11.2)

1638188

1101 (7.4)

<.0001

569 (10.7)

(9.7, 11.7)

1792043

2039 (8.6)

<.0001

<.0001

0.001

<.0001

1.45 (0.02)

1.84 (0.02)

0.001

3133 (87.7)

(86.6, 88.9)

14272846

14162 (86.3)

4849 (89.7)

(88.8, 90.6)

14987051

21383 (86.2)

363 (10.0)

(9.0, 11.1)

1632026

1781 (10.1)

505 (8.1)

(7.3, 8.9)

1347889

2942 (10.7)

86 (2.3)

(1.7, 2.8)

366100

602 (3.6)

136 (14.0)

(1.8, 2.7)

378064

857 (86.0)

* Adjusted for age, sex, race/ethnicity **Adjusted for age, sex, race/ethnicity
Note: Column Percentages show based on 2000 Census data
based on 2010 Census
data
a. Includes diabetes, kidney disease, Gastrointestinal disorder (including ulcer and/or abdominal pain, digestive allergy, heartburn), respiratory conditions (Asthma, emphesema, and.or chronic bronchitis), dyslipidemia, liver condition,
Rheumatoid Arthritis, CVD, hypertension, non-specific arthritis, gout, migraines, mental health condition
aa. Includes: bowel conditions and ulcers (2007); past 12 month abdominal pain, digestive allergy, heartburn, and ever having ulcer (2012)
b. Asthma, emphysema, and/or chronic bronchitis
c. Myocardial Infarction, Heart Disease, Angina pectoris
d. Migraines (past 3 months), nonspecific arthritis, gout, non-specific joint pain for 3+ months, Rheumatoid Arthritis
e. Depression, bipolar disorder, phobias, often anxious in past year
W. p-values obtained by comparing weighted estimates
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Table 3a: Demographic and Lifestyle Characteristics of two National U.S. samples (NHIS 2007 & 2012), stratified by herbal use in past 30 days
2007 (N = 20,127)
Herbal use
Yes
Characteristic
N (%)
Total

2623 (13.9)

95% CI
(13.3, 14.6)

Weighted
population
estimate*
11859568

2012 (N= 30,672)
Herbal use

P
No

Yes

N (%)

N (%)

17504 (86.1)

4120 (13.9)

P

Overall P W

No
95% CI
(13.4, 14.5)

Weighted
population
estimate**
12603256

N (%)
<.0001

26552 (86.1)

Age in years
18-24
<.0001

25-44

<.0001

<.0001

<.0001

0.0592

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

0.0005

<.0001

<.0001

<.0001

45-64
65-75
75+

155 (6.7)

(5.2, 8.1)

790687

1998 (11.7)

208 (5.2)

(4.2, 6.2)

658449

2820 (11.3)

754 (28.2)

(26.1, 30.2)

3340364

6610 (36.6)

1165 (28.0)

(26.2, 29.8)

3529186

9489 (34.6)

1100 (42.3)

(40.1, 44.5)

5014017

5628 (32.4)

1717 (41.3)

(39.5, 43.1)

5207028

8824 (33.1)

392 (14.3)

(12.9, 15.8)

1697704

1669 (9.4)

661 (16.8)

(15.4, 18.1)

2111431

2857 (11.1)

222 (8.6)

(7.4, 9.8)

1016796

1599 (9.9)

369 (8.7)

(7.6, 9.8)

1097162

2562 (9.9)

51.05 (0.39)

(50.29, 51.82)

52.06 (0.36)

(51.35, 52.76)

Mean (SE)
Gender
Male
Female
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Asian
Other Race/ethnicity
Education
<12th grade
HS/GED
Tech Training/some College
>Bachelor’s degree
Employment

46.90 (0.26)

<.0001

47.91 (0.19)

Employed for pay
Employed but not for pay

0.022

Unemployed
Income
$1 - $24,999

1154 (44.6)

(42.5, 46.8)

5291066

8025 (47.3)

1731 (42.1)

(40.2, 44.1)

5311074

12175 (47.2)

1469 (55.4)

(53.2, 57.5)

6568502

9479 (52.7)

2389 (57.9)

(55.9, 59.8)

7292182

14377 (52.8)

$25,000 - $44,999
$45,000 - $74,999
$75,000 and over
Don't know
Missing
Marital Status

<.0001

Married/Cohabitating
Never married
Divorced/Sep/Widow
Insurance status

2020 (83.8)

(82.4, 85.3)

9939278

10115 (70.3)

3065 (80.4)

(79.1, 81.8)

10135774

15551 (67.7)

218 (6.1)

(5.1, 7.1)

725090

2923 (13.2)

351 (6.9)

(6.0, 7.8)

871677

4220 (13.1)

258 (6.6)

(5.7, 7.5)

787286

3460 (12.4)

419 (8.1)

(7.3, 8.9)

1017455

4999 (14.2)

76 (1.9)

(1.4, 2.5)

229743

570 (2.3)

139 (2.4)

(1.9, 2.8)

302167

1032 (2.9)

51 (1.5)

(1.1, 1.9)

178171

436 (1.8)

146 (2.2)

(1.7, 2.7)

276183

750 (2.0)

Uninsured
Medicaid
Medicare
Disability
Private insurance
Out of pocket costs, past year$
None
<$500
$500-$1999
$2000-$2999
$3000-$4999
$5000+
Don't know
Delayed Care because could not
afford/worried about cost
Geographic location

<.0001

Northeast
Midwest

193 (6.6)

(5.7, 7.5)

783942

3386 (16.0)

315 (6.5)

(5.6, 7.4)

814077

4522 (14.7)

602 (22.8)

(21.1, 24.6)

2706476

5036 (29.1)

801 (18.7)

(17.3, 20.2)

2362123

7102 (26.3)

837 (31.9)

(29.8, 34.0)

3780874

4875 (29.0)

1403 (34.5)

(32.6, 36.4)

4348552

8069 (31.1)

991 (38.7)

(36.4, 41.0)

4588276

4207 (25.9)

1601 (40.3)

(38.4, 42.2)

5078504

6859 (28.0)

South
West
Place of birth
US born
Physical Activity R
None
Low/Moderate
High
Mean (SE) (weekly)(min)
Tobacco Use
Never

0.002

Former
Current
Alcohol Use
None
Light

1546 (59.7)

(57.6, 61.8)

7078796

10461 (60.0)

2384 (57.9)

(56.0, 59.7)

7291127

14774 (56.0)

121 (4.7)

(3.8, 5.6)

553445

506 (3.2)

168 (4.1)

(3.4, 4.9)

521755

762 (3.1)

956 (35.7)

(33.6, 37.7)

4227327

6537 (36.8)

1568 (38.0)

(36.1, 39.9)

4790374

11016 (40.9)

Moderate to heavy
Substance Abuse
Use of other Complementary
Approache
Other Natural Products a

Health

Mind-bodyb
Manipulative/Bodyworkc
Energy healing/Reiki

<.0001

Spiritual practicesd
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Alternative medical systems e

548 (21.3)

(19.5, 23.1)

2521574

3982 (22.6)

834 (19.5)

(18.1, 20.9)

2458527

6022 (21.8)

412 (15.4)

(13.8, 16.9)

1823695

2709 (16.0)

640 (15.3)

(14.0, 16.6)

1930363

3929 (14.8)

348 (13.4)

(11.8, 14.9)

1586462

1773 (10.8)

572 (14.03)

(12.8, 15.2)

1768090

2958 (11.8)

256 (10.3)

(8.9, 11.7)

1225529

943 (5.8)

454 (11.9)

(10.6, 13.2)

1503329

1812 (7.7)

86 (3.3)

(2.6, 4.0)

388584

987 (5.2)

131 (3.0)

(2.4, 3.6)

379531

1161 (4.3)

973 (36.4)

(34.1, 38.6)

4313724

7110 (39.6)

1489 (36.2)

(34.5, 38.0)

4563416

10670 (39.6)

0.0003

<.0001

<.0001

<.0001

1403 (52.4)

(50.0, 54.7)

6210153

9007 (51.3)

2160 (52.2)

(50.3, 54.2)

6582911

13059 (49.5)

477 (19.4)

(17.6, 21.3)

2302205

4033 (23.2)

807 (20.3)

(18.6, 21.9)

2552328

6583 (25.1)

743 (28.2)

(26.3, 30.2)

3347210

4464 (25.5)

1153 (27.5)

(25.9, 29.2)

3468017

6910 (25.5)

334 (12.2)

(11.1, 13.3)

1442171

3170 (16.2)

<.0001

535 (11.4)

(10.5, 12.4)

1440406

4960 (16.6)

<.0001

100 (3.2)

(2.5, 3.9)

382615

1565 (7.5)

<.0001

199 (4.0)

(3.3, 4.6)

498246

2824 (9.1)

<.0001

0.008

655 (24.5)

(22.5, 26.4)

2902188

3597 (21.2)

0.0003

1117 (27.3)

(25.5, 29.1)

3444310

6082 (23.2)

<.0001

<.0001

41 (1.9)

(1.1, 2.8)

228975

187 (1.0)

0.008

88 (2.2)

(1.7, 2.7)

273708

281 (1.1)

<.0001

<.0001

1885 (73.9)

(72.0, 75.7)

8761977

10863 (65.6)

<.0001

2834 (71.0)

(69.3, 72.7)

8950546

15140 (60.6)

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

197 (7.3)

(6.1, 8.4)

861372

2244 (11.5)

330 (7.2)

(6.2, 8.1)

902927

3964 (13.8)

907 (34.5)

(32.5, 36.6)

4095033

7061 (39.4)

1322 (30.9)

(29.1, 32.7)

3894734

10051 (37.0)

910 (34.4)

(32.5, 36.3)

4078211

5081 (29.8)

1388 (35.0)

(33.4, 36.6)

4410820

7359 (28.4)

242 (9.3)

(8.1, 10.5)

1104356

1242 (7.8)

440 (10.7)

(9.6, 11.7)

1343206

2139 (8.8)

173 (6.8)

(5.7, 7.9)

810726

735 (4.5)

304 (8.0)

(7.0, 8.9)

1002071

1353 (5.4)

168 (6.7)

(5.7, 7.7)

792257

689 (4.2)

298 (7.3)

(6.4, 8.3)

923040

1278 (5.2)

26 (0.99)

(0.57, 1.4)

117613

452 (2.9)

38 (1.0)

(0.63, 1.4)

126458

408 (1.5)

425 (16.5)

(14.9, 18.2)

1957497

700 (16.1)

(14.8, 17.4)

2025158

3742 (13.5)

2143 (12.5)

<.0001

<.0001

386 (15.2)

(13.4, 17.0)

1799932

2938 (17.3)

599 (14.7)

(13.1, 16.2)

1850077

4488 (17.9)

631 (25.7)

(23.1, 28.4)

3051859

3861 (25.0)

917 (26.0)

(24.1, 27.9)

3280781

5486 (23.4)

875 (32.8)

(30.0, 35.5)

3885028

6652 (37.4)

1127 (29.0)

(26.6, 31.4)

3653277

10062 (38.4)

731 (26.3)

(23.9, 28.8)

3122749

4053 (20.2)

1477 (30.3)

(28.3, 32.3)

3819121

6516 (20.2)

<.0001

2324 (91.1)

(90.1, 92.2)

10805693

13956 (85.7)

<.0001

663 (23.9)

(21.9, 25.9)

2831382

7680 (41.3)

1696 (66.1)

(63.8, 68.4)

7838030

8106 (48.4)

3614 (90.2)

(89.2, 91.1)

11362696

<.0001

841 (19.6)

(18.2, 21.1)

2475988

<.0001

2856 (70.4)

21289 (83.8)

<.0001

9373 (33.8)

<.0001

<.0001

14410 (55.7)

<.0001

<.0001

115

1179 (46.8)

(44.5, 49.2)

5554793

291.87 (11.8) (268.59, 315.14)

5598 (34.6)
202.10 (5.9)

<.0001

<.0001

2145 (53.4)

(68.8, 71.9)

8869651

(51.4, 55.4)

6729515

328.76 (11.7) (305.82, 351.69)

10596 (41.5)

<.0001

243.55 (4.6)

<.0001

<.0001

1378 (51.2)

(49.0, 53.4)

6071327

10493 (57.2)

2304 (55.7)

(53.9, 57.5)

7018240

15749 (58.3)

823 (31.7)

(29.8, 33.5)

3755974

3536 (21.6)

1228 (30.4)

(28.8, 32.1)

3834185

5592 (22.1)

422 (17.1)

(15.1, 19.2)

2032267

3475 (21.2)

588 (13.9)

(12.6, 15.1)

1750831

5211 (19.6)

<.0001

756 (27.7)

(25.7, 29.6)

3283147

7208 (38.1)

1146 (25.4)

(23.6, 27.2)

3203003

10205 (35.7)

1249 (46.6)

(44.4, 48.8)

5526656

7100 (41.7)

1975 (49.3)

(47.5, 51.2)

6221233

11113 (43.1)

618 (25.7)

(23.8, 27.7)

3049765

3196 (20.2)

999 (25.2)

(23.6, 26.8)

3179020

5234 (21.2)

<.0001

<.0001

<.0001

<.0001

<.0001

16 (0.62)

(0.32, 0.93)

73924

110 (0.66)

0.832

38 (0.94)

(0.54, 1.3)

118622

188 (0.74)

0.324

<.0001

2592 (98.9)

(98.5, 99.3)

11728276

15097 (86.9)

<.0001

4045 (98.4)

(98.0, 98.8)

12400511

19001 (73.3)

<.0001

<.0001

2460 (94.1)

(93.0, 95.2)

11157170

11114 (66.1)

<.0001

3972 (96.7)

(96.1, 97.4)

12191074

17049 (66.0)

<.0001

<.0001

1337 (51.9)

(49.8, 54.1)

6158756

4154 (25.5)

<.0001

1575 (39.6)

(37.7, 41.6)

4997184

3809 (15.3)

<.0001

<.0001

1520 (59.4)

(57.2, 61.6)

7044988

4658 (28.8)

<.0001

2144 (53.0)

(51.1, 54.8)

6674207

6714 (26.5)

<.0001

<.0001

173 (6.5)

(5.5, 7.6)

775716

182 (1.1)

<.0001

196 (4.8)

(4.0, 5.6)

608722

167 (0.65)

<.0001

<.0001

1691 (64.2)

(61.9, 66.5)

7610988

10280 (57.1)

<.0001

504 (12.8)

(11.5, 14.1)

1615648

857 (3.3)

<.0001

<.0001

661 (25.1)

(23.1, 27.1)

2975378

1333 (7.7)

<.0001

815 (19.9)

(18.4, 21.4)

2510445

1453 (5.5)

<.0001

<.0001

* Adjusted for age, sex,
**Adjusted for age, sex,
Note: Column Percentages shown
race/ethnicity based on 2000
race/ethnicity based on 2010
Census data
Census data
a. Supplements other than herbs, including Vitamins/Minerals, probiotics (past 30 days), fish oil (past 30 days), chelation therapies
b. Tai Chi/Qi Gong, Yoga, guided imagery, progressive relaxation, deep breathing exercises, Meditation (for which singular term "meditation" is used in 2007; was expanded in 2012 to include mantra, and mindfulness meditation), Stressmanagement class and support group (2007), mindfulness meditation: including mindfulness-base stress reduction and congitive therapy (2012) Biofeedback, hypnosis c. (Ever) Practitioner-based massage, chiropractic/osteopathic
manipulation, Sobador visit
d. Prayed for one's own health (2007) or centering prayer/contemplative meditation (2012); and/or, visit with espiritista (2007 only), cuarandero, shaman, and/or Native American healer e.
Acupuncture, Ayurveda, homeopathy, naturopathy
$ family costs aside from deductibles, premiums, copays
R. Defined as >10 min increments
W. p-values obtained by comparing weighted estimates

Table 3b: Health Characteristics of two National U.S. samples (NHIS 2007 & 2012) , stratified by herbal use in past 30 days
2007 (N = 20,127)

2012

Herbal use

P

Yes
Characteristic
N (%)

95% CI

Weighted
population
estimate*

No

Yes

N (%)

N (%)

Body Mass Index (BMI)

(N = 30,672)

Herbal use

P

Overall P

W

No
95% CI

Weighted
population
estimate**

N (%)

0.56

0.102

<.0001

0.088

0.0945

<.0001

<.0001

<24.9
25-29.9
30-35
35+

1012 (39.2)

(37.1, 41.4)

4651169 6615 (38.6)

932 (35.0)

(33.1, 36.9)

4151454 6189 (35.2)

1474 (35.6)

(35.7, 39.5)
(33.8, 37.4

4484736 9159 (34.6)

440 (16.7)

(15.1,18.2)

1975771 2905 (16.2)

679 (16.2)

(14.8, 17.6)

2043500 4649 (17.3)

239 (9.1)

(8.0,10.3)

1081174 1795 (9.9)

461 (10.6)

(9.6, 11.7)

1337195 3154 (11.5)

27.56 (0.10)

(27.37, 27.76)

27.75 (0.05)

Mean (SE)

Comorbidity Indexa

1506 (37.6)

4737825

9590 (36.6)

0
1
2
3+
Mean (SE)

Chronic Health Conditions
Diabetes
Kidney disease
GI diseaseaa

27.26 (0.12)

(27.02, 27.51)

27.40 (0.06)

0.434

Chronic Respiratory conditions b
CVDc
<.0001

Hypertension
Dyslipidemia
Liver disease
Chronic pain conditions d

631 (24.0)

(22.1, 25.9)

2844176 6819 (37.9)

735 (17.6)

(16.2, 19.0)

2216922 7888 (29.3)

662 (25.7)

(24.0, 27.5)

3051748 4096 (23.9)

890 (21.5)

(20.1, 22.9)

2711153 6045 (23.0)

497 (18.8)

(17.0, 20.5)

2224006 2653 (15.6)

798 (19.2)

(17.9, 20.5)

2417833 4528 (17.4)

833 (31.5)

(29.7, 33.4)

3739638 3936 (22.6)

1697 (41.7)

(39.9, 43.5)

5257348 8091 (30.3)

Mental health conditions e
Insomnia
History of Cancer
Perceived health status
Excellent/very good/good
Fair
Poor
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1.88 (0.04)

(1.81, 1.95)

1.46 (0.02)

<.0001

2.31 (0.03)

(2.24, 2.38)

1.84 (0.02)

<.0001

0.0001

1401593 3076 (11.0)

246 (8.8)

(7.7, 10.0)

1046551 1701 (9.2)

0.547

485 (11.1)

(9.9, 12.3)

45 (1.8)

(1.2, 2.4)

212862 301 (1.6)

0.558

68 (1.6)

(1.1, 2.0)

0.048

<.0001

529 (1.9)

0.173

441 (17.4)

(15.7, 19.1)

2061656 1845 (11.0)

<.0001

1637 (40.4)

<.0001

(38.6, 42.1)

5089779 8017 (30.5)

<.0001

434 (16.2)

(14.8, 17.7)

1923974 2325 (13.7)

0.0009

<.0001

750 (18.4)

(17.0, 19.8)

2322524 3997 (15.2)

<.0001

206 (7.7)

(6.6, 8.7)

911835 1129 (6.7)

<.0001

0.071

318 (7.7)

(6.8, 8.7)

1904 (7.2)

0.314

877 (32.4)

(30.3, 34.4)

<.0001

3836843 5023 (28.6)

0.0003

1508 (36.4)

(34.7, 38.2)

4589502 8516 (31.8)

<.0001

925 (35.1)

<.0001

(33.2, 37.1)

4166974 4211 (24.5)

<.0001

1510 (36.6)

(34.6, 38.5)

4607481 6999 (26.7)

<.0001

<.0001

38 (1.4)

(0.94, 1.9)

169692 214 (1.2)

0.329

72 (1.7)

(1.2, 2.1)

0.146

<.0001

1378 (52.8)

(50.8, 54.8)

6259209 6398 (37.6)

<.0001

2347 (57.5)

(55.7, 59.3)

7245512 10614
(40.4)

<.0001

<.0001

583 (23.2)

(21.1, 25.4)

2753361 2872 (16.6)

<.0001

1196 (28.9)

(27.3, 30.6)

3645993 6332 (23.6)

<.0001

<.0001

679 (26.8)

(24.8, 28.9)

3179543 3154 (18.3)

<.0001

1133 (27.1)

(25.5, 28.7)

3416688 5083 (19.1)

<.0001

<.0001

282 (10.7)

(9.4, 12.1)

1272814 1174 (7.5)

<.0001

477 (11.9)

(10.7, 13.0)

1495165

<.0001

<.0001

0.0001

<.0001

195466

973750

209745

367 (1.4)

2131 (8.6)

0.005

2296 (87.7)

(86.3, 89.1)

10400152 14999 (86.4)

3613 (89.1)

(88.0, 90.2)

268 (10.1)

(8.8, 11.4)

1201167 1876 (10.1)

404 (8.6)

(7.7, 9.5)

59 (2.2)

(1.6, 2.8)

258249 629 (3.5)

103 (2.3)

(1.7, 2.8)

11230927 22619
(86.4)
1084958 3043 (10.5)

287371

890 (3.1)

* Adjusted for age, sex,
**Adjusted for age, sex, race/ethnicity
Note: Column Percentages shown race/ethnicity based on 2000 based on 2010 Census data Census data
a. Includes diabetes, kidney disease, Gastrointestinal disorder (including ulcer and/or abdominal pain, digestive allergy, heartburn), respiratory conditions (Asthma, emphesema, and.or chronic bronchitis), dyslipidemia, liver condition, Rheumatoid Arthritis, CVD,
hypertension, non-specific arthritis, gout, migraines, mental health condition
aa. Includes: bowel conditions and ulcers (2007); past 12 month abdominal pain, digestive allergy, heartburn, and ever having ulcer (2012) b. Asthma,
emphysema, and/or chronic bronchitis
c. Myocardial Infarction, Heart Disease, Angina pectoris
d. Migraines (past 3 months), nonspecific arthritis, gout, non-specific joint pain for 3+ months, Rheumatoid Arthritis
e. Depression, bipolar disorder, phobias, often anxious in past year
W. p-values obtained by comparing weighted estimates
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Images
Chapter 1
Image 1: Current harvesting of medicinal plants in West Virginia

(Photo taken by author July 10, 2014 near Hookersville, WV)
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Image 1: Percentage of adults who used nonvitamin, nonmineral dietary supplements in the past 12 months, by
region: United States, 2012
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Figures
Chapter 1
Figure 1: Taxonomy of Folk Illnesses in Appalachia

(Matthews et al 1992)

Figure 2: Evolution of Folk Medicine in Appalachia

(Amjad 2006)
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Figure 3: Information Flow Pathways of Efficacy Research for use of Herbal Product vs.
Prescription Drug
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Figure 4. Conceptual Model of the Rela tionships between Chronic Pain, Inflammation, and Herbal Medicine
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Chapter 3
Figure 1. Study Flow for two NHIS datasets

Chapter 4
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Figure 1. The Transtheoretical Model’s Six Stages of Change
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Figure 2. Flow diagram for the CHAPS 2014-2016

Response Rate = 88%
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Additional Files

Appendix A.

Search Results for Cochrane
FMS/CFS/Chronic Pain

Reviews

on

Herbal

Medicine

and

Results: 206; search performed 10/10/14 using search terms "herb" "herbal" GUIDE
"botanical" "fibromyalgia" in Cochrane Summaries
Relevant studies to non-cancerous chronic pain relating to fibromyalgia or
chronic fatigue and herbs manually pulled: 22

herbs mentioned
treatment

Description

non-herbal
therapies
as treatment
N (if clear)

Type of herb or
intervention
Traditional Chinese medicinal herbs No studies met
for the treatment of idiopathic
inclusion criteria
chronic fatigue and chronic fatigue
and specific herbs
syndrome;"Traditional Chinese
used were not
medicinal herbs for chronic
specified
fatigue";CD006348;http://su
mmaries.cochrane.org/CD006
348/DEPRESSN_traditionalchinesemedicinal-herbs-forchronic-fatigue

Results

Anticonvulsants for
fibromyalgia;"Anticonvulsant s for
fibromyalgia";CD010782;http
://summaries.cochrane.org/C
D010782/MUSKEL_anticonv
ulsants-for-fibromyalgia

anti-epileptic drug

reliable conclusions
for pregabalin only

Exercise for treating fibromyalgia
syndrome;"Exercise for
fibromyalgia";CD003786;http
://summaries.cochrane.org/C
D003786/MUSKEL_exercise
-for-fibromyalgia

exercise

There is 'gold' level
evidence
(www.cochranemsk.o
rg) that supervised
aerobic exercise
training has beneficial
effects on physical
capacity and FM
symptoms. Strength
training may also

This is an original
review which was
withdrawn in 2009
and replaced by the
same group's
"Antiepileptic
drugs for
neuropathic pain
and fibromyalgia"
in
2013
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have benefits on some FM
symptoms.
Further studies on muscle
strengthening and flexibility
are needed. Research on the
long-term benefit of exercise
for FM is needed. - See more
at:
http://summaries.coch
rane.org/CD003786/
MUSKEL_exerciseforfibromyalgia#sthash.
BzwierwV.dpuf

Resistance exercise training
resistance training
for fibromyalgia;"Resistance
training (such as
weightlifting) for
fibromyalgia";CD010884;http
://summaries.cochrane.org/C
D010884/MUSKEL_resistanc
e-training-such-asweightlifting-for-fibromyalgia

For women with
fibromyalgia, resistance
training for 16 to 21 weeks
likely improves
ability to do normal
activities
pain, tenderness,
muscle strength and overall
well-being. Quality of the
evidence -Because so few
studies have been done so far,
more research is likely to
change these results.
See more at:
http://summaries.coch
rane.org/CD010884/
MUSKEL_resistancetrainingsuch-asweight-liftingforfibromyalgia#sthash.
76OJ4uGl.dpuf
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Acupuncture for treating
fibromyalgia;"Acupuncture
for
fibromyalgia";CD007070;http
://summaries.cochrane.org/C
D007070/MUSKEL_acupunc
ture-for-fibromyalgia

electric acupuncture
and manual
acupuncture

There is low to
moderate-level
evidence that
compared with no
treatment and
standard therapy,
acupuncture improves
pain and stiffness in
people with
fibromyalgia. There is
moderate-level
evidence that the
effect of acupuncture
does not differ from
sham acupuncture in
reducing pain or
fatigue, or improving
sleep or global
wellbeing. EA is
probably better than
MA for pain and
stiffness reduction
and improvement of
global well-being,
sleep and fatigue. The
effect lasts up to one
month, but is not
maintained at six
months follow-up.
MA probably does
not improve pain or
physical functioning.
Acupuncture appears
safe. People with
fibromyalgia may
consider using EA
alone or with exercise
and medication. The
small sample size,
scarcity of studies for
each comparison, lack
of an ideal sham
acupuncture weaken
the level of evidence
and its clinical
implications. Larger
studies are warranted.
- See more at:
http://summaries.coch
rane.org/CD007070/
MUSKEL_acupunctu
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reforfibromyalgia#sthash.
ZhGfzRsC.dpuf

Cognitive behavioural
CBT
therapies for
fibromyalgia;"Cognitive
behavioural therapies for
fibromyalgia
syndrome";CD009796;http://s
ummaries.cochrane.org/CD00
9796/cognitivebehaviouraltherapies-forfibromyalgiasyndrome
Phenytoin for neuropathic
phenytoin is for
pain and fibromyalgia in
neuropathic pain and
fibromyalgia. - See
adults;"Phenytoin for
more at:
neuropathic pain and
http://summaries.coc
fibromyalgia in
adults";CD009485;http://sum hrane.org/CD00948
maries.cochrane.org/CD0094 5/SYMPT_phenytoi
n-for85/SYMPT_phenytoinneuropathicpainforneuropathic-painandfibromyalgiaandfibromyalgia-in-adults
inadults#sthash.BniKq
Zkm.dpuf
Multidisciplinary
the combo of
rehabilitation for
psychological,
fibromyalgia and
behavioral and
musculoskeletal pain in
educational
working age
interventions
adults;"Multidisciplinary
practiced in pain
rehabilitation for
clinics and
fibromyalgia and
rehabilitation centers
musculoskeletal pain in
working age
adults";CD001984;http://sum
maries.cochrane.org/CD0019
84/MUSKEL_multidisciplina

CBTs provided a small
incremental benefit
over control
interventions in
reducing pain, negative
mood and disability at
the end of treatment
and at long-term
follow-up.

23 studies with up
to 2031 people

No studies met
inclusion criteria

little scientific evidence
for the effectiveness of
multidisciplinary
rehabilitation for these
musculoskeletal
disorders

1808 abstracts, and
the references of 65
reviews, we found
only seven relevant
studies (1050
patients)
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ry-rehabilitationforfibromyalgiaandmusculoskeletal-paininworking-age-adults

Clonazepam for neuropathic
pain and fibromyalgia in
adults;"Clonazepam for
neuropathic pain and
fibromyalgia in
adults";CD009486;http://sum
maries.cochrane.org/CD0094
86/SYMPT_clonazepamforneuropathic-painandfibromyalgia-in-adults
Gabapentin for chronic
neuropathic pain and
fibromyalgia in
adults;"Gabapentin for chronic
neuropathic pain and
fibromyalgia in
adults";CD007938;http://sum
maries.cochrane.org/CD0079
38/SYMPT_gabapentinforchronic-neuropathicpainand-fibromyalgia-inadults

Some antiepileptic
medications can help
neuropathic pain.
Clonazepam is an
antiepileptic
medication

no good quality
studies

Medicines like
paracetamol or
ibuprofen are not
effective in
neuropathic pain,
while medicines that
are sometimes used
to treat depression or
epilepsy can be very
effective in some
people with
neuropathic pain.
Our understanding of
fibromyalgia (a
condition of
persistent,
widespread pain and
tenderness, sleep
problems, and
fatigue) is poor, but
fibromyalgia can
respond to the same
medicines as
neuropathic pain.

There were
insufficient data for
direct comparisons
with other active
treatments, and only
third tier evidence for
other painful
conditions.

Seven new studies
with 1919 participants
were added in this
third update.

Gabapentin was
developed to treat
epilepsy, but it is
now used to treat
various forms of
chronic pain.
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Milnacipran for neuropathic
pain and fibromyalgia in
adults;"Milnacipran for
chronic neuropathic pain and
fibromyalgia in
adults";CD008244;http://sum
maries.cochrane.org/CD0082
44/SYMPT_milnacipranforchronic-neuropathicpainand-fibromyalgia-inadults

milnacipran is for
treating chronic
neuropathic pain or
fibromyalgia. We
identified no studies
using milnacipran in
neuropathic pain, but
five studies in
fibromyalgia satisfied
the inclusion criteria.
- See more at:
http://summaries.coc
hrane.org/CD00824
4/SYMPT_milnacipr
an-forchronicneuropathicpainand-fibromyalgiainadults#sthash.sszfV2
Ug.dpuf

Milnacipran has shown
modest effects in a
minority of participants
with fibromyalgia, and
several technical issues
indicate that even this
modest effect may
overstate effectiveness
in clinical practice The
drug may be a useful
option if first-line
treatments fail. - See
more at:
http://summaries.coch
rane.org/CD008244/S
YMPT_milnacipranforchronicneuropathicpain-andfibromyalgiainadults#sthash.sszfV2
Ug.dpuf

4000 participants
treated with
milnacipran 100 mg or
200 mg, or placebo, for
eight to 24 weeks at the
target dose. - See more
at:
http://summaries.coch
rane.org/CD008244/S
YMPT_milnacipranforchronicneuropathicpain-andfibromyalgiainadults#sthash.sszfV2
Ug.dpuf

Amitriptyline for neuropathic
pain and fibromyalgia in
adults;"Amitriptyline for
neuropathic pain and
fibromyalgia in
adults";CD008242;http://sum
maries.cochrane.org/CD0082
42/SYMPT_amitriptylineforneuropathic-painandfibromyalgia-in-adults

Amitriptyline is a
tricyclic
antidepressant that is
widely used to treat
chronic neuropathic
pain (pain due to
nerve damage) and
fibromyalgia, and is
recommended in many
guidelines.

There was no top-tier
evidence for
amitriptyline in treating
neuropathic pain or
fibromyalgia. Secondtier evidence indicated
some evidence of effect
in painful diabetic
neuropathy (PDN),
mixed neuropathic
pain, and fibromyalgia.
Amitriptyline has been
a first-line treatment
for neuropathic pain for
many years. The fact
that there is no
supportive unbiased
evidence for a
beneficial effect is
disappointing, but has
to be balanced against
decades of successful
treatment in many
patients with
neuropathic pain or

Twenty-one studies
(1437 participants)
were included; they
individually involved
between 15 and 235
participants, only four
involved over 100
participants, and the
median study size was
44 participants. The
median duration was
six weeks. Ten studies
had a crossover design.
Doses of amitriptyline
were generally
between 25 mg and
125 mg, and dose
escalation was
common.
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fibromyalgia. There is
no good evidence of a
lack of effect; rather
our concern should be
of overestimation of
treatment effect.
Amitriptyline should
continue to be used as
part of the treatment
of neuropathic pain or
fibromyalgia, but
only a minority of
patients will achieve
satisfactory pain
relief.
Duloxetine for treating painful
neuropathy, chronic pain or
fibromyalgia;"Duloxetine for
treating chronic pain or
fibromyalgia";CD007115;http
://summaries.cochrane.org/C
D007115/NEUROMUSC_dul
oxetine-for-treatingpainfulneuropathy-chronicpain-orfibromyalgia painful
neuropathy

Duloxetine is a
balanced serotonin
and noradrenaline
reuptake inhibitor
licensed for the
treatment of major
depressive disorders,
urinary stress
incontinence and the
management of
neuropathic pain
associated with
diabetic peripheral
neuropathy.

There are adequate
amounts of moderate
quality evidence from
eight studies
performed by the
manufacturers of
duloxetine that doses
of 60 mg and 120 mg
daily are efficacious
for treating pain in
diabetic peripheral
neuropathy but lower
daily doses are not.
Further trials are not
required. In
fibromyalgia, there is
lower quality
evidence that
duloxetine is effective
at similar doses to
those used in diabetic
peripheral neuropathy
and with a similar
magnitude of effect.
The effect in
fibromyalgia may be
achieved through a
greater improvement
in mental symptoms
than in somatic
physical pain. There is
low to moderate
quality evidence that
pain relief is also
achieved in pain

18 trials, which
included 6407
participants. We
found 12 of these
studies in the
literature search for
this update. Eight
studies included a
total of 2728
participants with
painful diabetic
neuropathy and six
studies involved 2249
participants with
fibromyalgia. Three
studies included
participants with
depression and painful
physical symptoms
and one included
participants with
central neuropathic
pain.
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associated with
depressive symptoms,
but the NNTB of 8 in
fibromyalgia and
depression is not an
indication of
substantial efficacy.

Lacosamide for neuropathic
Antiepileptic drugs
pain and fibromyalgia in
like lacosamide
adults;"Lacosamide for
neuropathic pain and
fibromyalgia in
adults";CD009318;http://sum
maries.cochrane.org/CD0093
18/NEUROMUSC_lacosamid
e-for-neuropathic-painandfibromyalgia-in-adults

In people with painful
diabetic neuropathy,
lacosamide had only a
modest effect, with a
specific effect due to
its use in 1 person in
10. This is a minor
effect and may be an
over-estimate due to
use of the last
observation carried
forward method for
analysis. There was
insufficient
information in
fibromyalgia to draw
any conclusions about
the effect of
lacosamide. - See more
at:
http://summaries.coch
rane.org/CD009318/
NEUROMUSC_lacos
amide-forneuropathic-painandfibromyalgiainadults#sthash.6W9bIi
Q5.dpuf

five studies in painful
diabetic neuropathy
(1863 participants) and
one in fibromyalgia
(159 participants). See more at:
http://summaries.coch
rane.org/CD009318/
NEUROMUSC_lacos
amide-forneuropathicpain-andfibromyalgiainadults#sthash.6W9bIi
Q5.dpuf
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Topiramate for neuropathic pain
and fibromyalgia in
adults;"Topiramate for treating
neuropathic pain or
fibromyalgia";CD008314;http
://summaries.cochrane.org/C
D008314/NEUROMUSC_top
iramate-for-treatingneuropathicpain-orfibromyalgia

Topiramate is a
medicine used to
treat epilepsy,
and so it might
be a useful
medicine for
neuropathic pain
or fibromyalgia.

Topiramate did not help
the pain and was no
different from placebo
except in causing more
sideeffects, which made
many more people
withdraw from the
studies early. About 3
people in 10 withdrew
because of side-effects
with topiramate
compared with 1 in 10
with placebo.
Topiramate has not been
shown to work as a pain
medicine in diabetic
neuropathy.

Monoamine oxidase inhibitors
(MAOIs) for fibromyalgia
syndrome;"Monoamine oxidase
inhibitors (MAOIs) for
fibromyalgia";CD009807;http
://summaries.cochrane.org/C
D009807/monoamineoxidase-inhibitors-maoisforfibromyalgia

MAOIs may
slightly improve
pain and tender
points in the
short term
compared to
placebo. Of the
MAOIs studied,
pirlindole seems
more effective
than
moclobemide.

Pirlindole showed
statistically
significant results
compared with placebo
for several outcomes
(pain, tender points and
overall assessment by
the patient and the
physician), whereas
moclobemide did not
show statistically
significant differences
between groups.

Valproic acid and sodium
valproate for neuropathic pain
and fibromyalgia in
adults;"Valproic acid and
sodium valproate for
neuropathic pain and
fibromyalgia";CD009183;http
://summaries.cochrane.org/C
D009183/SYMPT_valproicacidand-sodium-valproateforneuropathic-painandfibromyalgia

Valproic acid
and its sodium
salt (sodium
valproate) are
antiepileptic
drugs that are
sometimes used
to treat chronic
neuropathic pain
and
fibromyalgia,
although they
are not licensed
for this use.

There is insufficient
evidence to support the
use of valproic acid or
sodium valproate as a
firstline treatment for
neuropathic pain. - See
more at:
http://summaries.coch
rane.org/CD009183/S
YMPT_valproicacidandsodiumvalproateforneuropathic-painandfibromyalgia#sthash.
xiAvcyI1.dpuf

four studies of
reasonable quality that
tested topiramate
against placebo for a
number of weeks.
Almost all of the 1684
people in the studies
had painful limbs
because of damaged
nerves caused by
diabetes. - See more
at:
http://summaries.coch
rane.org/CD008314/
NEUROMUSC_topir
amate-fortreatingneuropathicpainorfibromyalgia#sthash.
9txXjI9A.dpuf
two studies of
inconsistent risk of
bias with a total of 230
patients diagnosed
with FM. We
evaluated two MAOIs:
pirlindole and
moclobemide.

three studies, two in
diabetic neuropathy
(42 participants
treated with valproate,
42 with placebo), and
one in post-herpetic
neuralgia (23 treated
with divalproex
sodium, 22 with
placebo). Study
duration was eight or
12 weeks. No studies
were found in
fibromyalgia.
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Oxycodone for neuropathic
pain and fibromyalgia in
adults;"Oxycodone for
neuropathic pain and
fibromyalgia in
adults";CD010692;http://sum
maries.cochrane.org/CD0106
92/SYMPT_oxycodoneforneuropathic-painandfibromyalgia-in-adults

Oxycodone is used to
treat acute and some
forms of chronic pain,
and so might be a
useful medicine for
neuropathic pain or
fibromyalgia. - See
more at:
http://summaries.coc
hrane.org/CD01069
2/SYMPT_oxycodo
ne-forneuropathicpainandfibromyalgiainadults#sthash.VtfS5l
3z.dpuf

Oxycodone was not
convincingly shown
to help relieve the
pain (very low quality
evidence). Compared
with placebo, fewer
people stopped taking
oxycodone because
they felt it was not
effective, but more
people experienced
adverse effects (very
low quality
evidence).
Oxycodone has not
been shown to work
as a pain medicine in
diabetic neuropathy
or postherpetic
neuralgia.

three studies of
modest quality that
tested oxycodone
against placebo for
several weeks.
Almost all of the 254
people in the studies
had painful limbs
because of damaged
nerves caused by
diabetes. No studies
have examined its use
in other types of
neuropathic pain, or
in fibromyalgia.
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Antiepileptic drugs for
neuropathic pain and
fibromyalgia - an overview of
Cochrane
reviews;"Antiepileptic drugs to
treat neuropathic pain or
fibromyalgia- an overview of
Cochrane
reviews";CD010567;http://su
mmaries.cochrane.org/CD010
567/SYMPT_antiepilepticdrugsto-treat-neuropathicpain-orfibromyalgia-anoverview-ofcochranereviews

Antiepileptic drugs
(previously called
anticonvulsants) are
used for treating
epilepsy, but have
also been used for
treating neuropathic
pain and
fibromyalgia. Many
of the drugs have
been the subject of
individual Cochrane
reviews. In August
2013 we collected
all these Cochrane
reviews on
antiepileptic drugs
together to provide
an overview.
Individual
antiepileptic drugs
work in different
ways, and there is no
expectation that they
are equally effective.
- See more at:
http://summaries.coc
hrane.org/CD01056
7/SYMPT_antiepile
ptic-drugs-totreatneuropathicpain-orfibromyalgiaanoverviewofcochranereviews#sthash.xqm
OPsy4.dpuf

No studies reported
top tier results. We
found that only for
gabapentin and
pregabalin was there
some evidence that
they worked in
longterm nerve pain
with diabetes (painful
diabetic neuropathy)
and pain after
shingles (postherpetic
neuralgia).
Pregabalin also had
evidence of efficacy
in central neuropathic
pain (typically pain
after stroke) and in
fibromyalgia. The
drugs work very well
in some people with
these painful
conditions, with pain
reduced by half.
However, only
between 1 in 10 and 1
in 4 people will get
this level of benefit,
depending on the
pain condition and
the drug. Most people
will get no pain
relief.
The antiepileptic
drugs produced side
effects in most
people taking them,
and for about 1 in 4
these could not be
tolerated so they
stopped taking the
drug. Serious side
effects were no more
common with
antiepileptic drugs
than with a harmless
placebo.
The evidence we
found did not meet
current best
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standards, and as a
result it may
overestimate benefit.
The biggest concern is
a lack of any evidence
for most drugs in
most types of
neuropathic pain and
fibromyalgia. For
lacosamide and
lamotrigine there is
evidence of a lack of
effect; for other
antiepileptic drugs
(including
carbamazepine,
clonazepam,
phenytoin, valproate)
there is no evidence of
effect or insufficient
evidence of effect.

Serotonin and noradrenaline
reuptake inhibitors (SNRIs)
for fibromyalgia
syndrome;"Serotonin and
noradrenaline reuptake
inhibitors for
fibromyalgia";CD010292;http
://summaries.cochrane.org/C
D010292/serotoninandnoradrenalinereuptakeinhibitors-forfibromyalgia

serotonin and
noradrenaline
reuptake inhibitors
(SNRIs)

The SNRIs duloxetine
and milnacipran
provided a small
incremental benefit
over placebo in
reducing pain. The
superiority of
duloxetine and
milnacipran over
placebo in reducing
fatigue and limitations
of QOL was not
substantial.
Duloxetine and
milnacipran were not
superior to placebo in
reducing sleep
problems. The
dropout rates due to

Ten studies were
included with a total
of 6038 participants.
Five studies
investigated
duloxetine against
placebo, and five
investigated
milnacipran against
placebo. A total of
3611 participants were
included into
duloxetine or
milnacipran groups
and 2427 participants
into placebo groups.
The studies had a low
risk of bias in general.
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adverse events were
higher for duloxetine
and milnacipran than
for placebo.

Lamotrigine for chronic
neuropathic pain and
fibromyalgia in
adults;"Lamotrigine (an
antiepileptic drug) for chronic
neuropathic pain or
fibromyalgia";CD006044;http
://summaries.cochrane.org/C
D006044/SYMPT_lamotrigin
e-an-antiepileptic-drugforchronic-neuropathic-painorfibromyalgia

Lamotrigine is a
Lamotrigine did not
help the pain, and
medicine used to
treat epilepsy, and so was no different from
placebo except in
might be a useful
causing more side
medicine for
effects. Adverse
neuropathic pain or
events were more
fibromyalgia.
frequent with
lamotrigine than
placebo, with rash in
1 person in 27. -

12 studies of
reasonable quality
that tested lamotrigine
against placebo for a
number of weeks.
Almost half of the
1511 people in the
studies had painful
limbs because of
damaged nerves
caused by diabetes,
and seven different
painful neuropathic
conditions were
examined. No studies
looked at
fibromyalgia. - See
more at:
http://summaries.coch
rane.org/CD006044/S
YMPT_lamotriginean-antiepilepticdrugforchronicneuropathicpainorfibromyalgia#sthash.
VyD9Kv3y.dpuf
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Carbamazepine for chronic
neuropathic pain and
fibromyalgia in
adults;"Carbamazepine for
chronic neuropathic pain and
fibromyalgia in
adults";CD005451;http://sum
maries.cochrane.org/CD0054
51/SYMPT_carbamazepinefor-chronic-neuropathicpainand-fibromyalgia-inadults

Carbamazepine was
developed to treat
epilepsy, but it is now
used to treat various
forms of chronic pain.
- See more at:
http://summaries.coc
hrane.org/CD00545
1/SYMPT_carbamaz
epine-forchronicneuropathicpainandfibromyalgiainadults#sthash.vNNP
XVgz.dpuf

There was not
enough good quality
evidence to say how
well carbamazepine
worked in any
neuropathic pain
condition. Pooling
four small studies
showed that it was
better than placebo,
but the result cannot
be relied upon.
There was not
enough information
from these studies to
make any reliable
comment on adverse
events or harm.
Carbamazepine is
probably helpful for
some people with
chronic neuropathic
pain. It is not
possible to know
beforehand who will
benefit and who will
not.

10 studies involving
418 people involved
in testing
carbamazepine. Studies
were not generally of
very good quality. Most
were very small, as
well as of short
duration. Studies
lasting only one or two
weeks are unhelpful
when pain can last for
years. - See more at:
http://summaries.coch
rane.org/CD005451/S
YMPT_carbamazepin
e-forchronicneuropathicpain-andfibromyalgiainadults#sthash.vNNPX
Vgz.dpuf
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PycnogenolÂ® (extract of
French maritime pine bark)
for the treatment of chronic
disorders;"Use of the
antioxidant supplement
PycnogenolÂ® to treat a
variety of chronic
disorders";CD008294;http://s
ummaries.cochrane.org/CD00
8294/CF_use-oftheantioxidantsupplementpycnogenolr-totreat-avariety-of-chronicdisorders

Pycnogenol® is a
herbal dietary
supplement extracted
from French
maritime pine bark
whose main
ingredient is
procyanidin.
Procyanidin is a
powerful antioxidant
also found in food
such as grapes,
berries,
pomegranates, red
wine and various
nuts. Supplements
containing
procyanidin are
widely marketed
worldwide for the
promotion of health,
and for the
prevention and
treatment of chronic
disorders. The
rationale for this is
that antioxidants
neutralise reactive
oxygen species
(ROS; frequently
referred to as "free
radicals") which,
apart from
performing
important bodily
functions, can cause
damage to cells and
tissues if present in
excessive amounts.
Available
supplements vary in
the source and
quantity of
procyanidin, as well
as in number and
type of other
ingredients they
contain. We chose to
focus on
Pycnogenol® as this
supplement is a

Due to small sample
size, limited number
of trials per condition,
variation in outcomes
evaluated and
outcome measures
used, as well as the
risk of bias in the
included studies, no
definite conclusions
regarding the efficacy
and safety of
Pycnogenol® are
possible.

15 eligible
randomised controlled
trials with a total of
791 participants
which addressed
seven different
chronic conditions:
asthma (two studies);
attention deficit
hyperactivity disorder
(one study), chronic
venous insufficiency
(two studies), diabetes
(four studies), erectile
dysfunction (one
study), hypertension
(two studies) and
osteoarthritis (three
studies).

154

standardised
product, many trials
have been
conducted, and it is
extensively
marketed
internationally

Results: 193 search performed 10/16/14 using search terms "herbal medicine" and "Chronic
pain" in Cochrane Summaries
Relevant studies to non-cancerous fibromyalgia comorbidities (depression, anxiety, headache,
irritable bowel syndrome, chronic fatigue syndrome, systemic lupus erythematosus, and
rheumatoid arthritis) and related chronic pain conditions and herbs manually pulled from
search: 17
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Cui X, Trinh K, Wang Y-J. Chinese
herbal medicine for chronic neck pain
due to cervical degenerative disc
disease . Cochrane Database of
Systematic Reviews 2010, Issue 1.
Art. No.: CD006556.
DOI:
10.1002/14651858.CD00655
6.pub2 - See more at:
http://summaries.cochrane.or
g/CD006556/BACK_herbalmedicinefor-cervicaldegenerativediscdisease#sthash.0bXFNG9M.d puf

Compound
Qishe
Tablet &
Compound
Extractum
Nucis
Vomicae

For chronic neck
pain with or
without radicular
symptoms, there
is low quality
evidence
that
Compound Qishe
Tablet is more
effective than
placebo for pain
relief, measured
at the end of the
treatment.
However, the
size of the studies
was small and the
effect was
measured in the
short-term.
Further research
is very likely to
change both the
effect size and
our confidence in
the results. There
is a need for trials
with adequate
numbers of
participants that
address longterm efficacy or
effectiveness of
herbal medicine
compared to
placebo.

Two Chinese oral herbal
medications
were tested in three
randomized
controlled trials that
included 701 adults with
chronic neck pain with
radicular signs or
symptoms or
myelopathy. One oral
herbal medication was
compared with Mobicox
(nonsteroidal
antiinflammatory
medication) and
Methycobal (drug to
reduce numbness,
tingling in the arms),
and the other
(Compound Qishe
Tablet) with placebo and
Jingfukang. A
topical herbal medicine
(Compound
Extractum Nucis
Vomicae)
was
compared
with
Diclofenac
Diethylamine Emulgel
(nonsteroidal
antiinflammatory
medication). - See more
at:
http://summaries.coch
rane.org/CD006556/
BACK_herbalmedicineforcervicaldegenerativediscdisease#sthash.0bXF
NG9M.dpuf
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Gagnier JJ, van Tulder MW, Berman herbal medicine
BM, Bombardier C. Herbal medicine for non-specific
for low back pain. Cochrane
lowback pain.
Database of Systematic Reviews
2006, Issue 2. Art. No.: CD004504.
DOI:
10.1002/14651858.CD00450 4.pub3
Assessed as up to date: 15
December 2005 - See
more at:
http://summaries.cochrane.or
g/CD004504/BACK_herbalmedicinefor-lowbackpain#sthash.MDoTN5GZ.dpu f

Harpagophytum
Procumbens, Salix
Alba and Capsicum
Frutescens seem to
reduce pain more
than placebo.
Additional trials
testing these herbal
medicines against
standard treatments
are needed. The
quality of reporting
in these trials was
generally poor. Two
high quality trials
examining the
effects of
Harpagophytum
Procumbens
(Devil's Claw)
found strong
evidence that daily
doses standardized
to 50 mg or 100 mg
harpagoside were
better than placebo
for short-term
improvements in
pain and rescue
medication.
Another high
quality trial
demonstrated
relative equivalence
to 12.5 mg per day
of rofecoxib
(Vioxx). Two trials
examining the
effects of Salix
Alba (White Willow
Bark) found
moderate evidence
that daily doses
standardized to 120
mg or 240 mg
salicin were better
than placebo for
short-term
improvements in
pain and rescue
medication. An
additional trial
demonstrated

en randomized
controlled trials that
included 1567
adults with nonspecific acute or
chronic lowback
pain. Two oral
herbal medications,
Harpagophytum
Procumbens
(Devil's
Claw) and Salix
Alba (White Willow
Bark), were
compared with
placebo (fake pills)
and with rofecoxib
(Vioxx). Topical
Capsicum
frutescens
(Cayenne) was
compared with
placebo and a
homeopathic gel.
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relative equivalence
to 12.5 mg per day
of rofecoxib. Three
low
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quality trials on
Capsicum
Frutescens
(Cayenne),
examining various
topical preparations,
found moderate
evidence that
Capsicum
Frutescens produced
more favourable
results than placebo
and one trial found
equivalence to a
homeopathic
ointment.

Liu JP, Yang M, Liu Y, Wei ML,
Various herbal
Grimsgaard S. Herbal medicines for preparations for
treatment of irritable bowel
IBS
syndrome. Cochrane Database of
Systematic Reviews 2006, Issue 1.
Art. No.: CD004116.
DOI:
10.1002/14651858.CD00411
6.pub2 - See more at:
http://summaries.cochrane.or
g/CD004116/IBD_herbalmedicinesfor-treatment-ofirritable-bowelsyndrome#sthash.hU9phi70.d puf

various herbal
preparations
(including single
herbs or mixtures of
different herbs) for
treating people with
irritable bowel
syndrome were
assessed.
individualised
Chinese herbal
medicine, STW 5
and STW 5-II,
Tibetan herbal
medicine Padma
Lax, traditional
Chinese formula
Tongxie
Yaofang, and
Ayurvedic
preparation. some
herbal medicines
improve global
symptoms such as
abdominal pain,
diarrhoea and/or
constipation.
However, the
methodological
quality of the
majority of clinical

Seventy-five
randomised trials,
involving 7957
participants with
irritable bowel
syndrome, met the
inclusion criteria.
The methodological
quality of three
double-blind,
placebo-controlled
trials was high, but
the quality of
remaining trials was
generally low.
Seventy-one
different herbal
medicines were
tested in the
included trials, in
which herbal
medicines were
compared with
placebo or
conventional
pharmacologic
therapy.
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trials evaluating
these
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herbs was
generally poor.
There is evidence
indicating that
small, poor quality
trials with positive
findings are more
likely to be
associated with
exaggerated
effects. Although
the included trials
did not report
serious adverse
effects from using
herbal medicines
more research is
needed to
determine the
safety of herbal
medicines. In
conclusion, herbal
medicines might
be promising for
the treatment of
irritable bowel
syndrome.
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Seidel S, Aigner M, Ossege
antipsychotics
M, Pernicka E, Wildner B, Sycha T.
Antipsychotics for acute and chronic
pain in adults. Cochrane Database of
Systematic Reviews 2013, Issue 8.
Art. No.: CD004844.
DOI:
10.1002/14651858.CD00484
4.pub3 - See more at:
http://summaries.cochrane.or
g/CD004844/SYMPT_analge
sic-effects-of-antipsychoticsinacute-and-chronicpainfulstates#sthash.Xo1fwfPH.dpuf

Antipsychotics
might be used as
an add-on therapy
in the treatment of
painful conditions.
Nevertheless,
extrapyramidal
and sedating side
effects have to be
considered before
using
antipsychotics for
treating painful
conditions.
Results for
antipsychotics in
the treatment of
different painful
conditions are
mixed and most
sample sizes in
the reviewed
RCTs are small.
Further studies on
atypical
antipsychotics in
larger doubleblind placebocontrolled studies
that include
standardised pain
assessment and

A total of 770
participants were
involved in the 11
included studies. See more at:
http://summaries.coch
rane.org/CD004844/S
YMPT_analgesiceffectsofantipsychoticsinacute-andchronicpainfulstates#sthash.Xo1fwf
PH.dpuf

documentation are
warranted.
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Moore RA, Straube S, Wiffen
PJ, Derry S, McQuay HJ.
Pregabalin for acute and
chronic pain in adults.
Cochrane Database of
Systematic Reviews 2009,
Issue 3. Art. No.: CD007076.
DOI:
10.1002/14651858.CD00707
6.pub2 - See more at:
http://summaries.cochrane.or
g/CD007076/SYMPT_pregab
alin-for-acute-andchronicpain-inadults#sthash.6lvmfRNw.dpu
f

Antiepileptics (such
as pregabalin) are
medicines used for
treating epilepsy See more at:

Pregabalin at doses of
300 mg, 450 mg, and
600 mg daily was
effective in patients
with postherpetic
neuralgia, painful
diabetic neuropathy,
central neuropathic
pain, and
fibromyalgia (19
studies, 7003
participants).
Pregabalin at 150 mg
daily was generally
ineffective. Efficacy
was demonstrated for
dichotomous
outcomes equating to
moderate or
substantial pain relief,
alongside lower rates
for lack of efficacy
discontinuations with
increasing dose. The
best (lowest) NNT for
each condition for at
least 50% pain relief
over baseline
(substantial benefit)
for 600 mg
pregabalin daily
compared with
placebo were 3.9
(95% confidence
interval 3.1 to 5.1) for
postherpetic
neuralgia, 5.0 (4.0 to
6.6) for painful
diabetic neuropathy,

not stated
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5.6 (3.5 to 14) for
central neuropathic
pain, and 11 (7.1 to
21) for
fibromyalgia. There
was no clear
evidence of
beneficial effects of
pregabalin in
established acute
postoperative pain.
No studies
evaluated
pregabalin in
chronic nociceptive
pain, like arthritis.
Pregabalin has
proven efficacy in
neuropathic pain
conditions and
fibromyalgia.
Williams AC de C, Eccleston C, CBT and behavior Small to moderate
Morley S. Psychological
therapy
benefits, more for
therapies for the management of
disability, mood and
chronic pain (excluding
catastrophic
headache) in adults. Cochrane
thinking than for
Database of Systematic
pain, were found in
Reviews 2012, Issue 11. Art.
trials which
No.: CD007407. DOI:
compared CBT with
10.1002/14651858.CD00740
no treatment. Some
7.pub3 - See more at:
of these were still
http://summaries.cochrane.or
positive six months
g/CD007407/SYMPT_psycho
later. Behaviour
logical-therapy-for-adultswiththerapy showed few
longstandingdistressing-painand only brief
anddisability#sthash.B2SouCUv.
benefits.
dpuf
Psychological
therapies can help
people with chronic
pain reduce negative
mood (depression
and anxiety),
disability,
catastrophic
thinking, and in
some cases, pain.
Although the overall
effect is positive, we
do not know enough
about exactly which

42 trials of treatments
which met our criteria,
but only 35 provided
data in a form that could
be used. The two main
types of psychological
treatment are called
cognitive behavioural
therapy (CBT) and
behaviour therapy. - See
more at:
http://summaries.coch
rane.org/CD007407/S
YMPT_psychological
-therapy-for-adultswithlongstandingdistressingpainanddisability#sthash.B2S
ouCUv.dpuf
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type of treatment is
best for which
person.

Matthews P, Derry S, Moore
topical salicylates
RA, McQuay HJ. Topical
rubefacients for acute and
chronic pain in adults.
Cochrane Database of
Systematic Reviews 2009, Issue
3. Art. No.: CD007403.
DOI:
10.1002/14651858.CD00740
3.pub2 - See more at:
http://summaries.cochrane.or
g/CD007403/SYMPT_topical
-rubefacients-for-acuteandchronicmusculoskeletalpain-inadults#sthash.TXMzmN3h.dp uf

The evidence does
Six placebo and one
not support the use of active controlled
topical rubefacients
studies (560 and 137
containing salicylates participants) in acute
for acute injuries, and pain, and seven
suggests that in
placebo and two
chronic conditions
active controlled
their efficacy
studies (489 and 90
compares poorly with participants) in
topical non-steroidal
chronic pain were
antiinflammatory
included.
drugs (NSAIDs).
Topical salicylates
seem to be relatively
well tolerated in the
short-term, based on
limited data.
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Eccleston C, Fisher E, Craig
L, Duggan GB, Rosser BA,
Keogh E. Psychological
therapies (Internet-delivered) for
the management of chronic pain
in adults.
Cochrane Database of
Systematic Reviews 2014, Issue
2. Art. No.: CD010152.
DOI:
10.1002/14651858.CD01015
2.pub2 - See more at:
http://summaries.cochrane.or
g/CD010152/SYMPT_psycho
logical-therapies-deliveredviathe-internet-for-adultswithlongstandingdistressing-painanddisability#sthash.uFGoYr5V.
dpuf

Psychological
therapies (e.g.
cognitive
behavioural therapy)
delivered via the
internet

Miyasaka LS, Atallah ÁN,
Passiflora, a herbal
Soares B. Passiflora for
medicine
anxiety disorder. Cochrane
Database of Systematic
Reviews 2007, Issue 1. Art.
No.: CD004518. DOI:
10.1002/14651858.CD00451
8.pub2 - See more at:
http://summaries.cochrane.or
g/CD004518/DEPRESSN_pa
ssiflora-for-the-treatmentofanxiety-disordersinadults#sthash.pA0lREr6.dpuf

We conclude that
15 trials that met our
these findings are
inclusion criteria.
promising for
Four trials included
psychological
individuals with
treatments delivered
headache pain, 10
via the Internet for
trials included
the management of
individuals with
chronic pain in
nonheadache pain,
adults, but more trials and one trial included
are needed to
individuals with both
determine the
headache and
efficacy of such
nonheadache pain.
therapies.

Given the lack of
studies, it is not
possible to draw any
conclusions on the
effectiveness or
safety of passiflora in
the treatment of
anxiety disorders.
Although the findings
from one study
suggested an
improvement in job
performance in
favour of passiflora
(post-hoc outcome)
and one study
showed a lower rate
of drowsiness as a
side effect with
passiflora as
compared with
mexazolam, neither
of these findings
reached statistical
significance.

Two studies, with a
total of 198
participants, were
eligible for inclusion
in this review. Used
Relevant randomised
and quasi-randomised
controlled trials of
passiflora using any
dose, regime, or
method of
administration for
people with any
primary diagnosis of
general anxiety
disorder, anxiety
neurosis, chronic
anxiety status or any
other mental health
disorder in which
anxiety is a core
symptom (panic
disorder, obsessive
compulsive disorder,
social phobia,
agoraphobia, other
types of phobia,
postraumatic stress
disorder).
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Miyasaka LS, Atallah ÁN, Soares B. Valerian, an
Valerian for anxiety disorders.
herbal remedy
Cochrane Database of Systematic
Reviews 2006, Issue 4. Art.
No.: CD004515. DOI:
10.1002/14651858.CD00451
5.pub2 - See more at:
http://summaries.cochrane.or
g/CD004515/DEPRESSN_va lerianforanxietydisorders#sthash.3dwXF2Hx.
dpuf

Since only one
One RCT involving
36 patients with
small study is
generalised anxiety
currently available,
disorder was eligible
there is insufficient
for inclusion. This
evidence to draw
was a 4 week pilot
any conclusions
about the efficacy or study of valerian,
diazepam and
safety of valerian
placebo. search was
compared with
Randomised
placebo or
controlled trials
diazepam for
(RCTs) and
anxiety disorders.
quasirandomised
RCTs involving
trials of valerian
larger samples and
extract of any dose,
comparing valerian regime, or method
with placebo or
of administration,
other interventions
for people with any
primary diagnosis of
used to treat of
general anxiety
anxiety disorders,
disorder, anxiety
such as
antidepressants, are neurosis, chronic
anxiety status, or
needed.
any other disorder in
which anxiety is the
primary symptom
(panic disorder,
obsessive
compulsive
disorder, social
phobia,
agoraphobia, other
types of phobia,
postraumatic stress
disorder).
Effectiveness was
measured using
clinical outcome
measures and other
scales for anxiety
symptoms.
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Cameron M, Gagnier JJ, Chrubasik S.
Herbal therapy for treating rheumatoid
arthritis. Cochrane Database of
Systematic Reviews 2011, Issue 2. Art.
No.: CD002948.
DOI:
10.1002/14651858.CD00294
8.pub2 - See more at:
http://summaries.cochrane.or
g/CD002948/MUSKEL_herb
al-therapy-forrheumatoidarthritis#sthash.dFv5Qoew.dp
uf

Herbal
Several
herbal Twelve new
are studies were
interventions are interventions
inadequately
defined as any
added to the
justified
by
single
plant preparation
update, a total
(whole, powder, studies or
of 22 studies
non-comparable
extract,
were included.
studies
in
the
standardised
treatment of
mixture) used
rheumatoid arthritis.
for medicinal
There is moderate
purposes. . RA,
evidence that oils
your immune
containing GLA
system, which
(evening primrose,
normally fights
borage, or
infection, attacks blackcurrant seed oil)
the lining of
afford some benefit in
your joints. This relieving symptoms
makes your
for RA, while
evidence for
joints swollen,
stiff and painful. Phytodolor® N is
The small joints less
convincing.Tripterygi
of your hands
um wilfordii products
and feet are
may reduce some RA
usually affected
first. There is no symptoms, however,
oral use may be
cure for
associated with
rheumatoid
several side effects.
arthritis at
Many trials of herbal
present, so
therapies are
treatments are
hampered by research
used to relieve
design flaws and
pain and
inadequate reporting.
stiffness and
Further investigation
improve your
of each herbal
therapy is warranted,
ability to move.
particularly via well
designed, fully
powered,
confirmatory clinical
trials that use
American College of
Rheumatology
improvement criteria
to measure outcomes
and report results
according to
CONSORT
guidelines.
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Cramp F, Hewlett S, Almeida
C, Kirwan JR, Choy EHS,
Chalder T, Pollock J, Christensen R. Nonpharmacological
interventions for fatigue in rheumatoid arthritis.
Cochrane Database of
Systematic Reviews 2013, Issue 8. Art. No.: CD008322.
DOI:
10.1002/14651858.CD00832
2.pub2 - See more at:
http://summaries.cochrane.or
g/CD008322/MUSKEL_nonpharmacologicalinterventionsfor-themanagement-of-patientreported-fatigueinrheumatoidarthritis#sthash.iSsGqRK9.dp uf

Physical
activity and
psychosocial
therapy
for Fatigue
is a common
and
potentially
distressing
symptom for
people with
rheumatoid
arthritis with
no accepted
evidence
based
management
guidelines.

This review provides
some evidence that
physical activity and
psychosocial
interventions provide
benefit in relation to
self-reported fatigue
in adults with
rheumatoid arthritis.
There is currently
insufficient evidence
of the effectiveness
of
other
nonpharmacological
interventions.
Physical activity
has a small benefit
for managing
fatigue in people
with rheumatoid
arthritis.
specifically: Psychosocial
therapy has a small
benefit for
managing fatigue in
people with
rheumatoid
arthritis.

24 were
identified for
inclusion in the
review with a
total of 2882
people.
Specifically,
physical
activity
interventions (n
= 6 studies; 388
participants),
psychosocial
interventions (n
= 13 studies;
1579
participants),
herbal medicine
(n = 1 study; 58
participants),
omega3 fatty acid
supplementation
(n =
1 study; 81
participants),
Mediterranean
diet (n
= 1 study; 51
participants),
reflexology (n
- No other
= 1 study; 11
interventions showed
participants)
a difference in
and the
managing fatigue in
provision of
people with
Health Tracker
rheumatoid arthritis.
information (n
This may have
= 1 study; 714
happened by chance.
participants).
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Pittler MH, Ernst E. Feverfew for preventing migraine.
Cochrane Database of Systematic Reviews 2004, Issue 1.
Art. No.: CD002286.
DOI:
10.1002/14651858.CD00228
6.pub2 - See more at:
http://summaries.cochrane.or
g/CD002286/SYMPT_feverfe w-forpreventingmigraine#sthash.UolN9Eue.d puf

Pittler MH, Ernst E. Kava extract
kava for anxiety
versus placebo for treating anxiety.
Cochrane Database of Systematic
Reviews 2003, Issue 1. Art.
No.: CD003383. DOI:
10.1002/14651858.CD00338
3 - See more at:
http://summaries.cochrane.or
g/CD003383/DEPRESSN_ka vaextract-fortreatinganxiety#sthash.vk8QIdpU.dp
uf

Feverfew

Results from these
Five trials (343
trials were mixed
patients) met
and did not
the inclusion
convincingly
criteria.
establish that
Randomised,
feverfew is
placeboefficacious for
controlled,
preventing migraine. double-blind
There is insufficient trials assessing
evidence from
the efficacy of
randomised,
feverfew for
doubleblind trials to preventing
suggest an effect of
migraine were
feverfew over and
included.
above placebo for
preventing migraine.

The meta-analysis
of seven trials
suggests a
significant treatment
effect for the total
score on the
Hamilton Anxiety
Scale in favour of
kava extract. Few
adverse events were
reported in the
reviewed trials,
which were all mild,
transient and
infrequent. These
data imply that,
compared with
placebo, kava
extract might be an
effective
symptomatic
treatment for
anxiety although, at
present, the size of
the effect seems to
be small. -

Twenty-two
potentially relevant
double-blind,
placebo-controlled
RCTs were
identified. Twelve
trials met the
inclusion criteria
((n=700)).
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Richards BL, Whittle SL, Buchbinder R.
Neuromodulators for pain management
in rheumatoid arthritis. Cochrane
Database of Systematic Reviews 2012,
Issue 1. Art. No.: CD008921.
DOI:
10.1002/14651858.CD00892
1.pub2 - See more at:
http://summaries.cochrane.or
g/CD008921/MUSKEL_neur
omodulators-for-painmanagement-inrheumatoidarthritis#sthash.NqAtL4XY.d
puf

neuromodulators
(broadly defined
as substances
which alter the
way nerves
communicate with
each other and,
consequently, the
overall activity
level of the brain.
By acting on these
nerve signals it is
thought that these
drugs can reduce
the amount of
pain felt by an
individual.
Neuromodulators
sometimes used in
pain management
and assessed here
include
anticonvulsants
(gabapentin,
pregabalin,
phenytoin, sodium
valproate,
lamotrigine,
carbamazepine,
levetiracetam,
oxcarbazepine,
tiagabine and
topiramate),
ketamine,
bupropion,
methylphenidate,
nefopam,
capsaicin and the
cannabinoids.) for
rhuematoid
arthritis

There is
We included
currently weak randomised
evidence that
controlled trials
oral nefopam,
which compared any
topical
neuromodulator to
capsaicin and
another therapy
oromucosal
(active or placebo,
cannabis are all including
superior to
nonpharmacological
placebo in
therapies) in adult
reducing pain
patients with RA
in patients with that had at least one
RA. However, clinically relevant
each agent is
outcome
associated with measure.Four trials
a significant
with high risk of bias
side effect
were included in this
profile. The
review. Two trials
confidence in
evaluated oral
our estimates is nefopam (52
not strong
participants) and one
given the
trial each evaluated
difficulties
topical capsaicin (31
with blinding,
participants) and
the small
oromucosal cannabis
numbers of
(58 participants).
participants
evaluated and
the lack of
adverse event
data. In some
patients,
however, even
a small degree
of pain relief
may be
considered
worthwhile.
Until further
research is
available,
given the
relatively mild
nature of the
adverse events,
capsaicin could
be considered
as an addon
therapy for
patients with
persistent local
171

pain and
inadequate
response or
intolerance to
other
treatments.
Oral nefopam
and
oromucosal
cannabis have
more
significant side
effect profiles
however and
the potential
harms seem to
outweigh any
modest benefit
achieved.
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Linde K, Berner MM, Kriston L. St
St JOHNS Wort
John's wort for major depression.
for depression
Cochrane
Database of Systematic
Reviews 2008, Issue 4. Art.
No.: CD000448. DOI:
10.1002/14651858.CD00044
8.pub3 - See more at:
http://summaries.cochrane.or
g/CD000448/DEPRESSN_st.
-johns-wort-fortreatingdepression.#sthash.cpTrZv0Y
.dpuf

The available
29 studies in 5489
patients with
evidence suggests
depression that
that the hypericum
compared treatment
extracts tested in
with extracts of St.
the included trials
John's wort for 4 to
a) are superior to
12 weeks with
placebo in patients
placebo treatment or
with major
standard
depression; b) are
antidepressants. The
similarly effective
studies came from a
as standard
variety of countries,
antidepressants; c)
tested
several
and have fewer side
different St. John's
effects than
wort extracts, and
standard
mostly
included
antidepressants. The
patients suffering
association of
from
mild
to
country of origin
moderately severe
and precision with
symptoms. Trials
effects sizes
were included if
complicates the
they:
(1)
were
interpretation.
randomised
and
double-blind;
(2)
included
patients
with
major
depression;
(3)
compared extracts
of St. John's wort
with placebo or
standard
antidepressants; (4)
included
clinical
outcomes assessing
depressive
symptoms.
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Price JR, Mitchell E, Tidy E, Hunot
V. Cognitive behaviour therapy for
chronic fatigue syndrome in adults.
Cochrane Database of
Systematic Reviews 2008, Issue 3.
Art. No.: CD001027.
DOI:
10.1002/14651858.CD00102
7.pub2 - See more at:
http://summaries.cochrane.or
g/CD001027/DEPRESSN_co
gnitive-behaviour-therapyforchronicfatiguesyndrome#sthash.eLgdVlPR.
dpuf

CBT for chronic
fatigue

CBT is effective in
reducing the
symptoms of fatigue
at post-treatment
compared with
usual care, and may
be more effective in
reducing
fatigue
symptoms compared
with other
psychological
therapies. The
evidence base at
follow-up is limited
to a small group of
studies with
inconsistent
findings. There is a
lack of evidence on
the
comparative
effectiveness of
CBT alone or in
combination with
other treatments,
and further studies
are required to
inform the
development of
effective treatment
programmes for
people with CFS.

Fifteen studies
(1043 CFS
participants) were
included in the
review. Randomised
controlled trials
involving adults
with a primary
diagnosis of CFS,
assigned to a CBT
condition compared
with usual care or
another
intervention, alone
or in combination.
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Appendix B.

Herbs used for Pain and Related Conditions in Appalachia:
Anecdotal Sources/Herbal Texts
Sources: Manual Search conducted March-April 2015 through West Virginia University Library
Service (including databases PubMed, AltmedWatch, Library of Congress), WV Public Library search,
Google Search (with additional cross-referencing in all materials yielding items of interest to
Appalachian herbs, botanicals, folk remedies, folk traditions, flora, non-timber plant products) with no
publishing time range; Physical sources manually searched for 'Rheumatism;' 'Analgesia;' 'Pain;'
'Arthritis;' 'Inflammation;' 'Gout;' and, 'Headache'
****Potential or known Narcotic - exercise caution
***potential toxicity
**known toxicity but not mentioned in this Red lettering indicates use for
literature
Inflammation
*known toxicity

Herb identified in
Appalachian Text

Alfalfa (Medicago
sativa)

Parts
Used/Prepation
Method(s)

Known for:

YELLOW indicates a replicate
herb

Source

Crellin, J. K., et al. (1990).
Herbal medicine past and
present. Durham, Duke
University Press.
tops

Rheumatism

Angelico (a.
atropurpurea)

Tonic, roots and
leaves

Chronic
Rheumatism

Apple

Tea, syrup, and
Tonic of Bark or
fresh leaves

Rheumatism;
arthritis

Crellin, J. K., et al. (1997).
Trying to give ease :
Tommie Bass and the
story of herbal medicine.
& Crellin, J. K., et al.
(1990). Herbal medicine
past
and
present.
Durham,
Duke
University Press.
Durham, Duke University
Press.

Crellin, J. K., et al. (1997). T
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Balm of Gilead

(not
given)
(contains
crystalline
populus, closely
resembling
salicin)

Rheumatism

Amjad, H. (2006). Folk
Medicine
of
Appalachia: A Vanishing
Tradition. , lulu.com
(selfpublished).
Shelton, F. (1965).
Pioneer comforts and
kitchen remedies;:
Oldtimey highland
secrets from the Blue
Ridge and Great Smoky
Mountains, Hutcraft.

Balm of Gilead sap

Buds boiled in oil Pain; salves

Balm of Gilead/Balsam
poplar/balm
buds/Carolina
poplar/cottonwood/hac Tincture from
kmatack/poplar
Winter buds in
balsam/tacamahac
February and
poplar/tackamahac
March, before
(Salicaea)
opening

Balm of Gilead/Bam
a Gilly (Populus
balsamifera, P.
candicans)

Salve, from
buds;infusion

Krochmal, A., et al.
(1971). A guide to
medicinal plants of
Appalachia. Washington,,
U.S. Forest Service; for
sale by the Supt. of Docs.
Rheumatism;Gout

Rheumatism;
Strengthen nerves

Bolyard, J. L. (1981).
Medicinal plants and
home remedies of
Appalachia. Springfield,
Ill., Thomas.
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Balmony/White
turtlehead/Bitter
herb/Fishmouth/Saltrheum
weed/Shellflower/smo
oth
snakehead/snakehead/
snakemouth/true
Herb, gathered
snakehead/turle
when flowering;
bloom/turle head
leaves, Gathered Reducing
(Scrophulariaceae)
in Spring
inflammation

Krochmal, A., et al.
(1971). A guide to
medicinal plants of
Appalachia.
Washington,, U.S.
Forest Service; for sale
by the Supt. of Docs.

Crellin, J. K., et al.
(1997). Trying to give
Rheumatism, sleep ease :

Bay (magnolia)

Tonic

Bearsfoot

Salve, Root and Rheumatism;
leaves
arthritis

Crellin, J. K., et al.
(1990). H

Beech

Tonic

Rheumatism

Crellin, J. K., et al. (1997).
T

Bergamot/White horsem

infusion,
leav

from Rheumatism

Bolyard, J. L. (1981).
Medi

Rheumatism;
headache

Crellin, J. K., et al.
(1990). H

Bethroot

Tea, Rhizome

Birch (B. lenta)

Bark,
juice

Black Birch

Sap (in salve)

Rheu; massage

Shelton,
Pionee

Black CohoshBlack
Cohosh/Black

Tonic, roots

Rheumatism

Crellin, J. K., et al. (1997).
T

snakeroot/Rattleweed/
Squawweed/Cocash
(Indian name)/Bugbane

Tincture,
Poultice or tea,
of boiled root

Rheumatism;
soothe pain

Bolyard, J. L. (1981).
Medi

Black Haw/Crampbark

Bark

Rheumatism

Crellin, J. K., et al.
(1990). H

Black Snakeroot

Root

Rheumatism

Crellin, J. K., et al.
(1990). H

leaves,(Rheumatism; Gout Crellin, J. K., et al.
(1990). H

Blue cohosh/Blueberry
cohosh/blueberry
root/papoose root/ Sqaw
root/ Yellow ginseng Rhizomes and
(Caulophyllum
roots, gathered Chronic
thalictroides L.)
in fall
rheumatism

F.

(1965).

Krochmal, A., et al.
(1971).
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Blue vervain/blue
verbena/ironweed/
simpler's joy/verbain/wild
hyssop (Verbenaceae)
Herb and root

Antirheumatic

Krochmal, A., et al.
(1971).
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Rheumatism;
headache

Crellin, J. K., et al. (1997). T

Boneset/Thoroughwort
/Feverwort/Indian
Sage/Agueweed
(Eupatorium
Decoction of roots
perfoliatum)
and leaves
Rheumatism

Bolyard, J. L. (1981). Medi

Bowman's
Root/ipecac/Indian
physic

Tonic, bark

Rheumatism

Crellin, J. K., et al. (1997). T

Buckeye

Fruit

Rheumatism

Wilson, C. R. and W. R.
Ferr

Buckeye

Salve, Seeds
(nonpoisonous
half) and bark

Boneset

Tea, Leaves and
roots

Rheumatism

Crellin, J. K., et al. (1990).
H

Buckeye*
(Aesculus
glabra, A. octandra )
Fruit

Rheumatism; used
in place of opium
(10 grains
powdered buckeye
fruit rind = 3 grains
opium)
Bolyard, J. L. (1981). Medi

Burdock

Roots, seeds

Rheumatism

Crellin, J. K., et al. (1990).
H

Burdock

Tea, roots & seeds Rheumatism

Shelton, F. (1965). Pionee

Burdock/Great Burdock
(Arctium lappa )
seed and roots

Rheumatism;Gout;
Inflammations
Bolyard, J. L. (1981). Medi

Butterfly Weed

Tea, Root

Rheumatism;
Anodyne

Button snakeroot

Root

Rheumatism; Gout Crellin, J. K., et al. (1997). T

Catnip (Nepeta cataria ) Tea
Cedar

Sleep Aid, Nervous
Depression,
Amjad, H. (2006). Folk
Debility
Med

Chronic
Oil, tops, "apples" Rheumatism

Rheumatism;
Inflammation;
Celery; Smallage (wild) fruits, roots, tops migraine

Chamomile

flowers

Crellin, J. K., et al. (1990).
H

Aches, pains,
bruises

Crellin, J. K., et al. (1990).
H
Crellin, J. K., et al. (1990).
H
Crellin, J. K., et al. (1990).
H
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Chaparral/Creosote
bush***

Tea and external,
leaves

Rheumatism

Crellin, J. K., et al. (1990). H

Chestnut/American
Chestnut (Fagaceae)

tea from leaves
and inner bark

Rheumatism;
arthritis

Bolyard, J. L. (1981). Medi

Chicory

Tea, of leaves

Rheu; stomach

Shelton, F. (1965). Pionee

Club
Moss/Moss/Running
Cedar

Tops

Rheumatism

Crellin, J. K., et al. (1990). H

Cohoshes (black, blue,
white)

Rheumatism,
soothe pain, allay
Rhizome, roots
irritability, possible
(beat up the root) anti-inflammatory Crellin, J. K., et al. (1990). H

Colic Root (Aletris)

Roots gathered in
fall
Rheumatism

Collards

Roots, applied
externally

Arthrtitic Joints for
pain

Corn Silk

Styles, stigmas

Rheumatism; Gout

Cottonwood Tree

in liniment with
turpentine, Bark,
leaves, green fruit Rheumatism

Cucumber tree
(magnolia)

Bark

Cucumber
tree/Wahoo/Cucumber
magnolia
(Magnoliaceae)
Bark
Dandelion (Taraxacum
officinale)

decoction,
and leaves

Devil's
shoestring/Goat's Rue

Tea, Root

Collins, K. C. and L. Hunter
Brunvand, J. H. (1996).
American folklore : an
encyclopedia. New York,
Garland Pub.
Crellin, J. K., et al. (1990). H

Crellin, J. K., et al. (1990). H

Rheumatism
(claimed "the best") Crellin, J. K., et al. (1997). T

Rheumatism
roots Rheumatism;
bursitis;arthritis
Rheumatism

Bolyard, J. L. (1981). Medi

Bolyard, J. L. (1981). Medi
Crellin, J. K., et al. (1997). T
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Extracts, of roots
Echinacea/Purple
gathered in the
Coneflower (Echinacea ) fall

Chronic
inflammation

Elderberry
(Sambucus Flowers and juice
canadensis )
of berries
Rheumatism

Collins, K. C. and L. Hunter

Amjad, H. (2006). Folk Med

Elderberry/Common
elder ( Sambucus
canadensis )

Berries

Rheumatismic gout Bolyard, J. L. (1981). Medi
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Garlic

Tea, fresh roots

Rheumatism

Shelton, F. (1965). Pionee

Gentian

Root

Rheumatism

Crellin, J. K., et al. (1997). T

Ginger (Zingiber
officinale)

(not given)

Rheumatic pain

Amjad, H. (2006). Folk
Med

Ginseng

Roots

Rheumatism?

Crellin, J. K., et al. (1990).
H

Roots, chewed

Arthritis/
Rheumatism

Goodwin, J. G. (1985).
Goin

Ginseng

Ginseng
quinquefolia )

(Panax Tea,
of
roots Arthritis;
calming Amjad, H. (2006). Folk
gathered in fall
effect on nerves
Med

Ginseng/Seng/Sang/Tar
tar
root/Fivefinger/Redber
ry/Garantoqueen (Panax
quinquefolium )
Tea, from root

Rheumatism;
arthritis;bursitis

Bolyard, J. L. (1981). Medi

Goldenseal/Yellowroot
(Hydrastis canadensis )

Rheumatism;
arthritis;bursitis

Bolyard, J. L. (1981). Medi

Tea, from root

Gotu Kola

Leaves, whole herb Rheumatism

Crellin, J. K., et al. (1990).
H

Ground Ivy

Tea, from Leaves
(green or dry)

Headache

Crellin, J. K., et al. (1990).
H

Holly/American
Holly/Huver Bush
(Aquifoliaceae)

Decoction of bark

In place of opium

Bolyard, J. L. (1981). Medi

Inflammatory
conditions

Amjad, H. (2006). Folk
Med

Rheumatism

Amjad, H. (2006). Folk
Med

Rheumatism

Krochmal,
(1971).

Hops (Humulus lupulus ) Poultice
Horehound
(Marrubium vulgare)

(not given)

Horse
Chestnut/Buckeye
Tree/Common
Bark and fruit,
horsechestnut (Aesculus gathered in fall
hippocastanum L.)
(carried around)

A.,

et

al.
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Poultice, Roots and
Leaves (used
Horseradish/Scurvy
Grass

as
counterirritant)bark, Rheumatism
and Crellin, J. K., et al. (1990).
leaves, and
paralytic complaints H

Hydrangea

root

Rheumatism

Crellin, J. K., et al. (1997). T

Indian hemp/Dogbane

Root

Rheumatism

Crellin, J. K., et al. (1997). T

Rheumatism;
arthritis;bursitis;
migraine

Bolyard, J. L. (1981). Medi

Indian hemp/Northandsouth root
Decoction of Root,
(Apocynum cannabinum) gathered in fall
Poultice, of dried
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Jimsonweed*/apple of
peru/apple peru/devil's
trumpet/Jamestown
weed/jimsonweed
datura/mad apple/stink
apple/stinkweed/stink
wort/stramonium/thor n
apple (Solanaceae)

Leaves and tops
when flowering,
seeds when
mature

Anodyne
sedative/Antispasm Krochmal,
odic
(1971).

Joe-Pye-Weed
(Eupatorium sp. )

Root

Rheumatism

Lady-slipper/Moccasin
flower/Nerve
root
(Cypripedium spp.)

Sedative;
Antispasmodic;
Root, dried leaves allays pain

Lemon

Rheumatism
Antifruit, peel, volatile
oil
inflammatory;

Licorice

Rhizome, roots

Rheumatism

Crellin, J. K., et al. (1990).
H
Crellin, J. K., et al. (1990).
H

Maidenhair Fern
(Adiantum pedatum )

Roots

Rheumatism

Collins, K. C. and L. Hunter

A.,

et

al.

Crellin, J. K., et al. (1997). T

Bolyard, J. L. (1981). Medi

Mayapple****/ Mandrake
Rheumatism;
(Berberidaceae)
Decotion, of Root bursitis;arthritis

Bolyard, J. L. (1981). Medi

Milkweed/Common
milkweed/Common
silkweed/cottonweed/s
ilkweed/swallowwort/wild Roots, gathered in
cotton (Asclepiadaceae) fall
Rheumatism

Krochmal,
(1971).

Milkweed/cottonweed/
silkweed/wild cotton
(Asclepiadaceae)

Bolyard, J. L. (1981). Medi

Inflammatory
Rheumatism

A.,

et

al.

184

Moonseed/common
moonseed/canada
moonseed/maple
vine/Texas
sarsaparilla/vine
maple/yellow
Rhizomes and
parilla/yellow sarsaparilla roots, gathered in
Krochmal,
(Menispermaceae)
fall
Arthritic conditions (1971).
Mountain
Tea/Checkerberry/Teab
erry (Gautheria

A.,

et

al.

Muscle
ache/Rheumatism
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Pennyroyal/pennyrile/
Pudding grass/Squaw
mint/Stinking
balm/Tickweed
fresh or dried
(Hedeoma pulegioides ) leaves

Peppermint
piperita )

Headache;
Rheumatism

headache; slight
(Mentha fresh leaves
anesthetic; local
applied externally pain

Bolyard, J. L. (1981). Medi

Bolyard, J. L. (1981). Medi

Pine

Sap and bark oil

Massage; stiffness

Shelton, F. (1965). Pionee

Pine

tops, bark, sap,
tar, turpentine,
rosin

Rheumatism

Crellin, J. K., et al. (1990). H

Pipsissewa/Common
pipsissewa/Bitter
wintergreen/fragrant
wintergreen/ground
holly/king's cure/loveinwinter/noble pine/Pine
tulip/prince's
pine/princess
pine/pyrole/rheumatis
m weed/
waxflower/wintergreen
(Pyrolaceae)

Leaves and herbs,
gathered in late
summer or early
fall
Anti-rheumatic

Krochmal, A., et al. (1971).

Pipsissewa/Spidercheck
ered
wintergreen/Striped
wintergreen
(not given)

Arthritis/Rheumatis
m/Bursitis
Bennett, Allen and Green,

Pleurisy Root (Asclepias
tuberosa )
Tea, of roots

Rheumatism

Pleurisy Root/Butterfly
Weed
(Asclepias Tea,
of
roots
tuberosa )
gathered in fall
Aching muscles
Poke
Poke
americana )*

Internal and
external, Root
(Phytolacca and berries

Poke*/Pokeweed/Poke
root/Poke salat/Poke

Rheumatism

Ash-roasted root
applied externally Inflamed joints

Amjad, H. (2006). Folk Med

Collins, K. C. and L. Hunter

Crellin, J. K., et al. (1997). T

Collins, K. C. and L. Hunter
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beryy/Jalap/Cancerroot
/Scoke/Garget
Tea or tincture of
berries; decoction Rheumatism;arthrit
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Pokeweed*

Berries (small
quantity)

Pokeweed*/American
nightshade/cancer
jalap/cancerroot/chong
ras/coakum/cocum/cok
an/common
pokeberry/crowberry/g
arget/
inkberry/jalap/pigeonb
erry/ pocan/pocan
bush/poke/pokeberry/
pokeroot/red-ink
plant/red
wood/scoke/skoke/Virg
inia poke

Root, gathered
in
fall;
ripe
berries
made
into wine
Rheumatism

Krochmal,
(1971).

Poplars (including
Yellow)

Tonic, from bark,
root bark, and
salves from buds Rheumatism

Crellin, J. K., et al. (1990).
H

Prickly Ash Prickly Ash

Chewed tree bark
(not root) and tea
from berries
Rheumatism

Crellin, J. K., et al. (1997). T

(Xanthoxylum
americanum)

Syrup of berries
and bark
Rheumatism

Amjad, H. (2006). Folk
Med

Prickly Pear

Crellin, J. K., et al. (1990).
fruit, fleshy leaves Acute rheumatism H

Pussy Willow/Possum
bush/Swamp willow
(Salix spp.)

tea, from limbs or Headache; Pain;
leaves
Gout

Bolyard, J. L. (1981). Medi

Quaking Aspen

Tea, of bark

Muscle pain

Shelton, F. (1965). Pionee

Queen Anne's Lace

Tops and roots

Rheumatism

Crellin, J. K., et al. (1997). T

Rheumatism

Amjad, H. (2006). Folk
Med

A.,

et

al.

Amjad, H. (2006). Folk
minute quantities Rheumatism; gout Med
Ratsbane/Quaker's
buttons (Nux vomica )* Leaves,
roots,
Ratsvane/Pipsissewa
whole plant
Rheumatism

Crellin, J. K., et al. (1997). T
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Redroot****/Blodroot/
puccoon
(Papaveraceae)
tonic or bitters

Rheumatism;Gout; Krochmal,
Arthritis
(1971).

A.,

et

al.

A.,

et

al.

Redroot*/Blodroot/coo
nroot/pauson/puccoon/
puccoon root/red
Indian paint/red
puccoon/snakebite/sw
eet
slumber/tetterwort/tur
meric/white puccoon
(Papaveraceae)

Rootstock when
flowering, in late
summer or early pain
fall
reliever;sedative

Krochmal,
(1971).

Sampson snakeroot

Tea, Tonic and
root

Crellin, J. K., et al. (1997).
T

Rheumatism

Sampson's
snakeroot/marsh
gentian/straw-colored
gentian/striped gentian Tonic of Roots,
Krochmal, A., et al.
(Gentianaceae)
gathered in fall
Rheumatism/Gout (1971).
Crellin, J. K., et al. (1990).
Sarsparilla
Rhizome, roots
Rheumatism
H
Sasparilla/Sasparillo/Sa
safarilla/Safarilla/Sasfril
ler/Sarsparilla/Moonse
Tea or tonic, from
ed (Menispermum
root
Rheumatism/Gout Bolyard, J. L. (1981). Medi
canadense)

Sassafras

Root bark, wood,
pith, leaves
Rheumatism

Sassafras

Tea
(roots
and bark), oil
of sassafras

Crellin, J. K., et al. (1997).
T

Rheu; general
tonic/massage; pain Shelton, F. (1965). Pionee
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Sassafras/Sassafac/Sass
afrax (Sassafras
Decoction from
albidum)
root

Seneca
snakeroot/Senneker
snakeroot/Sinnaker
snakeroot/Milkwort/Ra
ttlesnake Root (Polygala
senega )
Root

Rheumatism

Bolyard, J. L. (1981). Medi

Senega

Root

Rheumatism; gout Bolyard, J. L. (1981). Medi
Crellin, J. K., et al. (1990).
Rheumatism
H

Sevenbark

Leaves, roots,
bark

Arthritis/Rheumatis Crellin, J. K., et al. (1990).
m
H

Shepherd's Purse
(Capsella bursapastoris) Poultice

Inflammation

Amjad, H. (2006). Folk
Med

Tonic,
Leaves, Rheumatism,
stem, whole plant nervous conditions Crellin, J. K., et al. (1997). T

Skullcap

Smartweed/Celery/Pars Salves and tea,
ley
from Whole plant Rheumatism

Crellin, J. K., et al. (1990).
H

Soapwort

Tea, of
roots/external

Rheumatism;
gout/Boils;skin
sores

Solomon's Seal

Boiled root

Inflammation

Shelton, F. (1965). Pionee
Amjad, H. (2006). Folk
Med

Rheumatism

Amjad, H. (2006). Folk
Med

Rheumatism

Amjad, H. (2006). Folk
Med

Spicewood/Spicebush/
Wild allspice (Linderia oil from fruit,
benzoin)
applied externally Rheumatism

Bolyard, J. L. (1981). Medi

Spanish Moss
(Tillandsia usneiodes )
Spicebush
benzoin )

(not given)

(Linderia
Berries
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Root

Spikenard (Aralia racemosa )
Spikenard/American
spikenard/American
sarsaparilla/Indian root/life-ofman/old man's root/petty
morel/pigeon weed/spignet
(Araliaceae)

Rheumatism/Rheu
m accompanied by Amjad, H. (2006).
back pain/Arthritis Folk Med

Tea from roots,
gathered in
Summer and
fall
Rheumatism

Decoction

Krochmal, A., et al.
(1971).

Rheumatoid
Bolyard, J. L. (1981).
arthritis;backaches Medi

Rheumatism

Amjad, H. (2006).
Folk Med

Squaw root/cohosh
bugbane/battle weed/black
cohosh/black
snakeroot/blueberry/bl ue
ginseng/bugbane/coho sh/heartleaved rattletop/heart-leaved
snakeroot/meadow rue
leontice/papoose root/rattle
root/rattlesnake
Rhizomes and
root/rattletop/rattleweed/richwe roots,
ed/yellow ginseng
gathered in Chronic
(Ranunculaceae)
the fall
rheumatism

Krochmal, A., et al.
(1971).

Spikenard/Spignet/Spik
enard/Goutwort/Petty
morrell/Indian root (Aralia
racemosa )

(not given)

Squaw Root/Black Cohosh
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Star Grass

sip (in alcohol),
roots

Star-root/Stargrass**** Root

Rheumatism

Shelton, F. (1965). Pionee

Rheumatism

Crellin, J. K., et al. (1990).
H

Swamp Root

(not given)

Rheumatism

Amjad, H. (2006). Folk
Med

Sweet Birch

Roots, bark
(distilled)

Massage

Shelton, F. (1965). Pionee

Sweet
Birch/Black
birch/cherry
birch/mountain
mahogony/River
birch/Spice birch
(Corylaceae)

Bark and twigs,
gathered May to
September
Antirheumatic

Krochmal,
(1971).

A.,

et

al.

Sweet Birch/Black
Birch/Cherry
Birch/Spice
Twigs, cones,
Birch/Mountain
bark, leaves, and Pain relief;
Mahogony (Betulaceae) juice
antirheumatic

Bolyard, J. L. (1981). Medi

Sweet Fern (Comptonia Tea, of leaves and
tops
Rheumatism
peregrina )

Collins, K. C. and L. Hunter

Tansy

Tea

Tobacco (Nicotania
tabacum)

Juice or ointment,
applied externally Rheumatic pains

Aches and Pains

Bolyard, J. L. (1981). Medi

Salve,
from
rhizome
and
roots (much attn
given for many
alkoloids present
and their role in
muscle-relaxant
and
antihypertensive
actions -JF
Veratrum/hellebore*** Morton (1977,
Crellin, J. K., et al. (1990).
*
pp.58-64)
Rheumatism; gout H
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Virginia Snakeroot

Tea, or in wine or
whiskey, Rhizome
and roots
Arthritis

Crellin, J. K., et al. (1990).
H

Watercress/nasturtium/
true watercress
(Brassicaceae)
Herb, at any time Rheumatism

Krochmal,
(1971).

Waxflower
(Ratsbane)**

Rheumatism

Shelton, F. (1965). Pionee

White ash/American
Ash/American white
Inner bark of
ash/biltmore
trunk and roots,
ash/biltmore white
ash/cane ash/smallseed stem, both in
white ash (Oleaceae)
Spring

Antiarthritic

Krochmal,
(1971).

White Ash/Ash
(Fraxinus americana? ) Bark, and leaves

Rheumatism; gout;
arthritis
Bolyard, J. L. (1981). Medi

White Pine (Pinus
strobus)

Tea, of leaves

Resin from inner
bark, sprigs
Rheumatism
Applied to sore
joints

A.,

A.,

et

et

al.

al.

Bolyard, J. L. (1981). Medi

White Walnut Bark

Boiled, crushed

Wild Black Cherry
(Prunus serotina )

Bark, Inner Bark, Rheumatism; gout;
Leaves, Twigs
arthritis
Bolyard, J. L. (1981). Medi

Wild Yam

Tuber

Rheumatism

Shelton, F. (1965). Pionee

Crellin, J. K., et al. (1997). T

Twigs, chewed on Body pain

Stephenson, S. L. (2013).
A

Bark

Rheumatism

Amjad, H. (2006). Folk
Med

Willow/Red Root

Bark

Rheumatism

Wilson, C. R. and W. R.
Ferr

Wintergreen

salves, of leaves
and oil
Rheumatism

Willow

Willow (Salix sp)

Witch Grass ("Quack") Tea, of roots

Rheumatism

Crellin, J. K., et al. (1990).
H
Shelton, F. (1965). Pionee
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Appendix C.
Literature Review - Prevalence of Herbal Use in General US population (2002-2012)
3,985 Records identified Dec 2012 through AgeLine, PsycArticles, PsycInfo, PubMed Medline, Scopus, AltHealthWatch using terms "CAM Survey," "CAM Use," "CAM Usage," "Botanical,"
"Herb,", "Biological Supplement," "Herbal Remedy," or "Herbal Remedies," and NOT "Intervention," or "Trial;" Option 'Health Professions' and Geographic Location 'United States'
selected when available (Publication range 2001-2012; samples >500) --> Total studies reviewed = 34 (including 11 retrieved
from cross-referencing)--> 32 studies of adults 18+
Sample
Population
Type of sampling/
(criteria,
Response
tool and
Author 1 (year)
Sample geograpy,
Definition of CAM
Rate if
socio)
Location/Reference
(N)
used in study
app
Major findings
Prevalence/ Comments/limitations
only 33% of herbal and dietary supplement
users reported disclosing use of herbal and
dietary supplements to their conventional
health care provider. Among herbal and
dietary supplement users with chronic
conditions, less than 51% disclosed use to
their conventional health care provider.
Hispanic (adjusted odds ratio and 95%
confidence interval=0.70 [0.52, 0.94]) and
Asian American (adjusted odds ratio and
95% confidence interval=0.54 [0.33, 0.89])
adults were much less likely than
2002 National Health
nonHispanic white Americans to disclose
Interview
herbal and dietary supplement use. Having
Survey/crosssectional
less than a high school education (adjusted
study - 28 CAM therapies
odds ratio and 95% confidence interval=0.61
broken down into 6
Mehta DH,
LIMITATIONS w NHIS: disclosure of herbs and
[0.45, 0.82]) and not having insurance
dichotomous groups: Alt
Gardiner PM,
Med Systems, Biologicallysupps not supp-specific - it is only a general
(adjusted odds ratio and 95% confidence
Phillips RS,
based therapies,
interval=0.77 [0.59, 1.00]) were associated disclosure question!language, many herbs
McCarthy EP
Herbal
Manipulative &
. Herbal and dietary supplement
with being less likely to disclose herbal and inquired about are marketed to NHW pop, no
supplement
BodyBased methods,
disclosure to health care
dietary supplement use. Those more likely questions about physician
users (in past Mindproviders by individuals with
to discluse herbal and dietary supp use to characteristics
yr) in a
Body Interventions,
chronic conditions. J Altern
PREVALENCE ONLY FOR BBT.On
national adult
Energy Therapies,
Complement Med.
conv health
5456 sample
average,
2008;14(10):1263–1269
SelfPrayer
74.00%
2002 NHIS/ national providers were those with 4>= clinic 67.6% used CAM in the past 12 months, AA CAM users were slightly older
than cross-sectional -

A

when prayer for health was included.
nonusers

multistaged, clustered

Users were more likely older (43.3 +/- 0.4 (mean age [standard error] 43.3 [0.4]
versus 39.5 +/- 0.5 years; p < 0.0001);
versus 39.5 [0.5]

sample design was
used, and selfreported information female
computer-assisted
personal interview
(CAPI) techniques. 17

(60.9% versus 44.0%; p < 0.0001), years; p 0.0001). In addition, they were was obtained using
college educated (17.4% versus 9.8%; p <
more likely to be

0.0001); and insured (91.0% versus 88.1%; female (60.9% versus 44.0%; p 0.0001),
p < 0.0001) compared to nonusers. Prayer have a college CAM modalities into
was the most

common CAM used by education (17.4% versus 9.8%; p 0.0001),
C.M. Brown, J.C. Barner, K.M.

four broad categories:

Richards, T.M. Bohman

(1) Alternative
Medical Systems

Patterns of complementary
and alternative medicine use

(acupuncture,
Ayurveda, homeopathic
African-

coverage (91.0% versus 88.1%; p 0.0001).
(13.6%). A majority utilized CAM to treat Although

illness. The use of CAM was significantly a small difference, CAM users were more in African-Americans

treatment,

naturopathy); (2) (p < 0.0001) higher across all the disease likely to Americans in

states common in

AAs compared to

Biologically-Based

be married (p 0.0197) and have incomes

J Altern Complement Med, 13

non-

(2007), pp. 751–758

institutionalize (chelation therapy, folk
herbal

4256 sample

more than 60% of respondents, followed and have insurance
by herbals (14.2%) and relaxation

Therapies

products, special

nonuse. 19.6% of the sample had ever

$20,000 (p

used CAM, and 14.2% had used CAM in 0.0020). The proportion of participants d,national
74.30% the 12 months.

Of those who had used

who were not currently

medicine,

CAM - herbals - in the last year, 48.9%

K.T. Xu, T.W. Farrell
Determinants of utilization:
the
complementary
and
substitution
between
unconventional and mainstream
medicine among racial and ethnic
groups

Health Serv Res, 42 (2007), pp. 811–
826

Sawni A,
Thomas R
.
Pediatricians'
attitudes,
experience
and
referral
patterns regarding
complementary/alternative
medicine: a national survey. BMC
Complement Altern Med.
2007;7:18

46,673

noninstitutionalize
d, civilian adults
18+
from
a
national sample
.Hispanics
and
blacks
were
oversampled.

648

The Medical
Expenditure Panel Survey in
1996 and 1998 - 12 CAM
modalities. sampling frame
for the household survey
component was drawn from
respondents in the National
Health Interview Survey.
chiropractics,
massage
therapy, herbal remedies,
spiritual healings or
prayers,
nutritional
advice,
acupuncture,
meditation/imagery/
relaxation, homeopathy,
traditional
medicine,
biofeedback
training,
hypnosis, and others.
not given

fellows of the
American
Academy of
Pediatrics in
July 2004.

An anonymous, selfmade,
self-report,
27item
questionnaire - 17 CAM
therapies;
acupuncture/acupress
ure,
aromatherapy,
ayurvedic
medicine,
biofeedback, chiropractic,
energy healing/polarity,
herbs (North American,
Chinese), high dose antioxidant
vitamins,
minerals, homeopathy,
guided imagery, lifestyle
diets
(Ornish,
marcrobiotics
etc)
massage therapy, prayer
healing,
reflexology,
relaxation
(yoga,
mediation etc) touch. For
each
therapy
the
respondents
indicated
therapies
practiced,
personal/family
use,
referral for treatment,
and rated the therapies
as
effective,
safe,
harmful or didn't know.

Multivariate analyses were conducted to
test whether each type of CAM and MSM
(mainstream med) were complements or
substitutes within a racial and ethnic
group, controlling for respondents’
sociodemographics and health. More
complementary relationships between
CAM and physician visits were found in
Nonhispanic Whites and Asians than in
other groups. All significant relationships
betweenCAMtypes
and physician visits amongHispanics and
other races (predominantlyNative
American
Indians) were substitution.

Herbal CAM was used by 34.35% nonhispanic
whites, 33.31% of Hipanics, 18.83% of Blacks,
34.68% of Asians, and by 18.67% of
respondents who stated they were a race of
'other' (90% of which were Native American
Indians). Herbal use was top choice of CAM
for conditions cancer (31%), emphysema
(36%), arthritis (38%), asthma (35%),
depression and anxiety disorders (38%).
Herbal medicine was found to be a
complement to MSM among Asians (marginal
effects= .984) and the substitutions of herbal
remedies for MSM within the Other group
was the strongest of all sig relationships
found in the study (marginal effects = -3.23).
for each racial/etnic group, there are one or
two rpedominant CAM types and the
preveenct types differ by race.
LIMITATION: ghome or over-the-counter
CAM, such as herbs, was not specified so
underestimates are likley! additionally

The median age ranged from 46–59 yrs;
52% female, 81% Caucasian, 71%
generalists, & 85% trained in the US. Over
96% of pediatricians' responding believed
their patients were using CAM.
Discussions of CAM use were initiated by
the family (70%) & only 37% of
pediatricians asked about CAM use as
part of routine medical history. Majority
(84%) said more CME courses should be
offered on CAM and 71% said they would
consider referring patients to CAM
practitioners. Medical conditions referred
for CAM included; chronic problems
(headaches, pain
management, asthma, backaches) (86%),
diseases with no known cure (55.5%) or
failure of conventional therapies (56%),
behavioral problems (49%), & psychiatric
disorders (47%). American born, US
medical school graduates, general
pediatricians, & pediatricians who
ask/talk about CAM were most likely to
believe their patients used CAM (P <
0.01). 6/3/2013 Pediatricians who talk to
patients about CAM are generalists rather
18.50% than a subspecialists and in

herbs and megavitamins were used
personally by 17% of the pediatricians
although herbs was the therapy believed
to be the most harmful (61%). 5% practice
using herbs, 17% use on self or within their
families, 10% refer for herbs, 52% believe
herbs may be effective, and 15% believe
they are safe. LIMITATION: they didn't
include geographic location in their
analusis! also, this survey could have
assessed nurse practitioners and family
physicians but did not, and could have
gathered more info about CAM use for
specific therapies.
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Arcury TA, Grzywacz JG, Bell RA,
Neiberg RH, Lang W, Quandt SA.
(2007) Wake Forest Scool of
Medicine
NOT GIVEN!

Bardia A, Nisly NL,
Zimmerman B, Gryzlak B,
Wallace B (2007)

Barnes, PM, and Bloom, B
(2008)

609

75,764 +
31044

Herbs were an important component of the health
self-management of older adults.
11.9% OF ADULTS IN THIS SAMPLE USED HERBS.
Whereas about one quarter of Asian and
Hispanic elders used herbal remedies, about 10% of
Black and White elders used them. Older adults
differed by ethnicity in the herbs they used and their
reasons for using herbs (Most widely used:
echinacea (3%, garlic 2.9%, ginkgo 2.0%, ginger 1.3%
ginseng 1.3%and saw palmetto (1.2%)(most widely
used by ASIANS: ginger 9.1%, ginseng 6.6%, garlic
6.0%) (HISPANICS: chamomile 5.1%, echinacea3.6%)
(WHITES: echinacea 3.2%, garlic 2.9%, hinkgo 2.1%)
(BLACKS: garlic 3.2%, ginger 1.8%). Predictors of
herb use included gender, age, and health status.
Ethnicity and region of the country, indicators of
culture, and education, a personal resource, were
significant predictors of herb use when personal and
health characteristics were controlled.
A complex set of factors is associated with the
inclusion of herbs in the health selfmanagement of
older adults, with cultural and personal resources
being extremely important.Very few of the older
respondents (n = 29, 4.2%) who had used herbs had
used an
herbal provider. About 2 in 5 (41.6%) individuals
who had used an herbal remedy had told their
conventional health care provider about this use.
The most common reasons were to supplement
conventional treatment (31.7%), or because it
would be interesting (27.2%).

adults aged
65 and older
who were
Black,
Hispanic,
Asian, or

2002 NHIS/national White.
cross-sectional

all adults taking
echinacea,
garlic, ginseng,
kava, soy, st jons
wort
2002 NHIS

all
children
and adults in
the US

Although Asian older adults were the most
frequent users of herbal remedies (28.1%),
their list of specific herbs used was the
shortest. Ginger supplements (9.1%),
ginseng (6.6%), and garlic supplements
(6.0%) were Asian elders' most widely used
herbal remedies. However, 7.3% of Asian
respondents indicated that they did not
know the name of an herb that they had
used, and 6.4% indicated that they had
used another herb not on the list. Almost
one fourth (23.8%) of Hispanic older adults
reported having used an herbal remedy.
LIMITATION: i would have liked to have
seen a trend test for age, and where
sample sizes were low they should have
used Fisher's exact test. they also used
multiple imputation for missing values on
income but did not specify their
imputation methods. LIMITATION WITH
NHIS: specific herbs included in this
analysis may indicate a bias toward those
used by whites, limited sample size of
older adults from "all ethnic groups"

not given

Overall, 54.9% used herbs for their evidencebased
indications. When discluding echincacea but using
all other herbs combined, women (OR=1.81), those
with college edu (OR=1.55), graduate edu
(OR=2.91), were more likely to use the herbs based
on their scientific merit then their counterparts. In
contrast, blacks (OR=.51) and adults <40 (OR=.43);
40-59 yrs (OR=.48) were sig less likely to use herbs
in accordance to what their evidence-based usage
stipulates. For echinacea, no pattern existed. With
the exception of echinacea and ginseng, 2/3 of
respondents did not use commonly consumed
74.30% herbs in consonence with a scientific standard

87.1% in
2002 NHIS (adults only)
2007 and
and 2007 NHIS (adults and 74.3% in
children)
2002

In 2007, the CAM therapies most commonly used by
US adults in the past year were nonvitamin,
nomineral BBT (17.7%). These were also the most
common CAM therapies used by children in the
rpevious year (3.9%). Children whose parents used
CAM were about
2x as likely as all US children to have used BBT (9.2%
and 3.9%). In 2007, one of the most commonly
used BBT by adults was echinacea (19.8%), and by
children for health reasons was echinacea (37.2%)
and a combination herb pill (17.9%). For adults
younger than 65 yrs, in both 2002 and 2007, those
with provate health insurance were more likely than
those with public health insurance or uninsured
adults to use biologically-based therapies.

LIMITATION w NHIS: does not reveal the user's source
of info LIMITATION: didn’t include respondents who
used more than 1 herb. Evidence base for certain
herbs could have changed.
Did not evaluate
possibilities for any

182 type of interactions with

scripts or OTC.

The NHIS CAM supplement changed from 2002 to
2007. traditional healing traditions were added in,
while the # of diseases treated with CAM was
expanded by 8. The section on BBT was expanded by
10 and an additional component of 'use in the last 30
days' was added. Lastly, questions on CAM use on
children were added.

Bhargava, Vibha, hong GongSoon, Montalto, C.P. (2012)
University of Georgia, Iowa
State University, & Ohio State
University

23,393

nationally
representative
sample adults

2007 National
Health Interview
Survey/cross-sectional
study

Total Respondents more likely to live in the
South (36.7%), make $65k more per year (37.9%),
82.95% had health insurance, more likely to have
an education less than college (73.3%). This study
highlights the need for more data with information
not
on factors relevant to explaining CAM use such as
quantitative ly price of self-care and practitioner-based CAM and
stated in
health insurance coverage for practitionerbased
article
CAM for application of a health economic model.

nearly 17% of respondents had used herbs
within rpevious 12 months. those who
worked less than full time were more likely
to use herbs compared with those who
worked full time or more. individuals 65
and older were more likely to use herbs
than those aged 35–44. The predicted odds
of use of herbs among those who exercised
were almost 77% higher than those who
did not exercise. The predicted odds of use
of chiropractic and herbs were lower
among smokers than nonsmokers. The rate
of herbal use among the entire sample was
17%. Most prevalent herbal usage was in
the South (32.3%), an income of $65k+
(45.5%), had health insurance (86.1%),
worked full tim or more (47.2%), had 1-2
chronic health conditions (45.2%).
Although 87.3% of those who used herbs
self-described their health status as
'Excellent', 'Very good' or 'Good', 21.7%
said they were depressed.

11.7% of adults used herbals and
nonvitamin supps for helath promotion
purposes, which was in the top two
most common modalities used for
promotion.stat sig diffs between LIMITATION w NHIS: missing data for treatment
income so DID NOT INCLUDE IN THIS
and health promotion users,
inc health status,

Davis MA, West AN,
Weeks WB, Sirovich BE
(2011)

23393

national adult
sample 18+
2007 NHIS

not given

obese, active ANALYSIS. health status measures are selfsmoker, any func limitation.
reported and so susceptible to medical or therefore, there are two distinct types
psychological conds. They also stated of CAM users. Health promotion users that
health promotion users have rates of have sig better self-reported health conv
health services use comparable to status and have healthier behaviors those of nonusers but was a poisson reg overall when compared w tx users. poss given the
dataset? Not sure.
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Dawn M. Upchurch, Ph.D.,1 Claire
E. Dye, MSPH,1 Laura Chyu,
Ph.D.,2 Ellen B. Gold, Ph.D.,3 and
Gail A. Greendale, M.D.4 (2010)
UCLA, Northwestern, UC, UCLA

Ellison, C.G., Bradshaw M.,
Roberts, C.A. (2012) University
of Texas, Duke University, UNC
Chapel Hill

Elmer, G.W., Lafferty W.E., Tyree
P.T., Lind B.K.

5849

1995–1996
crosssectional
National Survey of
Midlife Development
in the United States.

74.30%

Compared to religious-only (OR=.56) or neither
spiritual or religious (OR=.61), spiritual AND religious
persons are relatively likely to employ BBT. Compared
to spiritual only persons, spiritual and religious
individuals are 43% more likely to use body–mind
therapies in general; however, when this category
does not contain prayer, meditation, or spiritual
healing, they are 44% less likely. Religious only
individuals are disinclined toward CAM use. After
controlling for established predictors including
not
educational attainment, personality, social support,
quantitative ly and access to conventional medicine, the present
stated in
study demonstrates that spirituality and religiousness
article
are associated, in unique ways, with CAM use.

3,032

25-74 yr olds,
national
sample from
1995

5052

5 years( time periods 1994,
1995, 1997, 1999
measured) of the 10year
prospective populationbased cohort study
(Cardiovascular
Health
white or African Study) - However, location
American adults is unclearaged 65 and older NW US?
not given

31044
Gardiner, P., Graham,R.,
Legedza A, Ahn, A, Eisenberg,
D.M. (2007)

Women Aged
40–59 Years

2002 NHIS / national
cross-sectional A
multistaged,
clustered
sample design was used,
and
selfreported
information was obtained
using computer-assisted
personal interview (CAPI)
techniques

Herbs***
TOTAL 25.4%
N= 5849
White N= 3933, 26.2%
Overall, 46% of midlife women used any Black n= 879, 19.5%
type of CAM in the past 12 months. The Hispanic N=896, 23.3%
top five specific CAM therapies used
Asian N=141,33.8% -------overall,
were herbs and natural products. Top
significant Ors among herbal use showed
health conditions used herbs for: other, Foreign-Born (1.4), hs grad (1.44), some
head/chest cold, menopause, stomach or college (2.26), college grad or more (2.7),
intestinal illness,
co-habitating status (1.9), live in the west
Arthritis/gout/lupus/fibromyalgia,
(1.64), insured (.8), 'Good' self-rated
Anxiety/depression, joint pain and
health status (1.27), former smoker
stiffness
(1.39),
lifetime alcohol abstainer (.54)

Garlis, ginkgo, and ginseng were all in the top
7 most commonly used products. African Americans
used significantly more garlic than their white
counterparts (p=.003), while there were no diffs
between race in the use of ginseng or ginkgo. Usage
of herbs increased in all 4 time periods, ranging from
6.3% to
15.1%. 5.8% of participants took combinations
considered to have a sig risk for an adverse reaction.
19% of sample reported using using an herb for their
own health and treatment. 10% of these respondents
had ever seen an herb practitioner, and 5% had seen
one in the past year. The most frequent conditions
for which herbs were used include both acute (head
or chest cold and stomach or intestinal illness) and
chronic conditions (musculoskeletal conditions such
as back pain, neck pain, arthritis, gout, fibromyalgia,
lupus, knee probs, joint pain, or stiffness).84% of
those who used herbs also used an OTC med, and
21% of OTC users took herbs in the prior 12 months.
72% of those who used herbs also used a prescription
med in the last year, while 21% of prescription-med
users took herbs in the prior 12 months. Factors

15.3% engaged in biological therapies. The Odds of
using biological therapies among those spiritiual &
religious & those only spiritual were less than 1
(around .5) among both adj and non-adj models.
POTENTIAL LIMITATON: they used so many
psychological variables as covariates in their model
but didn't specify whether or not they were valid
measures!

STRENGTH: all CAM products within 2 weeks assessed.
LIMITATION: no doses assessed and don’t know if CAM
products and rx meds were taken simultaneously

LIMITATIONS w NHIS: did not ask about all herbs with
substantial market share such as green tea, bilberry,
grapeseed, cranberry, aloe, goldenseal, or about herbs
commonly used by racial and ethnic minorities.
all adults 18 associated with herb use are living in the and over in the west (OR=1.41), being 45-64, female (OR=1.36),
LIMITATION: selfreport, term 'natural herbs' could have
US, national uninsured, having a higher edu, using meds
been misclassified by respondents, ethnocentric and
sample
2002 NHIS
74.30% (OR=1.46) and being a non-hispanic 'other'
medico-centric bias in the survey instrument which
may have contributed to an
underestimation of the prevalence of CAM and herb
use in particular especially among Nonwhite ethnic
groups.
race. Respondents who did not have medical
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Grzywacz JG, Lang W, Suerken
C, Quandt SA, Bell RA,
Arcury TA. Age, ethnicity, and
use of complementary and
alternative medicine in health
self-management. J
Health Soc
Behav 2007;48:84–98.

Results suggest that ailments such as bodily
pain, chronic conditions, and functional
impairment are associated with use of
complementary and alternative medicine
among midlife and younger adults, but
these associations are
generally
attenuated among older adults. Greater
impairment is associated with reduced odds
id BBT. An inc in the # of chronic conds is
assctd w an increase in the odds of using BBT
among midlife adults, whilse the effect of
increasing bodily pain on use of BBT are
strongest for young adults and weakest for
older adults, with midlife adults in the
middle.Hypothesized ethnic differences
received
weak support. These findings suggest that
different interpretations of ailments and
appropriate responses may explain why
complementary and alternative medicine is
used by fewer older adults.

white
black
hispanic and
asian national
30545 adult sample
NHIS

74.3% cited
in
other
literature
but 89.6%
cited in this
article

The three most widely used
forms of complementary medicine among all
adults in the past year were self-prayer,
biologically
based therapies (22.1% of all adults here), and
mind-body interventions. Asians reported
greater use
of an alternative medical system, biologically
based methods, mind-body interventions, and
energy therapies, whereas blacks and Hispanics
reported relatively low rates of use
of these modalities. Greater impairment is
associated with reduced
odds of reporting use of biologically based
therapies, but it is associated with
increased
odds of reporting self-prayer for health
purposes. LIMITATION w NHIS: does not
contain measures of how ailments are
interpeted - only asks one question about the
importance of each modality for health
maintenance - only asked of the indivduals who
used the modality. future

descriptions of CAM use by age and

2002 NHIS

Grzywacz, JG, Lang W, Suerken
C, Quandt SA, Bell RA, Arcury
TA (2005)

Gurjeet S. Birdee, MD, MPH,
Russell S. Phillips, MD, Roger
B. Davis, ScD, Paula Gardiner,

30,785

2007 National Health
Interview Survey data
excluding
vitamin/mineral
Fewer non-hispanic blacks use BBT than nonhisp
usagebut
including
others (predom Asian) and non-hisp whites. Appx 1/2
acupuncture; ayurveda;
of BBT users are using CAM to treat an existing
biofeedback; chelation
condition, but 45% use these modalities for illness
therapy; chiropractic or
prevention and health promotion. Use of CAM and
osteopathic
BBT to treat an existing condition increases linearly
manipulation;
energy
across adulthood. As age increases, use of BBT for
healing
therapy;
prevention decreases. The opposite is true for BBT
hypnosis;
massage;
and treatment. Therefore, BBT use among middlenaturopathy;
age is highest. The majority of Hisps and non-hisp
whites are using BBT for treatment , whereas the
movement techniques
majority of non-hisp blacks and non-hisp others use
(Feldenkreis,
these modalities for illness prevention and health
Alexander
technique,
pilates, and Trager
promotion. The log odds (logit model) of prev of BBT given (22%). Strength of this using BBT in
early adulthood are lower for study was that they used an age^2
Psychophysical
89.6% given hisps and non-hisp blacks than for non-hisp but that is whites, and the log odds of using a BBT variable in
Integration);
Asian the model to capture the for the increase across adulthood among hisps so curvilinear age-CAM association
all adults 18 and homeopathy;
household that later in life the odds of using a BBT are dicumented in the lit (and it was sig for response greater
over in the US, mind-body techniques
national sample (yoga, tai chi, and/or
among hisps than non-hisp whites
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BBT!) and they addressed missing data! rate here (and blacks). after midlife, the log odds of they used using BBT decrease for both non-hisp whites Limitation
potential retrospective recall other and blacks by age, gender, and edu.

MD, MPHc (2010) Harvard,
Beth Israel, Boston University

9,417

In 2007, pediatric CAM users were more likely to
take prescription medications, have a parent who
used CAM, and have chronic
conditions such as anxiety or stress, biologically-based therapies were used by 4.7% musculoskeletal
conditions, dermatologic of the sample. Use of biologically based conditions, or sinusitis (significant
therapies correlated with being an adolescent confounding factors were controlled for). CAM versus
being an infant or toddler, white versus use was least common in the South and most non-Hispanic
black or Hispanic, living in the common in the West. Research is required to West versus the South,
and parents being guide pediatricians in making college educated versus parents completing
recommendations on CAM modalities for less than high school. Biologically based children including
potential risks and/or therapies were also associated with delays in benefits and interactions with
conventional health care because of difficulties with access, therapies. There was nearly equal CAM
use and medical conditions including insomnia, between boys and girls, higher use among non- fever,
reflux, and sinusitis. LIMITATIONS: data Hispanic white patients, higher use among collected from an
adult proxy which is educated families, and regional variations susceptible to recall bias. # of children
with
76.50% with a low use in the South.
chronic conds small, limiting power,

nationally
distributed
sample among
individuals <18
years of age

Higher self-rated spirituality is
associated with a greater probability of
CAM use and the use of more
techniques. Although higher self-rated
religiosity does not distinguish CAM
users from nonusers, it is associated
with adopting significantly fewer
techniques. Assuming that the religious
versus spiritual worldviews are
differentiated by religious individuals’
greater embeddedness
in community and institutional
“orthodoxies” (e.g., adherence to a set
of prescribed beliefs), a religious
worldview appears to carry over to
constrain
the use of nonconventional practices
and providers. It may also be that
CAM’s tendency to secularize otherwise
sacred techniques makes this type of
care less attractive to these users
(Goldstein 1999). Openness shows
itself to be a

Hildreth and Elman, 2007
K.D. Hildreth, C. Elman
Alternative worldviews and
the
utilization of conventional
and
complementary
medicine

Sociol. Inq., 77 (2007), pp.
76–103
1,672

Jamie C. Barner, Ph.D.,
Thomas M. Bohman,
Ph.D., Carolyn M. Brown,
Ph.D., Kristin M.
Richards, Ph.D.
(2010) University of Texas
at
Austin

2,952

31-65 yr olds,
national
sample from
1995

1995–1996
crosssectional
National Survey of
Midlife
Development in the
United States (MIDUS) .

2002 NHIS/ national
cross-sectional A
multistaged, clustered
sample design was used,
and
selfreported
information
was
obtained
using
computer-assisted
personal
interview
AfricanAmericans who (CAPI) techniques. 15
used CAM in the cam
modalities
past 12 months measured

Limitation: interpretation of tables
confusing: means were given for
categorical variables, the diffs
between model 1 and 2 (and 3!) were
never explained, and OR's werent
given Herbal

WEIGHTED:
past
12
month
N=3,394,228 cam for
treatment: n= 1,660,353
(48.9%)
cam
for
Approximately 1 in 5 (20.2%) who used CAM in the prevention:
past 12 months used CAM to treat a
n=1,709,464 (50.4%)
specific condition. Less than 50% (48.9%) of AA
Folk medicine
CAM users used BBT for treatment, with the
exception of folk medicine. Ten of the 15 CAM WEIGHTED:
modalities were used primarily for treatment by past
12
month
African-Americans. CAM for treatment was
N=27,141 cam for
significantly (P < .05) associated with the following
factors: graduate education, smaller family size, treatment: n=21,259
cam
for
higher income, region (northeast, midwest, west (78.3%)
more likely than south), depression/anxiety, more prevention:
physician visits, less likely to engage in preventive
n=5,882 (21.7%)
LIMITATION: didnt
care, more frequent exercise behavior, more
activities of daily living (ADL) limitations, and neck break down CAM modality by table
pain. Twenty percent of African-Americans who LIMITATION w NHIS: CAM for treatment
used CAM in the past year were treating a specific answer 'no' does not necessarily imply
condition.
Alternative
medical
systems,
prevention, does it? wording of these
manipulative and body-based therapies, and folk
medicine, prayer, biofeedback, and energy/Reiki questions could be improved. terms such
as "home remedies" and culturally
74.30% were used most often.
60.80%

200

all adults 18 and
over in the US,
national sample
who
used herbs
alone
2007 NHIS

Jones, L., Sciamanna C.,
Lehman, E. (2009)

Kannan VD, Gaydos LM,
Atherly AJ, Druss BG (2010)

Kennedy, J, Wang, C, Wu C.
(2008)

Mehta DH, Phillips RS, Davis
RB, McCarthy EP. Use of
complementary and
alternative therapies by
Asian Americans. Results
from the National Health
Interview Survey.
J Gen Intern Med
2007;22:762–767.

not given

LIMITATION w NHIS: depends on respondents'
knowledge of CAM therapies and/or their
willingness to accurately report use. Also does not
survey nursing home and chronic care home
residents, who make up a huge portion of the
the association between herbal use in the individuals who should be receiving past 12 months
and receiving influenza and/or vaccinations. LIMITATION: could have also
pneumonococcal vaccine was not significant
assessed ever using CAM vs past year alone

not given

Motivaton for CAM use was neither
associated with a lower prob nor a
lower rate of conventional medicine
utilization.

1438

23393

5196

all adults

2007 NHIS

Using the unadjusted model -- Patients more
they say it likely to disclose herb and supp use: Females was 90% but
(OR=1.4), >65 yrs (OR=2.2) vs 18-24, those with
actually
public health insurance (OR=1.6) vs private LIMITATION: likely an underestimate of effect wasn't given
health insurance, poor/fair self-assessed since they ommitted respondents who used because
health status
(OR=1.5) , those hospitalized in
herbs and told a NP, PA, or dentist. This study they did
the past 12 months
(OR=1.9) vs not, and 6 or was not clearly written and they didn't even their
more MD visits in past year
(OR=2.2) vs 1.
describe which covariates they used in their
adults >=18 in
analysis
Patients least likely to report herb and supp
adjusted model. Therefore, the results of the
the US,
using
use were ALL races compared to whites,
unadjusted ORs were interpreted. they used an national 2002 NHIS/crossdifferent
Hispanic (OR=.6) vs non-hisp, not being a US
inflated response rate for a core they didnt
sample
sectional
cores
citizen (OR=.3)
even use (household at 90% when it was adult)!

all
nonhispanic
whites and
asian
amaericans
among a
national adult
21359 sample

2002 National Health
Herbal meds were used by 25% of the asian sample and 19% of the NHW sample
Interview
(p<.01). AA used herbs less freq than NHW to treat specific med conds (38% vs 59%
Survey/crosssectional
p<.01). Overall, 42% of AA and 38% of NHW reported using at least one CAM
study - 21 CAM therapies
modality in the past year (p=0.06) (Table 2). After adjustment for sociodemographic
excluding
prayer
characteristics, health care access, and illness burden, AA were as likely to use CAM
grouped into five broad
as NHW [aPR=1.09, 95% CI (0.94, 1.27)]. Asian Americans were less likely than NHW
categories: alternative
medical
systems
the use of herbal medicines (16 vs. 34%,
to disclose
prev of BBT given.
(Ayurveda, acupuncture,
p<0.001) and mind/body therapies (15 vs.
homeopathy,
folk
Limitation: they did log
reg but didn’t put
medicine, naturopathy),
results
in
a
tables,
then
25%,
p<0.05).
herbal
medicines
were
reported
bodywork
therapies
non-sig findings as sig! used more often by Chinese (32%) than
LIMITATION
(chiropractic
care,
by Filipinos (26%) and Asian Indians
massage),
WITH NHIS: they don’t
oversample
biologicallybased
AA, and don’t describe many (19%). Among AA, CAM use was
modalitlies
therapies
(dietbased
associated with being female, having
therapies, megavitamin
embedded in Asian traditions
(may create
therapy,
chelation
an
ethnocentric
bias
that
higher
education,
and
having
a
chronic
therapy),
mind/body
underestimates the prevalence of CAM medical condition; foreign-birth
therapies
associated with CAM use. For
(biofeedback, energy 74.3% cited
was not use among AAs). Many herbals described
healing, hypnosis, tai in other
both
chi, qigong, literature meditation,
in NHIS aerr unique to the US and are groups, almost half reported that
guided
but 89.6% imagery,
medicines used in combination with
progressive cited in this relaxation, herbal commonly marketed to middle-class
deep
article - breathing, yoga),
conventional medicine would
NHW. additionally, NHIS does not conduct
and
which is the herbal
medicines. total household response be more
the survey in any other language than helpful (49 vs. 48%; p=0.81) and
rate.

that they english and spanish
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self-made survey used herbal medicines because they based on the
revised
Health Promotion
Lifestyle, Profile II.
CAM use was
derived from
five questions
(three close-ended
and two openOlder age, female gender, unmarried, Indian

American ended) that
adults assessed

and higher income was associated with in seven U.S.

respondents’

use of dietary and herbal cities with

supplements. 30.4% used dietary high

vegetarian status:

‘‘Are you a and herbal

supplements. use of
concentration vegetarian?’’ ‘‘Are herbal and dietary of AIs: you currently taking
supplements among males indicated
Houston, TX;

dietary and herbal

they were older, moreeducated, had higher English

Phoenix, AZ; supplements?’’ and proficiency, and were tobacco Washington, ‘‘Do you use
any users compared to AI females.

Misra, Ranjita ;
Balagopal,
Padmini
;
Klatt,
Maryanna ;
Geraghty,
Maureen
(2010 )
Texas A&M

DC; Boston,

alternative medical

However, females were 1.8 times

MA; San

systems (AMS, also

more likely to Alt med systems and

Diego, CA;

referred to as

herbal supplements than males (table

Whole Medical

4). married respondents

Systems) such as

were 2.8 times more likely to use

strength: they did cronbachs a on

Ayurveda,

dietary and herbal supplements than

subscales!, assessed for inter-rater

Edison, NJ;
and
Parsippany,
1824

NJ.

homeopathic

37% non-married.

reliability,

treatment, and

Nahin RL, Barnes PM,
Stussman BJ, Bloom B.
Costs of complementary
and alternative medicine
(CAM) and frequency of
visits to CAM
practitioners: United
States, 2007. Natl Health
Stat Rep. 2009;
(18): 1-14.

22290+

In 2007, 3.9% of adults used BBT in the past year. In
2007, adults in the United States spent $33.9 billion
out of pocket on visits to CAM practitioners and
purchases of CAM products, classes, and materials.
Nearly twothirds of the total out-of-pocket costs that
adults spent on CAM were for self-care purchases of
CAM products, classes, and materials during the past
12 months ($22.0 billion), compared with about onethird spent on practitioner visits ($11.9 billion).
Despite
this emphasis on self-care therapies, 38.1
LIMITATION: total costs were calculated using million adults
made an estimated 354.2
estimates of the most recent purchase * # of million visits to practitioners of
Cross-sectional/ 2007
CAM. A total purchases per yr, which is not nec completely
nationally
National Health representative not of 44% of all out-of-pocket costs for CAM, or accurate. NHIS LIMITATIONS: recall bias quantitative about $14.8 billion, was
spent on the possible, prev estimates for small population ly stated in purchase of nonvitamin, nonmineral, natural subgroups
Interview Survey data.
not great bc only taken at one point
/ US
35 CAM therapies
article
products.
in time
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Nahin, R, Dalhammer, JM,
Stussman BJ (2010)

Nahin, RL, Dahlhamer JD,
Taylor BL, Barnes PM,
Stussman BJ, Simile CM,
Blackman MR, Chesney
MA, Jackson M, Miller H, and
McFann KK (2007)

Neiberg, Rebecca H. ; Aickin,
Mikel ; Grzywacz, Joseph G. ;
Lang, Wei ; Quandt, Sara A. ;
Bell, Ronny A. ; Arcury,
Thomas A. (2011) Division of
Public Health Sciences,
Department of Biostatistical
Sciences, , Winston-Salem,
NC.
College of Medicine, , Tucson, AZ.
Department of Family and
Community Medicine, ,
Winston-Salem, NC.
Division of Public Health
Sciences,
Department
of
Epidemiology and Prevention, ,
Winston-Salem, NC.

Nguyen, H.T., Grzywacz, JG
Lang, W, Walkup M, Arcury, T
(2010)

31044

31044

27,862

1683

all adults 18 and
over in the US,
national
sample

2002 NHIS

national
adult
sample 18+
2002 NHIS

national
adult
sample 18+
2002 NHIS

OR's only given for general CAM use and not
74.30% BBT

Engaging in liesure time physical
activity, having consumed alcohol in one's
life but not being a current heavy drinker,
and being a former smoker are
independently associated with the use of
CAM. Obese are slightly less likely to use
CAM than individuals with a healthy BMI.
No sig 74% bw flu vaccine and CAM use.

Linkset analysis, a method of estimating cooccurrence
beyond chance to identify possible sets of CAM use.
Results: Most adults use CAM therapies from a single
category. Approximately 20% of adults combined two
CAM categories, with the combination of mind-body
therapies and biologically based therapies estimated
to be most common. Only 5% of adults use therapies
representing three or more CAM categories.
Combining therapies across multiple CAM categories
was more common among those 46-64, women,
whites, and those with a college education.
Conclusions: The results of this study allow
researchers to refine descriptions of CAM use in the
adult population. Most adults do not use a wide
assortment of CAM; most use therapies within a single
CAM category. Sets of CAM use were found to differ
by age, gender, ethnicity, and education in ways
consistent with previous
74.30% research.

2002 NHIS + 2003 MEPS
longitudinal 89.6% for component on
the NHIS; not
adults aged 55+ same sample from
given for
nationally
2002 NHIS
MEPS

19.3% of adults did not use conventional care within the
past year despite the fact that 38.4% of these
individuals had one or mroe health needs, with almost
25% having a serious chronic or acute medical
condition. Instead of conventional care, 24.8% of these
individuals used CAM. 68.5% of those only using CAM
used BBT. 24.8% of those not using conventional care
used some form of CAM, with 12% reporting one or
more health needs and using CAM. Of all individuals
using CAM only, 21.6% thought conventional med
treatments wouldn't help, and 20.4% said conv med
treatments were too expensive. The majority (54.1%)
said they thought it would be interesting to try.

strengths: assessed colinearity to compare
models
Biologically-based therapies were observed in 5.5% of
those who used a single modality with a significant
probablity that biologically based and other CAM types
are linked. Among the 20.6% of linkset users, singificant
associations were seen between biologically-based
users and 10.6% of those who used mind-body
therapies, among other combinations of CAM use (less
than 10.6%). There was a significant difference by
genderbetween those who used both biologicallybased therapies and mindbody therapies (male 5.6%,
fem 7.6%), those who used biologically-based therapies
+ alt health systems + mindbody therapies (males .4%,
fem .8%), and those who used all 4 CAM modalities
(biologically-based, alt health systems, manipulative
methods, and mindbody therapies) (males .5%, fem
.8%). Among those who used both alt health systems
and biologically-based therapies, significant diffs
occurred for whites > blacks & whites > hispanics. For
biologically-based +
manipulative methods, whites > hispanics, for
biologically-based + mind-body, hispanics > whites.
Among those who used an alt system + biologicallybased + mind-body therapy, Hispanics> whites.
biologically-based + mindbody + manipulative methods
are significantly whites> asians & whites > blacks.
However, when all 4 modalities were used, whites were
> blacks & whites > hispanics utilized them together.
Those who used mind-body therapies + biologicallybased therapies were more significantly more likely to
be 45-54 yrs old.

interaction effects not possible due to low
sample sizes of other forms of CAM measured. RCTS mremain nec to evaluate the saftey and efficacy
of CAM in older adults STRENGTHS: dealth w missing income issue by using a dichotomous measure
which may have helped BBT was used by 20.4% of this sample. The use a little & reliability (a) of the
functional score of Biologically based therapies predicted assessed, LIMITATION: but not for the
physical better functional status (using a validated HRQoL and mental HRQoL. analysis reports scale
and adjusting for many factors) (-1.14 short-term 1 year effects, interaction effects lowered func
status score between those were not included due to low rates of some using BBT vs no BBT) (p<.01)
in 1 year modalities
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Susan J. Blalo37:37hD;
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PharmD; Rajul A. Patel,
PharmD, PhD; Linda L.
Norton, PharmD;
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Hill, Creighton University,
Thomas J Long School of
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Arthritis
Research
Center

2523

Upchurch DM , Chyu L,
Greendale GA, Utts J, Bair
YA, Zhang G, Gold E (2007) 17295

nationally
representative
sample

37% of U.S. adults used complementary and
alternative medicine and 63% did not use any
CAM. Compared to those who did not use CAM,
CAM users were more likely to rate their health
as 'Excellent' (adjusted-odds ratio (AOR) = 1.14,
95% CI = [1.03,1.26]). Conclusion:
We found a significant association between
2007 National
CAM use and self-rated excellent health and
Health
Interview
health improvement over the prior year.
Survey/crossProspective trials are required to determine
not
sectional
study. quantitative whether CAM use is causally related to
General CAM usage ly stated in excellent health status and better health than
and health status
article
in the prior year.

99-2000 and 20012002 NHANES national
All kids <=18 yrs survey (some pops
age
oversampled)

not given

Population-based
epidemiological study Johnston County
Osteoarthritis Project
(1991-2004) survey TWO COHORTS
COLLAPSED TOGETHER
- which contained a
list of 51 products
including herbs and
botanical products,
natural products
civilian,
obtained
from
animal
noninstitutiona sources natural lized,
white or hormones (eg,
African
phytoestrogen
American
pills), and foods that
residents, aged are sometimes 45 years
or
consumed for older, of
medicinal purposes as
Johnston
well as an open-ended
County, North
query. vitamins and
Carolina (AA's
minerals not assessed
oversampled)
in this survey
not given

national
adult
women sample
18+
2002 NHIS

NOT ASSESSED, ABSTRACT ONLY AVAIL

These data the first to include info on the use of
botanicals in addition to nutrient-containing
detary supps among children. I wish they had
.8% prevalence for any botanical supplements,
made a table of the botanicals, however - they
with no sig diffs by sex. The most commonly used were only available via reporting through the
botanical supplements were ginseng, echinacea, write-up. STRENGTH of NHANES is info from
ginkgo, and grape seed extract (they also inc citrus label recorded directly by trained pros in
bioflavenoids which are not a natrual herb or
interviewers homes, LIMITATIONS of NHANES
extract). Few children
are cross-sx data, use of proxies under 16 may
younger than 3 had used botanical supplements, have caused misclassification , diffs in
and the maximum prevalence was only 1% in
methodology and defs over time may limit the
teenagers.
comparison of prevalence data
19.3 (n=488) of participants used at least 1
herb/natural product and there were stat sig
diffs by gender (women), race (whites), and edu
(better eductated) in bivariate analyses. Among
those who used both conventional medications
and herbs/natural products, more than 1 in 5 (97
[21.9%]) were using a combination of products
associated with a
potential interaction. Odds of exposure to a
potential interaction'
were lower among people who had health
insurance and increased
with the number of products used. A total of 168
potential interactions were identified. As shown
in Table 4, 115 ofthe 168 potential interactions
(68.5%)
involved garlic and cytochrome P450 3A4
substrates (eg, amlodipine, atorvastatin,
simvastatin, verapamil). Although the
severity of most ofthe 168 potential interactions
was classified
as "moderate," 27 (16.1%) were classified as
"high" in severity. The bivariate analyses
indicate that the
odds of exposure to a potential interaction
increase as fatigue,
number of comorbidities, number of herbs used,
number of
excluded all missing data so sample size for full
OTC medications used, and number of prescription model (herb users who used at least one med as
well) went down to 419. STRENGTH: extensive
medications
used increase. In addition, individuals with health array of natural herbs/products LIMITATION:
interaction data utilized as basis were caseinsurance
reports

BBT the 2nd most freq reported
(23.8%) after prayer. Foreign-born
women were more likely to use BBT
than US-born women (but remember
they didnt control for confounders!)
menopause in the top 10 conditions
74% only for BBT

STRENGTHS: addressed income
nonresponse and compared missing vs
no missing: no diff in effects
LIMITATION: missing values for smoking
alcohol and
BMI imputed. No Cis reported
LIMITATION w NHIS:underestimates
likely in ethnic communities of women
since traditional healers not yet inc in
dataset. many trad practices maybe not
considered "alternative" since they may
be perceived as common in some
communities, resulting in potential
misclassification
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Wade, C, Chao M.T.,
Kronenberg, F (2007)

Yuanting Zhang, Elizabeth
B. Fein and Sara B. Fein
(2011)

804

2653

Adult Chinese
Women in the
US - national
sample

a nationally
distributed,
but not
representativ
e, consumer
opinion panel
and was
limited to
healthy
mothers with
healthy term
or near-term
singleton
infants.

national
telephone
survey
of
health
practices and services
utilization April-Sept
2001

at least 2 time
periods
documented: Infant
Feeding Practices
Study II, a
longitudinal survey
of women studied
from late pregnancy
through their
infant's first year of
life 2005-2007

Women didn't use CAM to treat cancer or conditions
related to pregnancy. The highest
rates of CAM use were for depression and
potential limitation: # of foreign-born Chinese
menopausal symptoms. Of those who used
women was very high, and higher SES found in
CAM, 29% used only chinese herbs and
this sample compared to other Chinese in the
acupuncture and 33% used chinese herbs and country, potentially limiting generalizability.
acupuncture along with other CAM therapies.
The only obviously significant OR was for Most
of the Chinese herb use was wo a script
herb/acu users who were less likely to have from
a TCM practitioner (18% of sample). excellent health status but there was no There was a
statistically significant difference reference category listed! income missing was in acculturation
score between those who
high but STRENGTH: no diffs found between
used Chinese herbs and acupuncture only vs.
those who withheld their income and those
73% other CAM use (p<.01).
who did not

ine percent of infants were given dietary
botanical supplements or teas in their first year
of life, including infants as young as 1 month.
Maternal herbal use (P < .0001), longer
breastfeeding (P < .0001), and being Hispanic
(P = .016) were significantly associated with
giving infants dietary botanical supplements or
teas in the multivariate model. Many
supplements and teas used were marketed
and sold specifically for 94% infants.

9% of mothers in the sample
reported giving DBS and teas to
their infants on at least one of the
questionnaires,
and 4% of the mothers reported
giving DBS and teas on more than
one questionnaire. mothers were
more likely to give their
infants DBS and teas if they had used
DBS themselves (OR 3.69) compared
to mothers who had not, were
primiparous, were older, had higher
education or higher income, and were
married (using
0.05). Geographically, giving
DBS and teas to infants was most
common in the West and least common
in the Midwest. The 4 most common
reasons that mothers fed DBS and teas
to their infants
were to help with fussiness, digestion,
colic, and relaxation STRENGTH AND
LIMITATION: short recall (2 weeks),
LIMITATION: likely an underestimiate of
effect exists bc of exposure to herbs
through breastfeeding mothers to
infants, no # of doses. likely an
overestimate of herbal use bc regular
tea was counted as
well. overrepresented NHW, older
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